risperidone has been researched along with Psychoses in 865 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Duloxetine adjuvant to risperidone seems to be a tolerable and efficacious treatment for primary negative symptoms of schizophrenia." | 9.22 | Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. ( Akhondzadeh, S; Arabzadeh, S; Ghaleiha, A; Khalili, Z; Mohammadinejad, P; Nikbakhat, MR; Rezaei, F; Zeinoddini, A, 2016) |
| "We compared clozapine (n = 53) to risperidone (n = 54) in a randomized, double-blind, 29-week trial in schizophrenia patients (diagnosed using DSM-IV) at 3 research outpatient clinics." | 9.22 | Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. ( Ames, D; Baker, RW; Chengappa, KN; Kane, JM; Marder, SR; McMeniman, M; Parepally, H; Petrides, G; Schooler, NR; Umbricht, D; Wirshing, WC, 2016) |
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 9.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this 4-week, double-blind, randomized controlled trial conducted in psychiatric care from September 2012 to March 2015, 103 patients with schizophrenia (ICD-10) who did not respond to olanzapine 10 mg/d or risperidone 3 mg/d were randomly allocated to a dose-increment or -continuation group." | 9.22 | Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. ( Bies, RR; Kapur, S; Mimura, M; Pollock, BG; Sakurai, H; Suzuki, T; Uchida, H, 2016) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 9.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 9.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 9.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 9.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 9.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| " The trial evaluated non-acute adult patients with psychotic disorders treated with a stable olanzapine dose who required a treatment change." | 9.16 | Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. ( Rosa, F; Schreiner, A; Sherif, T; Thomas, P, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 9.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder established by the Structured Clinical Interview for DSM-IV (N = 369) were randomized between 2006 and 2009 to long-acting risperidone or physician's choice of oral antipsychotic." | 9.16 | Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. ( Barnett, PG; Krystal, JH; Rosenheck, RA; Scott, JY, 2012) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 9.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| "To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders." | 9.14 | Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. ( Bagalà, A; Bernareggi, MM; Del Curatolo, V; Giustra, MG; Rossi, A; Scapati, F, 2009) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 9.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "Stable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial." | 9.14 | Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. ( De Marinis, T; Lambert, M; Naber, D; Pfeil, J; Schreiner, A, 2010) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 9.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 9.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| "Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia." | 9.13 | Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. ( Kapur, S; Labelle, A; Mamo, DC; Mann, SW; Mannaert, EJ; Remington, G; Shammi, C; Uchida, H, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 9.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| "The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD)." | 9.12 | Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. ( Caers, I; Gharabawi, G; Greenspan, A; Kushner, S; Mintzer, J; Schneider, LS; Van Hove, I; Weiner, M, 2006) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 9.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder." | 9.12 | A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Gharabawi, GM; Kujawa, M; Lasser, RA; Mahmoud, RA; Rodriguez, S; Simpson, GM; Turkoz, I, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 9.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 9.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 9.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 9.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "The efficacy and safety of risperidone, quetiapine, and placebo were compared in a 14-day monotherapy phase in patients experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder." | 9.12 | Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. ( Gharabawi, GM; Greenspan, A; Kosik-Gonzalez, C; Rupnow, MF; Stahl, SM; Zhu, Y, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 9.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 9.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| " In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments." | 9.11 | Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. ( Bossie, CA; Lasser, RA; van Os, J, 2004) |
| "This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses." | 9.11 | A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( Huq, ZU, 2004) |
| "To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders." | 9.11 | Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. ( Bossie, CA; Davidson, M; Eerdekens, M; Gharabawi, G; Lasser, RA; Zhu, Y, 2004) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia." | 9.11 | The effects of clozapine and risperidone on spatial working memory in schizophrenia. ( Carter, C; Goldman, R; Green, MF; Kane, JM; Marder, SR; McGurk, SR; Schooler, NR; Xie, H, 2005) |
| "In a 50-week, open-label trial, stable patients with schizophrenia or schizoaffective disorder who received long-acting risperidone injection every 2 weeks were assessed using the Positive and Negative Syndrome Scale (PANSS)." | 9.11 | Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. ( Bossie, CA; Gharabawi, GM; Kane, JM; Lasser, RA, 2005) |
| "This analysis aimed to assess the relationship between race and clinical response to long-acting, injectable risperidone treatment in patients with schizophrenia or schizoaffective disorder." | 9.11 | Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Ciliberto, N; Lasser, RA; Urioste, R, 2005) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 9.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 9.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 9.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "This open-label, multicentre study investigated the clinical efficacy of liquid peroral risperidone in psychotic disorders, the patients' attitudes toward the study medication vs." | 9.11 | Risperidone liquid in psychotic disorders--efficacy and attitudes. ( Damjanović, A; Jasović-Gasić, M; Marić, N, 2005) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 9.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 9.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 9.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| " In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders." | 9.09 | Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders. ( Adler, CM; Breier, A; Elman, I; Malhotra, AK; Pickar, D; Su, TP; Weisenfeld, NI, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 9.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 9.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 9.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 9.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| "We describe a consecutive series of 21 patients with HIV or AIDS who received risperidone for psychotic disorders." | 9.08 | Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. ( Catalan, J; Golledge, H; Singh, AN, 1997) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 8.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 8.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| "In the 10 studies analyzed, the taste of RD risperidone tablets was found to be acceptable in the majority of healthy subjects and patients with schizophrenia or schizoaffective disorder." | 8.84 | Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. ( D'Hoore, P; Kushner, S; Mannaert, E; Remmerie, B; Thyssen, A, 2007) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 8.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| " To report the case of a 53-year-old patient who developed neuroleptic malignant syndrome (NMS) - a rare but potentially life-threatening complication of neuroleptic therapy - 4 days after treatment with risperidone was initiated." | 8.79 | Risperidone-induced neuroleptic malignant syndrome: a case report and review. ( Meterissian, GB, 1996) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 7.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| "This study aimed to assess the comparative effectiveness of risperidone (RIS) versus aripiprazole (ARP) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment." | 7.88 | Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2018) |
| "This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase." | 7.85 | Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2017) |
| "Objective of this observational trial is to examine the effects of quetiapine in comparison with olanzapine and risperidone on clinical outcomes and quality of life in patients with schizophrenia and schizoaffective disorder in routine care." | 7.78 | Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. ( Becker, T; Croissant, D; Eschweiler, GW; Frasch, K; Jaeger, S; Kilian, R; Längle, G; Messer, T; Pfiffner, C; Schepp, W; Steinert, T; Weiser, P, 2012) |
| "A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study." | 7.78 | Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. ( Barteček, R; Juřica, J; Kašpárek, T; Pindurová, E; Žourková, A; Zrůstová, J, 2012) |
| "To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta)." | 7.76 | The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. ( Berntsson, A; Eriksson, B; Löthgren, M; Persson, U; Svensson, M; Willis, M, 2010) |
| "We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders." | 7.75 | A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. ( De Sarro, G; Ferraro, M; Gallelli, L; Palleria, C; Spagnuolo, V, 2009) |
| "To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia." | 7.75 | Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. ( Dirani, R; Flanders, S; Fuller, M; Russo, P; Secic, M; Shermock, K; Vallow, S, 2009) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 7.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "In this paper, we report on two subjects with psychotic disorders who were found to have peripheral edema during olanzapine therapy." | 7.75 | [Edema related to treatment with olanzapine]. ( Fiedler, T; Gutmann, P; Wustmann, T, 2009) |
| "The study was a retrospective analysis of administrative data from the New York-New Jersey region of the Veterans Health Administration for 2,436 individuals with schizophrenia or schizoaffective disorder who were prescribed risperidone from January 2001 through March 2003." | 7.74 | Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. ( Dellenbaugh, C; Weissman, EM, 2007) |
| "To monitor long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone long-acting injectable (RLAI)." | 7.74 | Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. ( Kissling, W; Llorca, PM; Lloyd, K; Medori, R; Sacchetti, E, 2008) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 7.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 7.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 7.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 7.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 7.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 7.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder." | 7.72 | Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. ( Binder, C; Chue, P; Welch, R, 2004) |
| "We report on the occurrence of galactorrhea associated with a prolactin elevation within weeks of treatment with risperidone." | 7.70 | Risperidone-induced galactorrhea associated with a prolactin elevation. ( Gupta, S; Popli, A; Rangwani, SR, 1998) |
| "We present a case of a 74-year-old patient with schizoaffective disorder, who developed risperidone-related neuroleptic malignant syndrome." | 7.70 | High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. ( Devarajan, S; Dursun, SM; Kutcher, SP; Oluboka, OJ, 1998) |
| "A patient with schizoaffective disorder developed signs of catatonia while on a regimen of valproic acid, sertraline, and risperidone." | 7.70 | Catatonia-like events after valproic acid with risperidone and sertraline. ( Lauterbach, EC, 1998) |
| "We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea." | 7.70 | Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 7.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 7.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia." | 7.69 | Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. ( Findling, RL; Friedman, L; Grcevich, SJ; Rowane, WA; Schulz, SC, 1996) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 6.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| "Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia." | 6.80 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. ( Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP, 2015) |
| " Sixty-nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs)." | 6.75 | Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. ( Curtis, V; Hawley, C; Latif, MA; Saleem, PT; Turner, M; Wilton, K, 2010) |
| "Chronic management of schizophrenia and schizoaffective disorders is frequently complicated by symptomatic relapse." | 6.75 | Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. ( Bergmans, P; Cordes, J; de Arce, R; Eriksson, L; Gaebel, W; Rouillon, F; Schreiner, A; Smeraldi, E, 2010) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 6.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| " Doses were adjusted to maximize efficacy and to minimize adverse events." | 6.70 | A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. ( Jibson, MD; Mullen, J; Sweitzer, D, 2001) |
| " This series covers four main areas of concern when treating the elderly: low-maintenance dosing minimising the likelihood of adverse events; successful treatment of patients previously uncontrolled and experiencing side effects with other antipsychotics; the possibility of intermittent rather than continuous treatment; and the benefits to patients, carers and the health services." | 6.41 | Risperidone in the treatment of psychoses in the elderly: a case report series. ( Bullock, R; Libretto, S, 2002) |
| "In a 6-week trial between December 2000 and January 2002, 1713 patients with DSM-IV schizophrenia and related psychoses were treated with risperidone, with the dose, daily changes in dose, and weekly changes in Brief Psychiatric Rating Scale score documented." | 6.21 | Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. ( Choi, SK; Hong, JP; Joo, YH; Kim, CY; Lee, GH; Shin, YW, 2005) |
| "Schizophrenia is one of the most expensive psychiatric illnesses." | 5.39 | Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. ( Chow, DP; Chung, WS; Lee, EH; Lee, KK; Lee, VW; Wong, MC; Wu, DB, 2013) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 5.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 5.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| "The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) compared the efficacy of risperidone, olanzapine, and molindone over 8 weeks in 119 youths age 8-19 years with early-onset schizophrenia or schizoaffective disorder." | 5.24 | Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. ( Artukoglu, BB; Bloch, MH; Gabriel, D; Jakubovski, E; Taylor, JH, 2017) |
| "Overall results demonstrate that, compared with placebo, quetiapine is not associated with improvement in psychosis in patients with dementia, while olanzapine and aripiprazole have non-significant small numerical improvements." | 5.22 | Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. ( Abler, VC; Demos, GN; Mahadik, BS; Rajagopalan, K; Rashid, N; Yunusa, I, 2022) |
| "Few studies have examined effectiveness and tolerability of risperidone long-acting injections (RLAI) in the early phase of a schizophrenia spectrum (SS) disorder using a randomized controlled trial (RCT) design." | 5.22 | An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. ( Adams, B; Chue, P; Jordan, G; Joseph, A; Koczerginski, D; Malla, A; Manchanda, R; Milliken, H; Oyewumi, K; Roy, MA; Stip, E; Williams, R, 2016) |
| "Duloxetine adjuvant to risperidone seems to be a tolerable and efficacious treatment for primary negative symptoms of schizophrenia." | 5.22 | Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. ( Akhondzadeh, S; Arabzadeh, S; Ghaleiha, A; Khalili, Z; Mohammadinejad, P; Nikbakhat, MR; Rezaei, F; Zeinoddini, A, 2016) |
| "We compared clozapine (n = 53) to risperidone (n = 54) in a randomized, double-blind, 29-week trial in schizophrenia patients (diagnosed using DSM-IV) at 3 research outpatient clinics." | 5.22 | Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. ( Ames, D; Baker, RW; Chengappa, KN; Kane, JM; Marder, SR; McMeniman, M; Parepally, H; Petrides, G; Schooler, NR; Umbricht, D; Wirshing, WC, 2016) |
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 5.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this 4-week, double-blind, randomized controlled trial conducted in psychiatric care from September 2012 to March 2015, 103 patients with schizophrenia (ICD-10) who did not respond to olanzapine 10 mg/d or risperidone 3 mg/d were randomly allocated to a dose-increment or -continuation group." | 5.22 | Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. ( Bies, RR; Kapur, S; Mimura, M; Pollock, BG; Sakurai, H; Suzuki, T; Uchida, H, 2016) |
| " At 8 US academic centers, 305 patients with schizophrenia or schizoaffective disorder were randomly assigned to LAI risperidone (LAI-R) or physician's choice oral SGAs." | 5.20 | Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. ( Ames, D; Buckley, PF; Bustillo, J; Goff, DC; Hsiao, J; Kane, JM; Kopelowicz, A; Lauriello, J; Manschreck, T; Mendelowitz, AJ; Miller, del D; Mintz, J; Schooler, NR; Severe, JB; Wilson, DR, 2015) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 5.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 5.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 5.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "A prospective, randomized, open-label study was carried out to compare the long-term neurocognitive effectiveness of haloperidol, olanzapine, and risperidone in the first episode of schizophrenia spectrum disorders." | 5.17 | Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. ( Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL, 2013) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 5.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 5.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| "To compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using DSM-IV-TR criteria." | 5.17 | Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. ( Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013) |
| "This was a post hoc analysis of a 52-week, prospective, randomized, double-blind study (N=323) comparing 2 doses of risperidone long-acting injectable (RLAI) in stable subjects with schizophrenia or schizoaffective disorder." | 5.17 | Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. ( Alphs, L; Bilder, R; Pandina, G; Turkoz, I, 2013) |
| " The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial." | 5.16 | The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. ( Andrews, H; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, S; Sultzer, D, 2012) |
| "The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4-8, 10-16, and 20-24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo." | 5.16 | Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. ( Citrome, L; Hochfeld, M; Meng, X; Stahl, SM, 2012) |
| " The trial evaluated non-acute adult patients with psychotic disorders treated with a stable olanzapine dose who required a treatment change." | 5.16 | Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. ( Rosa, F; Schreiner, A; Sherif, T; Thomas, P, 2012) |
| "Two plasma samples were collected at 2 separate given time points for the measurement of RIS and 9-OH-RIS concentrations from 50 patients with schizophrenia or schizoaffective disorder maintained on risperidone (mean ± SD age = 56 ± 15 years; 39 men)." | 5.16 | Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. ( Bies, RR; Mamo, DC; Mimura, M; Pollock, BG; Suzuki, T; Tsunoda, K; Uchida, H; Watanabe, K, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 5.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone." | 5.16 | Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. ( Breiger, D; Findling, RL; Frazier, JA; Giuliano, AJ; Hamer, RM; Hooper, SR; Johnson, JL; Lieberman, JA; McClellan, J; Sikich, L; Vitiello, B; Yakutis, L; Youngstrom, EA, 2012) |
| "Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder established by the Structured Clinical Interview for DSM-IV (N = 369) were randomized between 2006 and 2009 to long-acting risperidone or physician's choice of oral antipsychotic." | 5.16 | Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. ( Barnett, PG; Krystal, JH; Rosenheck, RA; Scott, JY, 2012) |
| "Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks." | 5.16 | Relapse risk after discontinuation of risperidone in Alzheimer's disease. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "Growth mixture modeling (GMM) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affective disorder treated with risperidone or olanzapine." | 5.15 | The heterogeneity of antipsychotic response in the treatment of schizophrenia. ( Ascher-Svanum, H; Case, M; Conley, R; Jacob, J; Kane, JM; Kapur, S; Kinon, BJ; Kollack-Walker, S; Stauffer, VL, 2011) |
| "Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)." | 5.15 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). ( Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| "This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment." | 5.15 | A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 5.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| " One hundred two patients with first episode schizophrenia or schizoaffective disorder were assessed on cognitive measures of speed of processing, episodic memory, executive function, and visual spatial processing at baseline (when patients were drug naive and after 16 weeks of olanzapine or risperidone treatment), so that a change score could be derived." | 5.14 | Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. ( Burdick, KE; Goldberg, TE; Goldman, R; Kane, JM; Lencz, T; Malhotra, AK; McCormack, J; Napolitano, B; Patel, RC; Robinson, DG; Sevy, SM, 2009) |
| "To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder." | 5.14 | Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. ( Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A, 2009) |
| "To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders." | 5.14 | Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. ( Bagalà, A; Bernareggi, MM; Del Curatolo, V; Giustra, MG; Rossi, A; Scapati, F, 2009) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 5.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "Stable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial." | 5.14 | Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. ( De Marinis, T; Lambert, M; Naber, D; Pfeil, J; Schreiner, A, 2010) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 5.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 5.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| " Sixty patients with DSM-IV schizophrenia (n = 58) or schizoaffective disorder (n = 2) met the DSM-IV research criteria for neuroleptic-induced tardive dyskinesia and were randomly assigned to a risperidone or olanzapine group." | 5.14 | A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. ( Chan, HY; Chang, CJ; Chen, CH; Chen, JJ; Chiang, SC; Gau, SS; Hwu, HG; Lai, MS, 2010) |
| "Data are from a one-year, open-label, international, multicenter trial (n=670) of long-acting risperidone in adult symptomatically stable patients with schizophrenia or schizoaffective disorder." | 5.14 | Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. ( David, AS; Fleischhacker, WW; Rabinowitz, J; Wiffen, BD, 2010) |
| "In a 6-week, randomized, open-label, rater-blinded study, patients with schizophrenia or schizoaffective disorder, on a stable drug dose for more than 30 days at entry, who were intolerant of or exhibiting a suboptimal symptom response to more than 30 days of olanzapine treatment, were randomly assigned to the following switch strategies (common risperidone initiation scheme; varying olanzapine discontinuation): (i) abrupt strategy, where olanzapine was discontinued at risperidone initiation; (ii) gradual 1 strategy, where olanzapine was given at 50% entry dose for 1 week after risperidone initiation and then discontinued; or (iii) gradual 2 strategy, where olanzapine was given at 100% entry dose for 1 week, then at 50% in the second week, and then discontinued." | 5.13 | Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. ( Berry, SA; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, GJ, 2008) |
| "Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia." | 5.13 | Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. ( Kapur, S; Labelle, A; Mamo, DC; Mann, SW; Mannaert, EJ; Remington, G; Shammi, C; Uchida, H, 2008) |
| "Risperidone and olanzapine did not demonstrate superior efficacy over molindone for treating early-onset schizophrenia and schizoaffective disorder." | 5.13 | Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. ( Ambler, D; Anderson, R; De Jong, S; Delporto-Bedoya, D; Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Lieberman, JA; Maloney, AE; McClellan, J; McNamara, NK; Michael, E; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Slifka, K; Vitiello, B, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 5.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| "We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia." | 5.13 | Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. ( Ader, M; Bergman, RN; Berry, SA; Garvey, WT; Gharabawi, G; Greenspan, A; Mahmoud, R; Mao, L; Morein, J; Musselman, DL; Nemeroff, CB; Phillips, LS; Zhu, Y, 2008) |
| "First-episode patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV) were randomly assigned to olanzapine (2." | 5.13 | Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( Gu, H; Hamer, RM; Lieberman, JA; McEvoy, JP; Perkins, DO; Weiden, PJ, 2008) |
| "One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder were randomized in a double-blind design to groups of 6 weeks' treatment with olanzapine (n = 59) or risperidone (n = 63), with a mean dose of 11." | 5.13 | Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. ( de Haan, L; Laan, W; Linszen, D; van Beveren, N; van den Brink, W; van Nimwegen, L, 2008) |
| "The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD)." | 5.12 | Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. ( Caers, I; Gharabawi, G; Greenspan, A; Kushner, S; Mintzer, J; Schneider, LS; Van Hove, I; Weiner, M, 2006) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 5.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "Adjunctive treatment with galantamine improves memory and attention in patients with schizophrenia who are stabilized on risperidone, providing the opportunity to improve functional outcome in these patients." | 5.12 | Galantamine improves cognition in schizophrenic patients stabilized on risperidone. ( Hicks, PB; Schubert, MH; Young, KA, 2006) |
| "This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder." | 5.12 | A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Gharabawi, GM; Kujawa, M; Lasser, RA; Mahmoud, RA; Rodriguez, S; Simpson, GM; Turkoz, I, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 5.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| "Forty-eight patients with remitted DSM-IV schizophrenia and comorbid major depression were randomized to placebo for 6 weeks or sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders." | 5.12 | Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. ( Addington, D; Addington, J; Patten, S; Pierson, K, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 5.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria." | 5.12 | Patient-based and clinician-based support for the remission criteria in schizophrenia. ( Bossie, CA; Bouhours, P; Docherty, JP; Gharabawi, GM; Lachaux, B; Lasser, R; Zhu, Y, 2007) |
| "This subgroup analysis of symptomatically stable patients with schizophrenia or other psychotic disorders in the StoRMi trial determined the efficacy and tolerability of risperidone long-acting injectable in patients changed from oral risperidone monotherapy." | 5.12 | Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. ( Kahn, JP; Medori, R; Sacchetti, E; Schmauss, M, 2007) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 5.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 5.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "The efficacy and safety of risperidone, quetiapine, and placebo were compared in a 14-day monotherapy phase in patients experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder." | 5.12 | Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. ( Gharabawi, GM; Greenspan, A; Kosik-Gonzalez, C; Rupnow, MF; Stahl, SM; Zhu, Y, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 5.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks." | 5.11 | A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. ( Bous, H; Bruggeman, R; Castelein, S; Kluiter, H; Knegtering, R; van den Bosch, RJ; Van Der Linde, J, 2004) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 5.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| " In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments." | 5.11 | Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. ( Bossie, CA; Lasser, RA; van Os, J, 2004) |
| "This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses." | 5.11 | A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( Huq, ZU, 2004) |
| "The effect of sertraline on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was studied in 11 patients with schizophrenia or schizoaffective disorder." | 5.11 | Plasma risperidone concentrations during combined treatment with sertraline. ( Ancione, M; D'Arrigo, C; Madia, A; Migliardi, G; Morgante, L; Spina, E; Zoccali, R, 2004) |
| "To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders." | 5.11 | Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. ( Bossie, CA; Davidson, M; Eerdekens, M; Gharabawi, G; Lasser, RA; Zhu, Y, 2004) |
| " However, the results suggest that quetiapine, when given within the recommended dosage range, has a benign EPS profile, with potentially greater tolerability and comparable efficacy to risperidone in older outpatients with psychotic disorders." | 5.11 | A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. ( Mintzer, JE; Mullen, JA; Sweitzer, DE, 2004) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication." | 5.11 | Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. ( Llorca, PM; Martin, SD; Medori, R; Möller, HJ; Parellada, E; Sacchetti, E, 2005) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia." | 5.11 | The effects of clozapine and risperidone on spatial working memory in schizophrenia. ( Carter, C; Goldman, R; Green, MF; Kane, JM; Marder, SR; McGurk, SR; Schooler, NR; Xie, H, 2005) |
| "In a 50-week, open-label trial, stable patients with schizophrenia or schizoaffective disorder who received long-acting risperidone injection every 2 weeks were assessed using the Positive and Negative Syndrome Scale (PANSS)." | 5.11 | Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. ( Bossie, CA; Gharabawi, GM; Kane, JM; Lasser, RA, 2005) |
| "Clinically stable subjects with schizophrenia or schizoaffective disorder participated in a 50-week, open-label trial of long-acting, injectable risperidone." | 5.11 | An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. ( Bossie, CA; Gharabawi, GM; Lasser, RA; Mao, L; Zhu, Y, 2005) |
| "This analysis aimed to assess the relationship between race and clinical response to long-acting, injectable risperidone treatment in patients with schizophrenia or schizoaffective disorder." | 5.11 | Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Ciliberto, N; Lasser, RA; Urioste, R, 2005) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 5.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 5.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment." | 5.11 | Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. ( Frazzingaro, S; Gastpar, M; Latif, MA; Lombertie, ER; Masiak, M; Medori, R, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 5.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "This open-label, multicentre study investigated the clinical efficacy of liquid peroral risperidone in psychotic disorders, the patients' attitudes toward the study medication vs." | 5.11 | Risperidone liquid in psychotic disorders--efficacy and attitudes. ( Damjanović, A; Jasović-Gasić, M; Marić, N, 2005) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 5.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "In a prospective, single-blinded, naturalistic study, a cohort of subjects (n=150) with schizophrenia or schizo-affective disorder (DSM-IV) were switched from conventional neuroleptic drugs to either risperidone (n=50), olanzepine (n=50) or quetiapine (n=50), and monitored for a period of 2 to 6 years." | 5.10 | Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. ( Awad, A; Cernovsky, Z; Cortese, L; Kotteda, V; Owyeumi, L; Voruganti, L; Zirul, S, 2002) |
| "In a double-blind, fixed-dose study, 49 acutely psychotic, neuroleptic-naive patients who were admitted for the first time and who met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder were randomly assigned to 2 or 4 mg/day of risperidone." | 5.10 | Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. ( Berger, G; Gekle, W; Hofer, H; Latour, G; Marder, SR; Merlo, MC; Panhuber, I; Ventura, J, 2002) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 5.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 5.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial." | 5.10 | The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. ( Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "We describe the design of a multicenter, randomized clinical trial to compare clinical, quality-of-life, and economic outcomes in patients with schizophrenia or schizoaffective disorder who were treated with risperidone or any of 13 conventional antipsychotic drugs approved for use in the United States." | 5.09 | The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. ( Engelhart, L; Mahmoud, R; Ollendorf, D; Oster, G, 1999) |
| " In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders." | 5.09 | Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders. ( Adler, CM; Breier, A; Elman, I; Malhotra, AK; Pickar, D; Su, TP; Weisenfeld, NI, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 5.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "Studies have shown that risperidone is safe and efficacious in young and middle-aged adults with chronic schizophrenia, but considerably fewer data are available on the treatment of elderly patients with schizophrenia or other psychotic disorders, particularly long-term outcomes." | 5.09 | A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. ( Barak, Y; Bray, G; Davidson, M; De Hooge, JD; Dose, M; Gagiano, CA; Harvey, PD; Haushofer, M; Vervarcke, J, 2000) |
| "Positron emission tomography (PET) was used to measure the effects of the atypical antipsychotic, risperidone, on glucose metabolism in eight first-episode schizophrenia patients." | 5.09 | Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. ( Lane, CJ; Liddle, PF; Ngan, ET, 2000) |
| "Two hundred nine outpatients with a DSM-IV diagnosis of schizophrenia or schizo-affective disorder who were clinically stable while being treated with a conventional antipsychotic drug or risperidone were openly randomly assigned to either abrupt or gradual discontinuation of their prior antipsychotic drug." | 5.09 | Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. ( Basson, BR; Gilmore, JA; Kinon, BJ; Malcolm, S; Stauffer, VL, 2000) |
| "Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)." | 5.09 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 5.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 5.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 5.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| "We describe a consecutive series of 21 patients with HIV or AIDS who received risperidone for psychotic disorders." | 5.08 | Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. ( Catalan, J; Golledge, H; Singh, AN, 1997) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Combination lithium, a mood stabilizer, and risperidone, an atypical antipsychotic drug, is widely used for treatment of psychotic disorders." | 4.93 | Neurotoxicity and nephrotoxicity caused by combined use of lithium and risperidone: a case report and literature review. ( Hsu, CW; Lee, CY; Lee, Y; Lin, PY, 2016) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 4.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 4.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| "In the 10 studies analyzed, the taste of RD risperidone tablets was found to be acceptable in the majority of healthy subjects and patients with schizophrenia or schizoaffective disorder." | 4.84 | Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. ( D'Hoore, P; Kushner, S; Mannaert, E; Remmerie, B; Thyssen, A, 2007) |
| " There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo." | 4.83 | The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. ( Ballard, C; Waite, J, 2006) |
| "Relevant data relating to the dosage of risperidone identified through an online (MEDLINE) search using the keywords risperidone, schizophrenia, schizoaffective disorder dementia, bipolar disorder, and dose were supplemented by a review of international and U." | 4.81 | Optimal dosing with risperidone: updated recommendations. ( Williams, R, 2001) |
| "A computerized search, using the MEDLINE database (1966-summer 2000), located cases of priapism associated with most conventional antipsychotics as well as with clozapine, risperidone, and olanzapine." | 4.81 | Priapism associated with conventional and atypical antipsychotic medications: a review. ( Compton, MT; Miller, AH, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone." | 4.80 | Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. ( Buckley, P; Hasan, S, 1998) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 4.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| "Risperidone (Risperdal, Janssen Pharmaceutica) is a second generation antipsychotic (SGA) for the treatment of schizophrenia and other psychotic disorders." | 4.80 | Pharmacology and clinical experience with risperidone. ( Love, RC; Nelson, MW, 2000) |
| " To report the case of a 53-year-old patient who developed neuroleptic malignant syndrome (NMS) - a rare but potentially life-threatening complication of neuroleptic therapy - 4 days after treatment with risperidone was initiated." | 4.79 | Risperidone-induced neuroleptic malignant syndrome: a case report and review. ( Meterissian, GB, 1996) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| " The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)." | 4.12 | Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022) |
| "Clozapine is a second-generation antipsychotic typically reserved for refractory psychotic disorders due to its high-risk side effect profile to include agranulocytosis, with its attendant need for regular blood draws." | 3.91 | An Unexpected Circumstance: Acute Dystonic Reaction in the Setting of Clozapine Administration. ( Ahmed, I; Kaplan, AM; Pitts, WB, 2019) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 3.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| " In this study, 264 Han Chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks." | 3.88 | T ( Gao, M; Gao, Y; He, Y; Jiang, R; Li, J; Li, S; Li, WD; Lv, H; Wang, L; Wang, X; Xu, C; Zhang, M, 2018) |
| "This study aimed to assess the comparative effectiveness of risperidone (RIS) versus aripiprazole (ARP) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment." | 3.88 | Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2018) |
| " The authors examined the risk of developing gestational diabetes associated with the continuation of treatment with aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine during pregnancy compared with discontinuation of these antipsychotic drugs." | 3.88 | Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. ( Bateman, BT; Cohen, JM; Cohen, LS; Desai, RJ; Glynn, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E, 2018) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "Thirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months." | 3.85 | Cognition and Dopamine D ( Caravaggio, F; Gerretsen, P; Graff-Guerrero, A; Mamo, DC; Mar, W; Mulsant, BH; Nakajima, S; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2017) |
| "This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase." | 3.85 | Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2017) |
| "The aim of this study was to find out whether elevated serum levels (≥5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone." | 3.83 | Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2016) |
| "Clozapine is an atypical antipsychotic primarily prescribed for treatment-resistant schizophrenia." | 3.83 | Gene-expression analysis of clozapine treatment in whole blood of patients with psychosis. ( Breen, G; Curtis, CJ; de Jong, S; Dempster, D; Dima, D; Gaughran, F; Harrison, RN; Lee, SH; Murray, RM; Paya Cano, J, 2016) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| "Objective of this observational trial is to examine the effects of quetiapine in comparison with olanzapine and risperidone on clinical outcomes and quality of life in patients with schizophrenia and schizoaffective disorder in routine care." | 3.78 | Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. ( Becker, T; Croissant, D; Eschweiler, GW; Frasch, K; Jaeger, S; Kilian, R; Längle, G; Messer, T; Pfiffner, C; Schepp, W; Steinert, T; Weiser, P, 2012) |
| "A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study." | 3.78 | Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. ( Barteček, R; Juřica, J; Kašpárek, T; Pindurová, E; Žourková, A; Zrůstová, J, 2012) |
| "In subproject Ι, 45 patients receiving the 2nd generation antipsychotics risperidone, clozapine or olanzapine were compared regarding prolactin (PRL), body mass index (BMI), insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and blood lipids." | 3.77 | Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. ( Berinder, K; Hulting, AL; Melkersson, K, 2011) |
| "To identify the factors associated with newly prescribed, first-line, second-generation antipsychotics (SgAs) associated with weight gain-olanzapine, risperidone, and quetiapine." | 3.77 | Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. ( Arndt, S; Chrischilles, EA; Coryell, WH; Ellingrod, VL; Fiedorowicz, JG; Haynes, WG; Miller, del D; Prabhakar, M; Warren, L, 2011) |
| " In the present study we investigated the influence of two common MDR1 polymorphisms on the improvement of psychopathological symptoms and occurrence of extrapyramidal side effects (EPS) in Slovenian schizophrenia patients acutely treated with risperidone." | 3.76 | MDR1 gene polymorphisms and response to acute risperidone treatment. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Locatelli, I; Mandelli, L; Plesnicar, BK; Serretti, A, 2010) |
| "To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta)." | 3.76 | The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. ( Berntsson, A; Eriksson, B; Löthgren, M; Persson, U; Svensson, M; Willis, M, 2010) |
| "This was a prospective 6-month, open-label, multicentre, phase IV trial in 303 subjects with recent onset ( | 3.76 | Correlates, change and 'state or trait' properties of insight in schizophrenia. ( David, AS; Lex, A; Rabinowitz, J; Wiffen, BD, 2010) |
| "Thirteen subjects aged 50 (mean +/- standard deviation age: 62 +/- 9 years) with schizophrenia or schizoaffective disorder who were receiving risperidone." | 3.75 | Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. ( Graff-Guerrero, A; Kapur, S; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H, 2009) |
| "We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders." | 3.75 | A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. ( De Sarro, G; Ferraro, M; Gallelli, L; Palleria, C; Spagnuolo, V, 2009) |
| "This 12-week open-label study was designed to investigate the pharmacokinetics and efficacy of a direct switch from a conventional depot to long-acting injectable risperidone in patients with schizophrenia and schizoaffective disorder." | 3.75 | Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. ( Chen, CH; Chiu, CC; Huang, MC; Lai, YC; Pan, CH; Tsai, CJ, 2009) |
| "To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia." | 3.75 | Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. ( Dirani, R; Flanders, S; Fuller, M; Russo, P; Secic, M; Shermock, K; Vallow, S, 2009) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 3.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "In this paper, we report on two subjects with psychotic disorders who were found to have peripheral edema during olanzapine therapy." | 3.75 | [Edema related to treatment with olanzapine]. ( Fiedler, T; Gutmann, P; Wustmann, T, 2009) |
| " His hallucinations and delusions remitted after treatment with risperidone, paralleling motor improvement." | 3.74 | Psychosis following acute Sydenham's chorea. ( Cardoso, F; Maia, DP; Teixeira, AL, 2007) |
| "The study was a retrospective analysis of administrative data from the New York-New Jersey region of the Veterans Health Administration for 2,436 individuals with schizophrenia or schizoaffective disorder who were prescribed risperidone from January 2001 through March 2003." | 3.74 | Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. ( Dellenbaugh, C; Weissman, EM, 2007) |
| "The authors conducted a prospective observational study of women treated with an atypical antipsychotic or haloperidol during pregnancy." | 3.74 | Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. ( Beach, AJ; Calamaras, MR; DeVane, CL; Donovan, J; Gibson, BB; Knight, BT; Nemeroff, CB; Newport, DJ; Owens, MJ; Stowe, ZN; Viguera, AC; Winn, S, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology." | 3.74 | Evaluating dose response from flexible dose clinical trials. ( Adams, DH; Baron, D; Faries, D; Houston, JP; Lipkovich, I; Mallinckrodt, C, 2008) |
| "To monitor long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone long-acting injectable (RLAI)." | 3.74 | Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. ( Kissling, W; Llorca, PM; Lloyd, K; Medori, R; Sacchetti, E, 2008) |
| "This retrospective study aimed to compare differences in hepatic enzyme elevation during treatment with either risperidone or olanzapine alone in patients with psychotic disorders." | 3.73 | Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. ( Kim, JJ; Kim, TS; Lee, C; Lee, CU; Lee, SJ; Lim, HK; Pae, CU; Paik, IH, 2005) |
| "Blood samples taken from 25 patients with psychotic disorders following 6 weeks of treatment with risperidone (mean dose=3 mg/day) were examined." | 3.73 | Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. ( Baselmans, P; Bosker, F; Bruggeman, R; Castelein, S; Knegtering, R; van den Bosch, RJ, 2005) |
| " The objective of this study was to apply a disease-specific utility mapping function for schizophrenia to data from a large, 1-year, open-label study of long-acting risperidone and to compare its performance with an SF-36-based utility mapping function." | 3.73 | Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. ( Elnitsky, C; Lenert, LA; Rupnow, MF, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 3.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Atypical antipsychotics, especially clozapine and olanzapine, have been increasingly associated with weight gain and other adverse metabolic events (diabetes mellitus, hyperlipidemia) in non-mentally retarded populations." | 3.73 | Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. ( Ball, MP; Bodfish, JW; Heeth, WL; Mahorney, SL; McKee, JR, 2005) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 3.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "After achieving stabilization with one of the doses, nine patients with a diagnosis of schizophrenia or schizoaffective disorder underwent [(11)C]raclopride PET to measure D(2) occupancy." | 3.73 | A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ( Kapur, S; Labelle, A; Mamo, D; Mann, S; Mannaert, E; Reiss, J; Remington, G; Shammi, C, 2006) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 3.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 3.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol." | 3.73 | Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders. ( Gorobets, LN, 2005) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 3.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "Twenty patients with psychotic disorders, on therapy with risperidone, were studied." | 3.73 | Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. ( Melkersson, KI, 2006) |
| " Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS-UK) program consisted of a retrospective review of medical notes and prescription charts for 501 patients with schizophrenia or schizoaffective disorder who had been admitted to the hospital for the treatment of psychosis." | 3.72 | Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. ( Libretto, SE; Taylor, DM; Wright, T, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 3.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "Positron emission tomography with the radioligands [(11)C]SCH23390 and [(11)C]raclopride was used to investigate D(1) and D(2) receptor occupancy in vivo in 25 schizophrenia patients receiving atypical antipsychotic treatment with clozapine, olanzapine, quetiapine, or risperidone." | 3.72 | Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. ( Agid, O; Houle, S; Hussain, T; Kapur, S; Remington, G; Tauscher, J; Verhoeff, NP; Wilson, AA; Zipursky, RB, 2004) |
| "To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder." | 3.72 | Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. ( Binder, C; Chue, P; Welch, R, 2004) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "Several years ago, we reported that the addition of risperidone to clozapine improved response in some patients with schizophrenia." | 3.71 | Risperidone added to clozapine: impact on serum prolactin levels. ( Borba, CP; Connolly, CE; Goff, DC; Hayden, D; Henderson, DC, 2001) |
| "This large study provides additional evidence that risperidone is effective and well tolerated when combined with mood stabilizers in the treatment of bipolar disorder and schizoaffective disorder, bipolar type." | 3.71 | Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. ( Benabarre, A; Colom, F; Corbella, B; Fernández, A; Goikolea, JM; Martínez, G; Martínez-Arán, A; Reinares, M; Torrent, C; Vieta, E, 2001) |
| "Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with conventional antipsychotic agents were compared by both between-group and within-group comparisons." | 3.71 | Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. ( Durkin, MB; Gianfrancesco, F; Mahmoud, R; Wang, RH, 2002) |
| "They obtained computerized pharmacy data on 1,283 inpatients with the diagnoses of schizophrenia or schizoaffective disorder who were treated with risperidone." | 3.70 | Alteration in the recommended dosing schedule for risperidone. ( Hanrahan, P; Harris, J; Klass, D; Luchins, DJ; Malan, R, 1998) |
| "We report on the occurrence of galactorrhea associated with a prolactin elevation within weeks of treatment with risperidone." | 3.70 | Risperidone-induced galactorrhea associated with a prolactin elevation. ( Gupta, S; Popli, A; Rangwani, SR, 1998) |
| "We present a case of a 74-year-old patient with schizoaffective disorder, who developed risperidone-related neuroleptic malignant syndrome." | 3.70 | High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. ( Devarajan, S; Dursun, SM; Kutcher, SP; Oluboka, OJ, 1998) |
| "A patient with schizoaffective disorder developed signs of catatonia while on a regimen of valproic acid, sertraline, and risperidone." | 3.70 | Catatonia-like events after valproic acid with risperidone and sertraline. ( Lauterbach, EC, 1998) |
| "One hundred sixty patients were discharged on risperidone, 75 having the diagnosis of schizophrenia." | 3.70 | Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. ( Bartko, JJ; Conley, RR; Kelly, DL; Love, RC, 1999) |
| "We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea." | 3.70 | Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999) |
| "During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain." | 3.70 | Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999) |
| "Serum triglyceride levels of four patients with psychotic disorders were decreased after switching therapy from clozapine to risperidone." | 3.70 | Elevated serum triglycerides with clozapine resolved with risperidone in four patients. ( Dufresne, RL; Ghaeli, P, 1999) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 3.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 3.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia." | 3.69 | Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. ( Findling, RL; Friedman, L; Grcevich, SJ; Rowane, WA; Schulz, SC, 1996) |
| "The effects of risperidone treatment on health care utilization and treatment costs were examined among patients with treatment-refractory schizophrenia or schizoaffective disorder." | 3.69 | Impact of risperidone on the use of mental health care resources. ( Durkin, M; Engelhart, L; Lawrence, BJ; Maislin, G; Mechling, L; Viale, G, 1997) |
| " Despite no statistically significant differences between groups regarding clinical efficacy, aripiprazole required higher chlorpromazine equivalent dosage (χ 2 = 2." | 3.11 | Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial. ( Ayesa-Arriola, R; Crespo-Facorro, B; Garrido-Sánchez, L; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-Van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Ruiz-Veguilla, M; Vázquez-Bourgon, J, 2022) |
| "Risperidone has been shown in several trials to have a statistically significant benefit when used in a therapeutic context." | 3.01 | Neuropharmacological effect of risperidone: From chemistry to medicine. ( Afzal, O; Al-Abbasi, FA; Alfawaz Altamimi, AS; Almalki, WH; Alzarea, SI; Bhat, AA; Dua, K; Gupta, G; Kazmi, I; Singh, SK, 2023) |
| " inverted U) association between changes in dentate gyrus/CA4 volume and cumulative antipsychotic dosage between the scans." | 2.84 | Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis. ( Gallego, JA; Malhotra, AK; Rhindress, K; Robinson, DG; Szeszko, PR; Wellington, R, 2017) |
| " Age, gender, years of education, total intracranial volume, apolipoprotein E genotype, dosage of risperidone, the baseline scores on the Korean version of the Mini-Mental State Examination, and the baseline psychotic and nonpsychotic symptoms scores on the K-NPI were measured as covariates of no interest." | 2.82 | Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients. ( Chung, YI; Jeong, HJ; Kim, HJ; Kim, JH; Kim, TH; Kim, YH; Lee, BD; Lee, YM; Moon, E; Mun, CW; Park, JM, 2016) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 2.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| "Risperidone was superior to Quetiapine in decreasing the PANSS general psychopathology sub-scores and total score (p<0." | 2.80 | Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study. ( Ahmadi, M; Mojtahedi, D; Monajemi, MB; Moosavi, SM; Yazdani, J, 2015) |
| "Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia." | 2.80 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. ( Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP, 2015) |
| "Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and antipsychotic class were examined as possible predictive variables." | 2.79 | Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. ( Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R, 2014) |
| "Psychotic disorders are characterized by significant deficits in attentional control, but the neurobiological mechanisms underlying these deficits early in the course of illness prior to extensive pharmacotherapy are not well understood." | 2.79 | Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. ( Gallego, JA; Gruner, P; Ikuta, T; John, M; Kane, J; Malhotra, AK; Peters, BD; Robinson, DG; Sevy, S; Szeszko, PR, 2014) |
| "Duration of untreated psychosis (DUP) has been significantly associated with poor clinical and social outcomes in First Episode Psychosis (FEP) patients, but an association with cognitive outcomes has not been clearly established." | 2.77 | Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. ( Campos, MS; Cuesta, MJ; García de Jalón, E; Ibáñez, B; Peralta, V; Sánchez-Torres, AM, 2012) |
| "Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD." | 2.76 | Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. ( Barak, Y; Paleacu, D; Plopski, I; Tadger, S, 2011) |
| "Risperidone was significantly more likely to be associated with elevation in serum prolactin levels in this population." | 2.75 | A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. ( Black, VC; Bobier, CM; Buchan, JC; Craig, BJ; Pirwani, NZ; Swadi, HS, 2010) |
| " Sixty-nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs)." | 2.75 | Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. ( Curtis, V; Hawley, C; Latif, MA; Saleem, PT; Turner, M; Wilton, K, 2010) |
| "Ziprasidone was superior to risperidone in decreasing the PANSS positive symptoms subscore and the CGI-S score, and in increasing the GAF-F score." | 2.75 | Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. ( Johnsen, E; Jørgensen, HA; Kroken, RA; Wentzel-Larsen, T, 2010) |
| " Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation." | 2.75 | Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. ( Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Johnson, JL; Kaufman, EM; Lieberman, JA; Lingler, J; Maloney, AE; McClellan, J; McNamara, NK; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Vitiello, B, 2010) |
| "Chronic management of schizophrenia and schizoaffective disorders is frequently complicated by symptomatic relapse." | 2.75 | Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. ( Bergmans, P; Cordes, J; de Arce, R; Eriksson, L; Gaebel, W; Rouillon, F; Schreiner, A; Smeraldi, E, 2010) |
| " Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile." | 2.73 | Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. ( Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008) |
| " Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were assessed as measures of safety and tolerability." | 2.73 | Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. ( Chan, HY; Chiang, SC; Hwang, TJ; Hwu, HG; Lin, SK; Lin, WW; Su, TP, 2007) |
| " Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction." | 2.73 | Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. ( Glue, P; Kissling, W; Medori, R; Simpson, S, 2007) |
| "Risperidone is an atypical antipsychotic drug with combined dopamine-2/serotonin-2 (D(2)/5-HT(2)) antagonist activity that has been effective in reducing cocaine use in some animal studies." | 2.73 | A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. ( Angarita, GA; Culhane, MA; Evins, AE; Huang, KL; Lee, SH; Loebl, T; Logvinenko, T; Nino, J; Pachas, GN, 2008) |
| "Psychosis has been identified in as many as 68% of patients with bipolar mania." | 2.73 | Psychotic symptoms in patients with bipolar mania. ( Bossie, CA; Canuso, CM; Dunner, DL; Youssef, E; Zhu, Y, 2008) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "In this systematic literature review (SLR), we qualitatively synthesized evidence on the comparative efficacy (based on neuropsychiatric inventory), tolerability (weight gain), and safety (cerebrovascular adverse events [CVAE], cardiovascular events, mortality, somnolence, extrapyramidal symptoms [EPS]) of AAPs used to treat DRP." | 2.72 | Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. ( Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I, 2021) |
| "Over the last ten years, the treatment of psychosis has seen a near explosion of creative development in both novel agents and new delivery modalities." | 2.72 | New Antipsychotic Medications in the Last Decade. ( El-Mallakh, RS; Elsayed, OH; Good, ME; Pahwa, M; Sleem, A, 2021) |
| "Aripiprazole was significantly inferior to olanzapine (SMD = 1." | 2.72 | Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. ( Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S, 2021) |
| "Antipsychotic (AP) dosing is well established in nonelderly patients with acute exacerbations of schizophrenia, but not in special populations." | 2.72 | Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. ( Baloche, E; Blin, O; Bourgin-Duchesnay, J; Corruble, E; Ferreri, F; Garay, RP; Llorca, PM; Mouaffak, F; Vandel, P; Vidailhet, P, 2021) |
| "Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine." | 2.72 | Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders. ( Balshaw, R; Kopala, L; Love, L; Malla, A; Smith, G; Talling, D; Williams, R, 2006) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 2.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ." | 2.72 | A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006) |
| "Risperidone was well tolerated with minimal extrapyramidal symptoms." | 2.71 | Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. ( Arana, GW; Faldowski, RA; Frueh, BC; Hamner, MB; Huber, MG; Ulmer, HG, 2003) |
| "The treatment of schizoaffective disorder is often complicated by the variety of symptoms that contribute to its pathology." | 2.71 | Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. ( Bossie, CA; Eerdekens, M; Gharabawi, G; Lasser, R; Nasrallah, HA, 2004) |
| " The failure to confirm previous claims of greater improvement on either risperidone or olanzapine in patients with a first episode of psychosis may be the result of methodological bias introduced by unequal dosing between the two drugs or the use of chronically ill and treatment-refractory patients in previous studies." | 2.71 | A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. ( Haricharan, R; Malla, A; Manchanda, R; Norman, R; Scholten, D; Takhar, J; Townsend, L, 2004) |
| "Lorazepam was administered to all of the patients assigned to risperidone and to 89% of those assigned to zuclopenthixol." | 2.71 | Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. ( Dries, PJ; Hovens, JE; Loonen, AJ; Melman, CT; Wapenaar, RJ, 2005) |
| "Amoxapine was associated with less EPS and less prolactin elevation than risperidone." | 2.71 | Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. ( Apiquian, R; de la Fuente-Sandoval, C; Fresan, A; Herrera-Estrella, M; Kapur, S; Nicolini, H; Ulloa, RE; Vazquez, A, 2005) |
| "Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD." | 2.71 | Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| "Patients aged > or = 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25 mg (increased to 37." | 2.71 | Long-acting risperidone in stable patients with schizoaffective disorder. ( Benoit, M; Bräunig, P; Lex, A; Medori, R; Mohl, A; Opjordsmoen, S; Schreiner, A; Westlye, K, 2005) |
| " Treatment was naturalistic, and dosing was based on the discretion of the treating physician." | 2.71 | Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. ( Cook, A; Kraus, JE; Lieberman, JA; Reviere, R; Sheitman, BB, 2005) |
| "Eligible patients had psychoses and demonstrated 1 of several DSM-IV diagnoses, including schizoaffective disorder, bipolar I disorder, major depressive disorder, delusional disorder, Alzheimer's dementia, schizophreniform disorder, vascular dementia, and substance abuse dementia." | 2.70 | Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. ( Mullen, JA; Sajatovic, M; Sweitzer, DE, 2002) |
| " The mean risperidone dosage was 2." | 2.70 | Risperidone in the treatment of first episode psychosis. ( Lee, A; Lim, D; Liow, PH; Mahendran, R; Phang, S; Tiong, A; Yap, HL, 2001) |
| "Risperidone was well tolerated; side effects were few and generally mild." | 2.70 | Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). ( Benabarre, A; Colom, F; Fernández, A; Gastó, C; Herraiz, M; Martínez-Arán, A; Reinares, M; Vieta, E, 2001) |
| " Doses were adjusted to maximize efficacy and to minimize adverse events." | 2.70 | A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. ( Jibson, MD; Mullen, J; Sweitzer, D, 2001) |
| " The severity and incidence of extrapyramidal symptoms and adverse events did not significantly increase when fluoxetine was added." | 2.70 | The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ( Baumann, P; Bertschy, G; Bondolfi, G; Eap, CB; Vermeulen, A; Zullino, D, 2002) |
| " A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6." | 2.69 | Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. ( Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H, 1998) |
| "Risperidone, at lower than recommended doses, shows promise in the treatment of late onset delusional disorders and behavior syndrome of dementia." | 2.69 | Risperidone: treatment response in adult and geriatric patients. ( Ancill, RJ; Gibson, RE; Holliday, SG; Kiraly, SJ, 1998) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Risperidone was better tolerated than haloperidol: the severity of extrapyramidal symptoms was significantly lower in the risperidone-treated patients; significantly fewer risperidone-treated patients required antiparkinsonian medication; and significantly fewer discontinued treatment because of adverse events." | 2.69 | Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. ( Emsley, RA, 1999) |
| "Although the mean motor Unified Parkinson's Disease Rating Scale score worsened in the risperidone group and improved in the clozapine group, this difference did not reach statistical significance." | 2.69 | Clozapine and risperidone treatment of psychosis in Parkinson's disease. ( Cudkowicz, ME; Ellis, T; Growdon, JH; Sexton, PM, 2000) |
| "Risperidone is an "atypical" antipsychotic with strong binding affinity for dopamine-2 and serotonin-2 receptors." | 2.69 | Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. ( Feifel, D; Moutier, CY; Perry, W, 2000) |
| "Cyclical menstrual psychosis is an uncommon, generally a self-limiting mental illness that occurs only in females." | 2.58 | An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature. ( Birur, B; Cohen, AW; Nagaraja, S; Thippaiah, SM, 2018) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| "Insufficient treatment of psychosis often manifests as violent and aggressive behaviors that are dangerous to the patient and others, and that warrant treatment strategies which are not considered first-line, evidence-based practices." | 2.50 | Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. ( Morrissette, DA; Stahl, SM, 2014) |
| "Treatment with olanzapine, risperidone and clozapine is often associated with weight gain." | 2.49 | Atypical antipsychotics for psychosis in adolescents. ( Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD, 2013) |
| " It is well-tolerated and rather safe for elderly patients." | 2.48 | [Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders]. ( Bocharov, AV; Kondakova, VE; Tuleninov, ES, 2012) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "Turner syndrome encompasses several chromosomal abnormalities and includes a typical clinical manifestation." | 2.45 | [Turner-syndrome and psychosis: a case report and brief review of the literature]. ( Preuss, UW; Wustmann, T, 2009) |
| "Even though akathisia is less prevalent with SGAs than with the first-generation drugs, it remains clinically important and all clinicians should be conversant with its recognition and management." | 2.45 | Akathisia and second-generation antipsychotic drugs. ( Kumar, R; Sachdev, PS, 2009) |
| "In patients with a psychotic disorder, substance abuse is a major problem." | 2.45 | Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. ( de Haan, L; Machielsen, MW, 2009) |
| "Risperidone is a relatively well-tolerated compound when it is prescribed at doses lower than 4 mg/d." | 2.44 | [Atypical antipsychotics in first-episode psychosis: a review]. ( Aouizerate, B; Rotgé, JY; Tignol, J, 2008) |
| "All of the medications developed for treatment of psychosis rely on tertiary prevention, and there is no a priori reason to assume that these treatments would be the safest and most effective primary preventive treatment of first-episode psychosis." | 2.44 | Serotonin and dopamine interactions in psychosis prevention. ( McNamara, RK; Richtand, NM, 2008) |
| " Mean CLZ dosage during the combined treatment was 474." | 2.43 | Risperidone augmentation of clozapine: a critical review. ( Christodoulou, GN; Ferentinos, PP; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG; Pappa, DA, 2006) |
| " The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another." | 2.42 | New antipsychotics and schizophrenia: a review on efficacy and side effects. ( Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004) |
| "However, diagnosis of schizoaffective disorder is included both in DSM-IV-TR and ICD-10." | 2.41 | [Schizoaffective disorder: clinical symptoms and present-day approach to treatment]. ( Danileviciūte, V, 2002) |
| "Risperidone is a relatively new antipsychotic available world-wide since the early 1990s." | 2.41 | Focus on risperidone. ( Green, B, 2000) |
| "Monosymptomatic hypochondriacal psychoses such as delusions of parasitosis are often difficult to treat." | 2.41 | Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. ( Elmer, KB; George, RM; Peterson, K, 2000) |
| "Patients with Alzheimer's disease exhibit aggressive behavior, and alterations in their serotonergic function have been identified." | 2.41 | Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. ( Mintzer, JE, 2001) |
| " This series covers four main areas of concern when treating the elderly: low-maintenance dosing minimising the likelihood of adverse events; successful treatment of patients previously uncontrolled and experiencing side effects with other antipsychotics; the possibility of intermittent rather than continuous treatment; and the benefits to patients, carers and the health services." | 2.41 | Risperidone in the treatment of psychoses in the elderly: a case report series. ( Bullock, R; Libretto, S, 2002) |
| "Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment." | 2.41 | Tardive dyskinesias and antipsychotics: a review. ( Bayle, FJ; Chereau, I; Lancon, C; Llorca, PM, 2002) |
| "Risperidone may be an alternative for treatment-resistant schizophrenia, but this has not yet been clearly proved." | 2.40 | New antipsychotic medications: what advantages do they offer? ( Citrome, L, 1997) |
| "Antipsychotic drugs are effective in psychoses, whatever the aetiology of the disorder." | 2.40 | Recent developments in the management of psychosis. ( Hoes, MJ, 1998) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| "Significant consequences of untreated psychosis in patients with dementia have led clinicians to seek improved therapeutic options." | 2.40 | Pharmacologic management of psychosis in dementia. ( Schneider, LS, 1999) |
| "2." | 2.39 | Psychosis in Parkinson's disease: diagnosis and treatment. ( Deveaugh-Geiss, J; Doraiswamy, M; Martin, W; Metz, A, 1995) |
| " Antipsychotic use in the elderly should be accompanied by careful conservative dosing and close patient monitoring." | 2.39 | Management of late-life psychosis. ( Eastham, JH; Field, MG; Gierz, M; Harris, MJ; Jeste, DV; Lacro, JP, 1996) |
| "In acute treatment studies of schizoaffective disorder, bipolar type (manic), typical antipsychotics and lithium were comparable in efficacy except in agitated patients for whom antipsychotics were superior." | 2.39 | New developments in the pharmacologic treatment of schizoaffective disorder. ( Keck, PE; McElroy, SL; Strakowski, SM, 1996) |
| "Risperidone has a relatively mild side effect profile when compared with conventional antipsychotics." | 2.39 | Clinical experience with risperidone. ( Marder, SR, 1996) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "It is possible that weight gain is mainly driven by APs." | 1.72 | Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. ( Bartels-Velthuis, AA; Bruggeman, R; Burin, LM; Cahn, W; da Rocha, NS; de Haan, L; Hahn, MK; Schirmbeck, F; Simons, CJP; van Amelsvoort, T; van Os, J, 2022) |
| "25 mg/day (85 years, MMSE of 5), to 1 mg/day (75 years, MMSE of 15), with alternate day dosing required for those with slower drug clearance." | 1.62 | Towards safer risperidone prescribing in Alzheimer's disease. ( Bertrand, J; Bies, R; Bramon, E; Howard, R; Liu, KY; Otani, Y; Ozer, M; Pollock, BG; Reeves, S; Uchida, H; Yoshida, K, 2021) |
| "Cotard syndrome was first described in 1880 by Jules Cotard as a novel subtype of anxious depression and is presently understood as a rare cluster of mood and psychotic symptoms centered on nihilistic delusions including the absence of organs and a perception of being dead." | 1.62 | Cotard Syndrome in an Adolescent With a First Episode of Psychosis. ( Boles, MK; Boyanchek, I; McGreal, AE, 2021) |
| "Little is known about the influence of substance use on side effects." | 1.62 | The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. ( Alisauskiene, R; Gjestad, R; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM, 2021) |
| "Duration of untreated psychosis (DUP) is one of the few potentially modifiable outcome predictors in psychosis." | 1.56 | Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis. ( Belangeiro, SI; Bressan, RA; Cavalcante, DA; Cordeiro, Q; Coutinho, LS; Gadelha, A; Noto, C; Noto, MN; Ortiz, BB; Ota, VK, 2020) |
| "Hyperprolactinemia was found in 120 (70." | 1.56 | Prolactin response to antipsychotics: An inpatient study. ( Bredicean, CA; Dehelean, L; Dumitrascu, V; Papava, I; Romosan, AM; Romosan, RS; Ursoniu, S, 2020) |
| " The goal of the study was to develop physiologically based pharmacokinetic (PBPK) models for the elderly aged 65+ years." | 1.56 | Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. ( Hempel, G; Kneller, LA, 2020) |
| " We showed that chronic administration of risperidone did not affect the DNA methylation status at this CpG site using common marmosets, and that in vitro DNA methylation at this CpG site diminished the promoter activity of SLC6A4." | 1.56 | Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia. ( Abe, O; Asai, T; Bundo, M; Fukunaga, M; Hashimoto, R; Ikeda, M; Ikegame, T; Ishigooka, J; Iwamoto, K; Iwashiro, N; Iwata, N; Kakiuchi, C; Kasai, K; Kato, T; Kawamura, Y; Koike, S; Koshiyama, D; Murata, Y; Natsubori, T; Nishimura, F; Okada, N; Owada, K; Saito, T; Sasaki, T; Sugawara, H; Yamashita, F; Yamasue, H; Yoshikawa, A, 2020) |
| " The duration of each adequate antipsychotic treatment at an optimal dosage was 4 weeks or more." | 1.51 | Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. ( Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019) |
| "Agmatine is an endogenous NMDA (N-methyl-d-aspartate) antagonist which is synthesized from l-Arginine and described as a novel neurotransmitter." | 1.51 | l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients. ( Garip, B; Kayir, H; Uzun, O, 2019) |
| "Treatment with risperidone significantly suppressed the IRS and CIRS." | 1.51 | Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. ( Belangero, SI; Bressan, RA; Cordeiro, Q; Gadelha, A; Maes, M; Noto, C; Noto, MN; Nunes, SOV; Ota, VK; Rossaneis, AC; Verri, WA, 2019) |
| "The aim of the study is to find a relationship between the individual intervariability of CYP2D6 and the incidence of hyperprolactinemia as side effect of atypical antipsychotics." | 1.51 | Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. ( Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019) |
| "1288 risperidone-treated patients and 1334 aripiprazole-treated patients were included in the study, of whom 725 (56%) risperidone-treated and 890 (67%) aripiprazole-treated patients were eligible for the pharmacokinetic analyses." | 1.51 | Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. ( Haslemo, T; Ingelman-Sundberg, M; Jukic, MM; Molden, E; Smith, RL, 2019) |
| " We report that low-dose risperidone treatment results in global immunosuppression in mice, observed following 5 days of dosing and exacerbated with longer term drug treatment (4 weeks)." | 1.51 | The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. ( Barlow, D; Beauchemin, M; Houseknecht, KL; May, M; Vary, C, 2019) |
| "Olanzapine (6 mg/kg) treatment significantly altered glucose and lipid homeostasis which was further accompanied by elevated levels of proinflammatory cytokines, ghrelin and leptin." | 1.51 | Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. ( Bansal, Y; Kuhad, A; Medhi, B; Saroj, P; Singh, R; Sodhi, RK, 2019) |
| "Risperidone with MECT was beneficial for the patient in our case." | 1.48 | A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy. ( Bai, Y; Yang, H; Yang, X; Zeng, Z, 2018) |
| " In a naturalistic cohort of chronic psychiatric inpatients, we demonstrated that clinicians adjust R dosage by CYP2D6 activity, despite being blinded to the genotype, which we described as an "intuitive pharmacogenetic" process." | 1.46 | Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. ( Bernardo, M; Bioque, M; Bobes, J; Castro-Fornieles, J; Corripio, I; Gassó, P; González-Pinto, A; Lafuente, A; Llerena, A; Lobo, A; Mas, S; Olmeda, MS; Rodriguez-Jimenez, R; Saiz-Ruiz, J; Torra, M; Usall, J; Vieta, E, 2017) |
| "Given this rare manifestation of arsenic poisoning for which there is no clearly defined treatment regimen, this case suggests that the use of a combination of an antipsychotic and an antidepressant may be considered in the rare event of psychosis with obsessive-compulsive features following arsenic poisoning." | 1.46 | An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning. ( Abdel-Gawad, NM; Gharbaoui, Y; Pigott, TA; Teixeira, AL; Wu, HE, 2017) |
| "Risperidone is a poorly water soluble atypical antipsychotic drug." | 1.43 | Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone. ( Ghorab, MM; Ibrahim, HK; Mohammed, KA, 2016) |
| "Risperidone monotherapy was the primary antipsychotic treatment." | 1.43 | Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. ( Badner, JA; Bishop, JR; Harris, MS; Keshavan, MS; Nimgaonkar, VL; Patel, SR; Prasad, KM; Reilly, JL; Stevenson, JM; Sweeney, JA; Weiden, PJ, 2016) |
| " NMS occurs most often during the first week of treatment or after increasing the dosage of the neuroleptic medication." | 1.43 | [Case report: Neuroleptic malignant syndrome and diagnostic difficulties]. ( Khouri, C; Logerot, S; Mallaret, M; Planès, S; Villier, C, 2016) |
| " The incremental dosage of olanzapine from 5 to 20 mg/day was given but failed to control her psychotic symptoms during the first week, and was therefore switched to risperidone." | 1.42 | Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour. ( Pongpirul, K; Puangthong, U, 2015) |
| "Risperidone treatment significantly increased PON1 activity and decreased LOOH levels." | 1.42 | Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. ( Barbosa, DS; Belangero, SI; Bonifácio, KL; Bressan, RA; Brietzke, E; Cordeiro, Q; Gadelha, A; Maes, M; Noto, C; Noto, MN; Nunes, SO; Ota, VK, 2015) |
| "Authors identified different types of eating disorders: external, restrictive and emotiogenic as well as the relationship of their prevalence and severity with sex, drug, presence and grade of obesity." | 1.42 | [Eating disorders in psychiatric patients during treatment with second generation antipsychotics]. ( Bulanov, VS; Gorobets, LN; Ivanova, GP; Litvinov, AV; Polyakovskaya, TP; Tsarenko, MA; Vasilenko, LM, 2015) |
| "The main goal in the treatment of psychotic disorders is to obtain a functional remission and to reduce the incidence of relapse." | 1.39 | [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. ( Bouju, S; Chiariny, JF; Comet, D; Delgado, A; Misdrahi, D, 2013) |
| "Schizophrenia is one of the most expensive psychiatric illnesses." | 1.39 | Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. ( Chow, DP; Chung, WS; Lee, EH; Lee, KK; Lee, VW; Wong, MC; Wu, DB, 2013) |
| "Psychiatric illnesses following cerebrovascular accidents has been a popular area of research in recent times." | 1.39 | Poststroke psychosis in an 8-year-old child with moyamoya disease. ( Gnanavel, S, 2013) |
| "Veterans with schizophrenia or schizoaffective disorder who were actually more satisfied with their current medications and who were currently taking the experimental agent were more likely to agree to participate in this randomized clinical trial in contrast to expectations that individuals who are unsatisfied with their current treatment would be more likely to enroll in such studies." | 1.39 | Veteran subjects willingness to participate in schizophrenia clinical trials. ( Hoblyn, JC; Leatherman, S; Lew, R; Rosenheck, RA; Weil, L, 2013) |
| "Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction." | 1.39 | Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. ( Franch, J; Labad, J; López, X; Monseny, R; Montalvo, I; Ortega, L; Solé, M; Vilella, E, 2013) |
| "A shorter duration of untreated psychosis has been associated with better prognosis in schizophrenia." | 1.39 | Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. ( Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M, 2013) |
| " Analysis of the ways in which the test results were reportedly utilized revealed that they generally played a supporting role with regard to dosing decisions, rather than being the main influence on clinician behaviour." | 1.38 | Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice. ( Butler, R; Dunbar, L; Miles, W; Pulford, J; Sheridan, J; Wheeler, A, 2012) |
| "Risperidone was started to treat psychotic symptoms." | 1.38 | Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. ( Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H, 2012) |
| "Risperidone was discontinued and, owing to ongoing psychosis, olanzapine was initiated." | 1.38 | Antipsychotics leading to neuroleptic malignant syndrome in pregnancy. ( Aghajanian, P; Dossett, E; Ghaffari, N; Lee, RH, 2012) |
| ": Among 5,391 individuals with parkinsonism who died during the study period (2002-2008) and a matched comparison group of 25,937 who were still alive, individuals exposed to atypical antipsychotic drugs had a higher risk of death (unadjusted odds ratio [OR] = 2." | 1.38 | Antipsychotics and mortality in Parkinsonism. ( Anderson, GM; Fischer, H; Gill, SS; Gruneir, A; Herrmann, N; Hyson, C; Marras, C; Rochon, PA; Wang, X, 2012) |
| "Steady-state plasma RIS, 9-OH-RIS, and active moiety levels were measured in 64 patients treated with an average dosage of 4." | 1.38 | Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. ( Fukui, N; Inoue, Y; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2012) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "Risperidone LAT was typically used with recommended age and diagnostic groups." | 1.37 | Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. ( Becker, MA; Boaz, TL; Constantine, RJ; Howe, AM; Robst, J, 2011) |
| "Later, Wegener's granulomatosis, a rare form of autoimmune induced vasculitis, was diagnosed." | 1.37 | [Delusion of parasitosis due to Wegener's granulomatosis]. ( Schmoll, D, 2011) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 1.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| " In this work we will present a 14-year old girl adolescent with psychotic symptoms, in which case the course of treatment and discontinuance of therapy was caused by a side effect - an oculogyric crisis." | 1.36 | The influence of side effect of antipsychotic on the course of treatment in adolescent. ( Dadić-Hero, E; Francisković, T; Graovac, M; Rebić, J; Ruzić, K, 2010) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| " Deficits were unrelated to drug dosage and clinical ratings." | 1.35 | Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia. ( Harris, MS; Keshavan, MS; Lencer, R; Reilly, JL; Sprenger, A; Sweeney, JA, 2008) |
| "Asenapine was highly potent (active at 0." | 1.35 | Asenapine effects in animal models of psychosis and cognitive function. ( Azar, MR; Geyer, MA; Gold, L; Marston, HM; Martin, FD; Meltzer, LT; Moore, CL; Serpa, KA; Shahid, M; Wong, EH; Young, JW, 2009) |
| "Narcolepsy is characterized by symptoms that include excessive sleepiness during the daytime, cataplexy, hypnagogic hallucinations and sleep paralysis." | 1.35 | Narcolepsy and psychotic states--a case report. ( Daliahu, Y; Melamed, Y; Paleacu, D, 2009) |
| "Significant weight gain is a serious side effect of many antipsychotic medications, yet successful strategies for significant weight loss are lacking." | 1.34 | Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? ( Akhtar-Danesh, N; Archie, SM; Goldberg, JO; Landeen, J; McColl, L; McNiven, J, 2007) |
| "Central pontine and extrapontine myelinolysis (CPEM) are rare conditions usually associated with rapid correction of hyponatremia." | 1.34 | Psychotic disorder in a patient with central and extrapontine myelinolysis. ( Krystal, A; Lim, L, 2007) |
| " During the subsequent week, rates of problem behavior typically decreased without reinstating the prior dosage of medication." | 1.34 | Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates. ( Dornbusch, K; Rapp, JT; Swanson, G, 2007) |
| " Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients." | 1.34 | Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. ( Aichhorn, W; Hinterhuber, H; Kemmler, G; Marksteiner, J; Stuppaeck, C; Walch, T; Zernig, G, 2007) |
| "Risperidone was the most commonly cited agent." | 1.33 | Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? ( Pandurangi, A; Silverman, JJ; Sood, AB; Vieweg, WV, 2005) |
| "Risperidone therapy was initiated because there was no remission after carbamazepine and sodium valproate treatment." | 1.33 | A case of psychosis with temporal lobe epilepsy: SPECT changes with treatment. ( Deda, G; Oner, O; Unal, O, 2005) |
| " These results suggest that a low dosage of levomepromazine, use as a sedative adjuvant to risperidone treatment, have no statistically significant effect on the trough plasma concentrations of risperidone." | 1.33 | Little effects of low dosage of levomepromazine on plasma risperidone levels. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "The risperidone-treated subjects demonstrated changes in grey matter and white matter in several brain regions, including superior temporal gyrus." | 1.33 | Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. ( Diwadkar, VA; Girgis, RR; Hardan, AY; Keshavan, MS; Nutche, JJ; Sweeney, JA, 2006) |
| "Risperidone treatment significantly elevated serum PRL level (range: 26." | 1.33 | The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. ( Kim, YK; Lee, BH, 2006) |
| "Risperidone plasma levels were determined and psychopathologic evaluations (Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale) were carried out." | 1.33 | Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. ( Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Martin, JC; Pérez, V; Schotte, A, 2006) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| "Risperidone is a widely used atypical antipsychotic with certain advantages over typical antipsychotics." | 1.32 | Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. ( Ikeda, M; Iwata, N; Kitajima, T; Ozaki, N; Suzuki, T; Yamanouchi, Y, 2003) |
| "Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2." | 1.32 | Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004) |
| " The failure to improve without an adequate dosage of LT4 suggests that hypothyroidism was probably an aggravating factor." | 1.32 | Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up. ( Alshari, MG; Bhatara, A; Bhatara, V; McMillin, JM; Warhol, P, 2004) |
| "Olanzapine has been considered to be similar to clozapine, but olanzapine intoxication appeared to have a relatively benign clinical course as compared with clozapine intoxication." | 1.32 | [Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław]. ( Antończyk, A; Kochman, K; Magdalan, J; Porebska, B; Przewłocki, M; Wasyko-Smolarek, M, 2004) |
| "Existing treatment options for bipolar depression include lithium, lamotrigine and conventional antidepressants." | 1.32 | Bipolar depression: the role of atypical antipsychotics. ( Calabrese, JR; Post, RM, 2004) |
| "2198 risperidone-treated patients were identified versus 3259 treated with other antipsychotics." | 1.31 | A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. ( Allingham, BH; Cienfuegos, A; Javitt, DC; Levine, J; Miniati, M; Robinson, J; Silipo, G, 2002) |
| "Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
| "Hyperprolactinemia is a side effect related to antipsychotics that can cause galactorrhea, gynecomastia, amenorrhea, anovulation, impaired spermatogenesis, decreased libido and sexual arousal, impotence, and anorgasmia, consequent to removal of tonic dopaminergic inhibition of prolactin secretion via hypothalamic dopaminergic receptor blockade in the tuberoinfundibolar tract." | 1.31 | Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. ( Keller, R; Mongini, F, 2002) |
| "The interictal "schizophrenia-like" psychoses of epilepsy conventionally are treated with antipsychotic medication with uncertain results." | 1.31 | Treatment of the interictal psychoses. ( Blumer, D; Montouris, G; Wakhlu, S; Wyler, AR, 2000) |
| "Less convincing suggestions relate jet lag to psychosis." | 1.31 | [Jet lag causing or exacerbating psychiatric disorders]. ( Durst, R; Katz, G; Knobler, H; Knobler, HY; Zislin, J, 2000) |
| "Risperidone has a substantial cost advantage over olanzapine, and was preferred by psychiatrists for more indications." | 1.31 | Comparison of cost, dosage and clinical preference for risperidone and olanzapine. ( Kaplan, Z; Lichtenberg, P; Rabinowitz, J, 2000) |
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 1.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| "Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications." | 1.31 | Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001) |
| "Usher's syndrome is a genetic disorder that causes congenital sensorineural hearing loss, visual impairment due to progressive pigmentary retinopathy, and, often, vestibular dysfunction." | 1.31 | The relationship between Usher's syndrome and psychosis with Capgras syndrome. ( Medalia, A; Waldeck, T; Wyszynski, B, 2001) |
| "Risperidone is an atypical antipsychotic drug which has been suggested to be beneficial for the treatment of elderly patients with psychotic symptoms." | 1.31 | The efficacy and safety of risperidone for the treatment of geriatric psychosis. ( Chang, JW; Cheng, CY; Hwang, JP; Tsai, SJ; Yang, CH; Yu, HC, 2001) |
| "A positive family history of Huntington's disease and DNA analysis helped to establish the diagnosis." | 1.30 | Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. ( Brafman, I; Brenner, R; Madhusoodanan, S; Moise, D; Sindagi, J, 1998) |
| "When treated with risperidone 2 mg/day, both his sleep and the delusional thoughts improved markedly and his daytime alertness increased." | 1.30 | Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. ( Gross, Y; Klag, E; Pick, CG; Schreiber, S; Segman, RH, 1998) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| "As risperidone use has risen each year since its introduction, mean doses in both inpatients and discharged patients have steadily declined." | 1.30 | A dose-outcome analysis of risperidone. ( Bartko, JJ; Conley, RR; Kelly, DL; Love, RC, 1999) |
| "Risperidone was more commonly used in combination with benzodiazepines and anticholinergics than olanzapine and clozapine, while clozapine was less likely to be combined with antidepressants and mood stabilisers." | 1.30 | Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. ( Altson, K; Bootle, A; Culhane, C; Doherty, P; Hope, J; Keks, NA; Krapivensky, N; Tanaghow, A, 1999) |
| "Risperidone appears to be an effective and well tolerated antipsychotic for elderly patients with chronic psychosis." | 1.29 | Outcome of risperidone therapy in elderly patients with chronic psychosis. ( Brescan, D; Jurjus, G; Ramirez, LF; Sajatovic, M; Simon, M; Vernon, L, 1996) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| "Risperidone was well tolerated despite this adolescent's severe cardiac and pulmonary illnesses." | 1.29 | Use of risperidone in psychotic disorder following ischemic brain damage. ( DeMaso, DR; Steingard, RJ; Zimnitzky, BM, 1996) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| "Risperidone (R 64766) was administered during 4 weeks in increasing doses to 17 psychotic patients, to evaluate the hematological and cardiovascular safety, the therapeutic effect, side effects, effects upon endocrinological parameters and the pharmacokinetic profile." | 1.28 | Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. ( Burton, P; Gelders, Y; Heylen, S; Mesotten, F; Pietquin, M; Suy, E, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.12) | 18.7374 |
| 1990's | 125 (14.45) | 18.2507 |
| 2000's | 383 (44.28) | 29.6817 |
| 2010's | 287 (33.18) | 24.3611 |
| 2020's | 69 (7.98) | 2.80 |
| Authors | Studies |
|---|---|
| Mattsson, C | 1 |
| Andreasson, T | 1 |
| Waters, N | 1 |
| Sonesson, C | 1 |
| Banerjee, A | 1 |
| Narayana, L | 1 |
| Raje, FA | 1 |
| Pisal, DV | 1 |
| Kadam, PA | 1 |
| Gullapalli, S | 1 |
| Kumar, H | 1 |
| More, SV | 1 |
| Bajpai, M | 1 |
| Sangana, RR | 1 |
| Jadhav, S | 1 |
| Gudi, GS | 1 |
| Khairatkar-Joshi, N | 1 |
| Merugu, RR | 1 |
| Voleti, SR | 1 |
| Gharat, LA | 1 |
| Yunusa, I | 2 |
| Rashid, N | 2 |
| Abler, V | 1 |
| Rajagopalan, K | 2 |
| Reyes-Madrigal, F | 3 |
| Guma, E | 1 |
| León-Ortiz, P | 4 |
| Gómez-Cruz, G | 1 |
| Mora-Durán, R | 1 |
| Graff-Guerrero, A | 5 |
| Kegeles, LS | 1 |
| Chakravarty, MM | 1 |
| de la Fuente-Sandoval, C | 6 |
| Dagenais-Beaulé, V | 1 |
| Pahwa, M | 1 |
| Sleem, A | 1 |
| Elsayed, OH | 1 |
| Good, ME | 1 |
| El-Mallakh, RS | 1 |
| Delgado-Sallent, C | 1 |
| Nebot, P | 1 |
| Gener, T | 1 |
| Fath, AB | 1 |
| Timplalexi, M | 1 |
| Puig, MV | 1 |
| Mühlbauer, V | 1 |
| Möhler, R | 1 |
| Dichter, MN | 1 |
| Zuidema, SU | 2 |
| Köpke, S | 1 |
| Luijendijk, HJ | 1 |
| Demos, GN | 1 |
| Mahadik, BS | 1 |
| Abler, VC | 1 |
| Taurines, R | 1 |
| Fekete, S | 1 |
| Preuss-Wiedenhoff, A | 1 |
| Warnke, A | 1 |
| Wewetzer, C | 1 |
| Plener, P | 1 |
| Burger, R | 1 |
| Gerlach, M | 1 |
| Romanos, M | 1 |
| Egberts, KM | 1 |
| Zeng, J | 1 |
| Raballo, A | 1 |
| Gan, R | 1 |
| Wu, G | 1 |
| Wei, Y | 1 |
| Xu, L | 1 |
| Tang, X | 1 |
| Hu, Y | 1 |
| Tang, Y | 1 |
| Chen, T | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Zhang, T | 1 |
| Jannini, TB | 1 |
| Sansone, A | 1 |
| Rossi, R | 1 |
| Di Lorenzo, G | 1 |
| Toscano, M | 1 |
| Siracusano, A | 1 |
| Jannini, EA | 1 |
| Lian, L | 1 |
| Kim, DD | 1 |
| Procyshyn, RM | 3 |
| Cázares, D | 1 |
| Honer, WG | 4 |
| Barr, AM | 2 |
| Vázquez-Bourgon, J | 4 |
| Ortiz-García de la Foz, V | 7 |
| Gómez-Revuelta, M | 4 |
| Mayoral-van Son, J | 3 |
| Juncal-Ruiz, M | 5 |
| Garrido-Torres, N | 1 |
| Crespo-Facorro, B | 24 |
| Burin, LM | 1 |
| Hahn, MK | 1 |
| da Rocha, NS | 1 |
| van Amelsvoort, T | 2 |
| Bartels-Velthuis, AA | 1 |
| Bruggeman, R | 3 |
| de Haan, L | 8 |
| Schirmbeck, F | 1 |
| Simons, CJP | 1 |
| van Os, J | 4 |
| Cahn, W | 1 |
| Garrido-Sánchez, L | 1 |
| Pelayo-Terán, JM | 12 |
| Ruiz-Veguilla, M | 1 |
| Ayesa-Arriola, R | 6 |
| Ikeda, M | 3 |
| Saito, T | 2 |
| Kanazawa, T | 1 |
| Kishi, T | 1 |
| Iwata, N | 3 |
| Hefner, G | 3 |
| Wolff, J | 1 |
| Toto, S | 1 |
| Reißner, P | 1 |
| Klimke, A | 1 |
| Bhat, AA | 2 |
| Gupta, G | 2 |
| Afzal, O | 2 |
| Kazmi, I | 2 |
| Al-Abbasi, FA | 2 |
| Alfawaz Altamimi, AS | 2 |
| Almalki, WH | 2 |
| Alzarea, SI | 2 |
| Singh, SK | 2 |
| Dua, K | 2 |
| Rogowska, M | 2 |
| Thornton, M | 2 |
| Creese, B | 2 |
| Velayudhan, L | 2 |
| Aarsland, D | 2 |
| Ballard, C | 3 |
| Tsamakis, K | 2 |
| Stewart, R | 2 |
| Mueller, C | 2 |
| Li, Z | 1 |
| Zong, X | 2 |
| Li, D | 1 |
| He, Y | 2 |
| Tang, J | 1 |
| Hu, M | 2 |
| Chen, X | 2 |
| Nelson, EA | 2 |
| Kraguljac, NV | 5 |
| Maximo, JO | 2 |
| Armstrong, W | 1 |
| Lahti, AC | 6 |
| Hsueh, L | 1 |
| Iturralde, E | 1 |
| Slama, NE | 1 |
| Spalding, SR | 1 |
| Sterling, SA | 1 |
| Rivera-Chávez, LF | 1 |
| Torres-Ruíz, J | 1 |
| Carrillo-Vázquez, D | 1 |
| Moncada-Habib, T | 1 |
| Cassiano-Quezada, F | 1 |
| Cadenhead, KS | 1 |
| Gómez-Martín, D | 1 |
| Allott, K | 2 |
| Yuen, HP | 4 |
| Baldwin, L | 2 |
| O'Donoghue, B | 2 |
| Fornito, A | 2 |
| Chopra, S | 2 |
| Nelson, B | 6 |
| Graham, J | 2 |
| Kerr, MJ | 1 |
| Proffitt, TM | 1 |
| Ratheesh, A | 1 |
| Alvarez-Jimenez, M | 3 |
| Harrigan, S | 2 |
| Brown, E | 1 |
| Thompson, AD | 2 |
| Pantelis, C | 4 |
| Berk, M | 2 |
| McGorry, PD | 7 |
| Francey, SM | 4 |
| Wood, SJ | 3 |
| MacNeill, BR | 1 |
| Opatrny, PM | 1 |
| Burke, MS | 1 |
| Heinen, LJ | 1 |
| Dysken, MW | 1 |
| Thurstone, C | 1 |
| Loh, R | 1 |
| Foreman, K | 1 |
| Thurstone, CA | 1 |
| Wolf, C | 1 |
| Kurhan, F | 1 |
| Aktas, S | 1 |
| Mustafa, S | 1 |
| Joober, R | 1 |
| Iyer, S | 2 |
| Shah, J | 1 |
| Lepage, M | 1 |
| Malla, A | 4 |
| van Renterghem, L | 1 |
| Titeca, K | 1 |
| Crunelle, CL | 1 |
| Geerts, P | 1 |
| Matthys, F | 1 |
| Cavalcante, DA | 2 |
| Coutinho, LS | 1 |
| Ortiz, BB | 3 |
| Noto, MN | 4 |
| Cordeiro, Q | 10 |
| Ota, VK | 10 |
| Belangeiro, SI | 1 |
| Bressan, RA | 11 |
| Gadelha, A | 11 |
| Noto, C | 10 |
| Gründer, P | 1 |
| Augustin, M | 1 |
| Paulzen, M | 1 |
| Gründer, G | 1 |
| Balamurugan, R | 1 |
| Gupta, PC | 1 |
| Kashyap, H | 1 |
| Ram, J | 1 |
| Melbourne, JK | 1 |
| Pang, Y | 2 |
| Park, MR | 1 |
| Sudhalkar, N | 1 |
| Rosen, C | 1 |
| Sharma, RP | 2 |
| Armstrong, WP | 1 |
| Suárez-Pinilla, P | 5 |
| Romero-Jiménez, R | 1 |
| Setién Suero, E | 1 |
| Dehelean, L | 1 |
| Romosan, AM | 1 |
| Papava, I | 1 |
| Bredicean, CA | 1 |
| Dumitrascu, V | 1 |
| Ursoniu, S | 1 |
| Romosan, RS | 1 |
| Birur, B | 2 |
| VerHoef, L | 1 |
| Morgan, CJ | 2 |
| Jindal, RD | 2 |
| Reid, MA | 2 |
| Luker, A | 1 |
| Pathak, S | 2 |
| Jiang, Y | 1 |
| DiPetrillo, L | 1 |
| Todtenkopf, MS | 1 |
| Liu, Y | 1 |
| Correll, CU | 6 |
| Xavier, G | 2 |
| Santoro, ML | 5 |
| Spindola, LM | 5 |
| Oliveira, G | 2 |
| Vieira, T | 1 |
| Micali, D | 1 |
| de Jong, S | 3 |
| Breen, G | 2 |
| Belangero, SI | 9 |
| Herrera-Huerta, CA | 1 |
| Hernández-Salas, LP | 1 |
| Magallanes-Cano, EM | 1 |
| Anthony, T | 1 |
| Burger, MS | 1 |
| Dhandapani, VR | 1 |
| Ramachandran, P | 1 |
| Mohan, G | 1 |
| Chandrasekaran, S | 1 |
| Paul, V | 1 |
| Pattabiraman, R | 1 |
| Mohan, M | 1 |
| Rangaswamy, T | 1 |
| Singh, SP | 1 |
| Clark, I | 1 |
| Taylor, D | 5 |
| Kneller, LA | 1 |
| Hempel, G | 1 |
| Ikegame, T | 1 |
| Bundo, M | 1 |
| Okada, N | 1 |
| Murata, Y | 1 |
| Koike, S | 1 |
| Sugawara, H | 1 |
| Owada, K | 1 |
| Fukunaga, M | 1 |
| Yamashita, F | 1 |
| Koshiyama, D | 1 |
| Natsubori, T | 1 |
| Iwashiro, N | 1 |
| Asai, T | 1 |
| Yoshikawa, A | 1 |
| Nishimura, F | 1 |
| Kawamura, Y | 1 |
| Ishigooka, J | 1 |
| Kakiuchi, C | 1 |
| Sasaki, T | 2 |
| Abe, O | 1 |
| Hashimoto, R | 1 |
| Yamasue, H | 2 |
| Kato, T | 1 |
| Kasai, K | 1 |
| Iwamoto, K | 1 |
| Teodorescu, A | 1 |
| Dima, L | 1 |
| Popa, MA | 1 |
| Moga, MA | 1 |
| Bîgiu, NF | 1 |
| Ifteni, P | 1 |
| Taylor, JH | 2 |
| Appel, S | 1 |
| Eli, M | 1 |
| Alexander-Bloch, A | 1 |
| Maayan, L | 1 |
| Gur, RE | 1 |
| Bloch, MH | 2 |
| Marques, DF | 1 |
| Talarico, F | 1 |
| Costa, GO | 1 |
| Cogo-Moreira, H | 1 |
| Carvalho, CM | 1 |
| Moretti, PN | 1 |
| Anta, L | 2 |
| Mata, E | 1 |
| Ochoa Díaz de Monasterioguren, L | 1 |
| Miller, M | 1 |
| Barbe, N | 1 |
| Poulsen, RJ | 1 |
| Coffey, BJ | 4 |
| Reeves, S | 1 |
| Bertrand, J | 1 |
| Uchida, H | 6 |
| Yoshida, K | 1 |
| Otani, Y | 1 |
| Ozer, M | 1 |
| Liu, KY | 1 |
| Bramon, E | 1 |
| Bies, R | 1 |
| Pollock, BG | 10 |
| Howard, R | 2 |
| Smith, RL | 2 |
| Tveito, M | 1 |
| Kyllesø, L | 1 |
| Jukic, MM | 2 |
| Ingelman-Sundberg, M | 2 |
| Andreassen, OA | 1 |
| Molden, E | 2 |
| Lyall, AE | 1 |
| Nägele, FL | 1 |
| Pasternak, O | 1 |
| Gallego, JA | 10 |
| Malhotra, AK | 12 |
| McNamara, RK | 4 |
| Kubicki, M | 1 |
| Peters, BD | 5 |
| Robinson, DG | 12 |
| Szeszko, PR | 7 |
| Catalan, A | 2 |
| García, L | 1 |
| Sanchez-Alonso, S | 1 |
| Gil, P | 1 |
| Díaz-Marsá, M | 1 |
| Olivares, JM | 1 |
| Rivera-Baltanás, T | 1 |
| Pérez-Martín, J | 1 |
| Torres, MÁG | 1 |
| Ovejero, S | 1 |
| Tost, M | 1 |
| Bergé, D | 1 |
| Rodríguez, A | 1 |
| Labad, J | 2 |
| Haddad, PM | 1 |
| Al Abdulla, M | 1 |
| Latoo, J | 1 |
| Iqbal, Y | 1 |
| Srisurapanont, M | 1 |
| Likhitsathian, S | 1 |
| Suttajit, S | 1 |
| Maneeton, N | 1 |
| Maneeton, B | 1 |
| Oon-Arom, A | 1 |
| Suradom, C | 1 |
| Govindarajulu, U | 1 |
| Ostuzzi, G | 2 |
| Bertolini, F | 1 |
| Del Giovane, C | 1 |
| Tedeschi, F | 1 |
| Bovo, C | 1 |
| Gastaldon, C | 1 |
| Nosé, M | 1 |
| Ogheri, F | 1 |
| Papola, D | 1 |
| Purgato, M | 1 |
| Turrini, G | 1 |
| Barbui, C | 3 |
| Cropley, V | 1 |
| Tahtalian, S | 1 |
| Sabaroedin, K | 1 |
| McGorry, P | 3 |
| Parker, C | 1 |
| Slan, A | 1 |
| Shalev, D | 1 |
| Critchfield, A | 1 |
| Otsuki, K | 1 |
| Izuhara, M | 1 |
| Miura, S | 1 |
| Yamashita, S | 1 |
| Nagahama, M | 1 |
| Hayashida, M | 1 |
| Hashioka, S | 1 |
| Miyaoka, T | 1 |
| Hotta, Y | 1 |
| Shimizu, Y | 1 |
| Inagaki, M | 1 |
| Setién-Suero, E | 2 |
| Canfrán-Duque, A | 1 |
| Pastor, Ó | 1 |
| García-Seisdedos, D | 1 |
| Molina, YL | 1 |
| Babiy, B | 1 |
| Lerma, M | 1 |
| Sánchez-Castellano, C | 1 |
| Martínez-Botas, J | 1 |
| Gómez-Coronado, D | 1 |
| Lasunción, MA | 1 |
| Cruz-Jentoft, AJ | 1 |
| Busto, R | 1 |
| McGreal, AE | 1 |
| Boles, MK | 1 |
| Boyanchek, I | 1 |
| Rush Ortegon, E | 1 |
| Ferguson, J | 1 |
| Fan, YS | 1 |
| Li, H | 1 |
| Guo, J | 1 |
| Li, L | 1 |
| Li, M | 1 |
| Wang, C | 1 |
| Sheng, W | 1 |
| Liu, H | 1 |
| Gao, Q | 1 |
| Chen, H | 2 |
| Ou, H | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Tzeng, NS | 1 |
| Maes, M | 4 |
| Vargas Nunes, SO | 1 |
| Cavalcante, D | 1 |
| Rossaneis, AC | 2 |
| Verri, WA | 2 |
| Mouaffak, F | 1 |
| Ferreri, F | 1 |
| Bourgin-Duchesnay, J | 1 |
| Baloche, E | 1 |
| Blin, O | 1 |
| Vandel, P | 1 |
| Garay, RP | 1 |
| Vidailhet, P | 1 |
| Corruble, E | 1 |
| Llorca, PM | 4 |
| Alisauskiene, R | 1 |
| Johnsen, E | 5 |
| Gjestad, R | 1 |
| Kroken, RA | 5 |
| Jørgensen, HA | 5 |
| Løberg, EM | 4 |
| Rasmussen, JØ | 1 |
| Jennum, P | 1 |
| Linnet, K | 1 |
| Glenthøj, BY | 1 |
| Baandrup, L | 1 |
| Lavretsky, H | 1 |
| Wilby, KJ | 1 |
| Johnson, EG | 1 |
| Johnson, HE | 1 |
| Ensom, MHH | 1 |
| Mas, S | 3 |
| Gassó, P | 3 |
| Torra, M | 1 |
| Bioque, M | 2 |
| Lobo, A | 1 |
| González-Pinto, A | 2 |
| Olmeda, MS | 1 |
| Corripio, I | 3 |
| Vieta, E | 4 |
| Castro-Fornieles, J | 2 |
| Rodriguez-Jimenez, R | 1 |
| Bobes, J | 2 |
| Usall, J | 1 |
| Llerena, A | 2 |
| Saiz-Ruiz, J | 2 |
| Bernardo, M | 4 |
| Lafuente, A | 3 |
| Bahramabadi, R | 1 |
| Samadi, M | 1 |
| Vakilian, A | 1 |
| Jafari, E | 1 |
| Fathollahi, MS | 1 |
| Arababadi, MK | 1 |
| Đorđević, SM | 1 |
| Santrač, A | 1 |
| Cekić, ND | 1 |
| Marković, BD | 1 |
| Divović, B | 1 |
| Ilić, TM | 1 |
| Savić, MM | 1 |
| Savić, SD | 1 |
| Ramirez-Bonilla, M | 7 |
| Gomez-Arnau, J | 1 |
| Martinez-Garcia, O | 14 |
| Neergaard, KD | 1 |
| Tabares-Seisdedos, R | 5 |
| Gabriel, D | 1 |
| Jakubovski, E | 1 |
| Artukoglu, BB | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Selvakumar, N | 1 |
| Kuppili, PP | 1 |
| Bharadwaj, B | 1 |
| Kandasamy, P | 1 |
| Santos, M | 1 |
| Madhusoodanan, S | 9 |
| Kaur, K | 1 |
| Brenner, R | 7 |
| Foster, A | 1 |
| Buckley, P | 2 |
| Lauriello, J | 3 |
| Looney, S | 1 |
| Schooler, N | 2 |
| Wu, HE | 1 |
| Abdel-Gawad, NM | 1 |
| Gharbaoui, Y | 1 |
| Teixeira, AL | 2 |
| Pigott, TA | 1 |
| Kaplan, AM | 1 |
| Pitts, WB | 1 |
| Ahmed, I | 1 |
| Mao, X | 1 |
| Rodríguez-Mayoral, O | 1 |
| Jung-Cook, H | 1 |
| Solís-Vivanco, R | 1 |
| Shungu, DC | 1 |
| Li, S | 1 |
| Gao, Y | 1 |
| Lv, H | 1 |
| Zhang, M | 1 |
| Wang, L | 1 |
| Jiang, R | 1 |
| Xu, C | 1 |
| Wang, X | 3 |
| Gao, M | 1 |
| Li, J | 2 |
| Li, WD | 1 |
| Hanlon, C | 1 |
| Chatterjee, S | 1 |
| Eaton, J | 1 |
| Jones, L | 1 |
| Silove, D | 1 |
| Ventevogel, P | 1 |
| Xia, L | 1 |
| Li, WZ | 1 |
| Liu, HZ | 1 |
| Hao, R | 1 |
| Zhang, XY | 1 |
| Nesvåg, R | 2 |
| Bramness, JG | 1 |
| Handal, M | 1 |
| Hartz, I | 1 |
| Hjellvik, V | 1 |
| Skurtveit, S | 1 |
| Fortea, A | 1 |
| Ilzarbe, D | 1 |
| Espinosa, L | 1 |
| Solerdelcoll, M | 1 |
| de Castro, C | 1 |
| Oriolo, G | 1 |
| Sugranyes, G | 1 |
| Baeza, I | 3 |
| Yoshimura, Y | 2 |
| Takeda, T | 2 |
| Kishi, Y | 2 |
| Harada, T | 2 |
| Nomura, A | 2 |
| Washida, K | 2 |
| Yoshimura, B | 4 |
| Sato, K | 3 |
| Yada, Y | 2 |
| Aoki, S | 2 |
| Prakash, R | 1 |
| Aggarwal, N | 1 |
| Kataria, D | 1 |
| Prasad, S | 1 |
| Sakamoto, S | 1 |
| Takaki, M | 1 |
| Yamada, N | 1 |
| Bai, Y | 1 |
| Yang, X | 1 |
| Zeng, Z | 1 |
| Yang, H | 1 |
| Schmidt, SJ | 1 |
| Behar, A | 1 |
| Schultze-Lutter, F | 1 |
| Schoretsanitis, G | 1 |
| Drukker, M | 1 |
| Schruers, KRJ | 1 |
| Bak, M | 2 |
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Xiong, Y | 1 |
| Narang, P | 1 |
| Lippman, S | 1 |
| Thippaiah, SM | 1 |
| Nagaraja, S | 1 |
| Cohen, AW | 1 |
| Park, Y | 1 |
| Hernandez-Diaz, S | 2 |
| Bateman, BT | 2 |
| Cohen, JM | 2 |
| Desai, RJ | 2 |
| Patorno, E | 2 |
| Glynn, RJ | 1 |
| Cohen, LS | 1 |
| Mogun, H | 2 |
| Huybrechts, KF | 2 |
| Thusius, N | 1 |
| Romanowicz, M | 1 |
| Mlynek, K | 1 |
| Sola, C | 1 |
| Fuchs, PA | 1 |
| Miller, L | 1 |
| Schiff, M | 1 |
| Riesco-Dávila, L | 1 |
| Ocejo-Viñals, JG | 1 |
| Leza, JC | 1 |
| López-Hoyos, M | 1 |
| Gimenez-Donoso, S | 1 |
| Treen-Calvo, D | 1 |
| Tirapu-Ustarroz, J | 1 |
| Kumar, P | 1 |
| Efstathopoulos, P | 1 |
| Millischer, V | 1 |
| Olsson, E | 1 |
| Wei, YB | 1 |
| Brüstle, O | 1 |
| Schalling, M | 1 |
| Villaescusa, JC | 1 |
| Ösby, U | 1 |
| Lavebratt, C | 1 |
| John, M | 5 |
| Hanna, LA | 1 |
| Zhang, JP | 4 |
| Birnbaum, ML | 1 |
| Greenberg, J | 2 |
| Naraine, M | 2 |
| Dias Alves, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Simon, N | 1 |
| Vion-Dury, J | 1 |
| Kc, Y | 1 |
| Baldridge, HM | 1 |
| Ojha, R | 1 |
| Mantere, O | 1 |
| Trontti, K | 1 |
| García-González, J | 1 |
| Balcells, I | 1 |
| Saarnio, S | 1 |
| Mäntylä, T | 1 |
| Lindgren, M | 1 |
| Kieseppä, T | 1 |
| Raij, T | 1 |
| Honkanen, JK | 1 |
| Vaarala, O | 1 |
| Hovatta, I | 1 |
| Suvisaari, J | 1 |
| Salgueiro, M | 1 |
| Segarra, R | 2 |
| Garip, B | 1 |
| Kayir, H | 1 |
| Uzun, O | 1 |
| Nunes, SOV | 1 |
| Wakuda, T | 1 |
| Suzuki, A | 1 |
| Hasegawa, M | 1 |
| Ichikawa, D | 1 |
| Schoemakers, RJ | 1 |
| van Kesteren, C | 1 |
| van Rosmalen, J | 1 |
| Eussen, MLJM | 1 |
| Dieleman, HG | 1 |
| Beex-Oosterhuis, MM | 1 |
| Grădinaru, R | 1 |
| Andreescu, N | 1 |
| Nussbaum, L | 1 |
| Suciu, L | 1 |
| Puiu, M | 1 |
| Kanahara, N | 4 |
| Yoshimura, K | 1 |
| Nakamura, M | 3 |
| Oda, Y | 1 |
| Watanabe, M | 1 |
| Iyo, M | 4 |
| Haslemo, T | 1 |
| Seeman, MV | 1 |
| Pitzianti, M | 1 |
| Casarelli, L | 1 |
| Pontillo, M | 1 |
| Vicari, S | 1 |
| Armando, M | 1 |
| Pasini, A | 1 |
| Kaštelan, A | 1 |
| Hladnik, A | 1 |
| Petrić, D | 1 |
| Gudelj, L | 1 |
| Graovac, M | 2 |
| Fadili, A | 1 |
| Attouche, N | 1 |
| Charra, B | 1 |
| Alami, KM | 1 |
| Agoub, M | 1 |
| May, M | 1 |
| Beauchemin, M | 1 |
| Vary, C | 1 |
| Barlow, D | 1 |
| Houseknecht, KL | 1 |
| Fowler, JC | 1 |
| Cope, N | 1 |
| Knights, J | 1 |
| Phiri, P | 1 |
| Makin, A | 1 |
| Peters-Strickland, T | 1 |
| Rathod, S | 1 |
| Singh, R | 2 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Saroj, P | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Bareis, N | 1 |
| Stroup, TS | 2 |
| Scruth, E | 1 |
| Kimura, H | 3 |
| Watanabe, H | 2 |
| Rodríguez-Sánchez, JM | 3 |
| Pérez-Iglesias, R | 15 |
| Roiz-Santiáñez, R | 1 |
| Sánchez-Moreno, J | 1 |
| Vázquez-Barquero, JL | 12 |
| Diaz, FJ | 1 |
| de León, J | 2 |
| Pisano, S | 1 |
| Gritti, A | 1 |
| Catone, G | 1 |
| Pascotto, A | 1 |
| Misdrahi, D | 1 |
| Delgado, A | 1 |
| Bouju, S | 1 |
| Comet, D | 1 |
| Chiariny, JF | 1 |
| Moisan, J | 1 |
| Turgeon, M | 1 |
| Desjardins, O | 1 |
| Grégoire, JP | 1 |
| Vasilyeva, I | 1 |
| Biscontri, RG | 1 |
| Enns, MW | 1 |
| Metge, CJ | 1 |
| Alessi-Severini, S | 1 |
| Chue, P | 2 |
| Jordan, G | 1 |
| Stip, E | 2 |
| Koczerginski, D | 1 |
| Milliken, H | 1 |
| Joseph, A | 1 |
| Williams, R | 3 |
| Adams, B | 1 |
| Manchanda, R | 2 |
| Oyewumi, K | 1 |
| Roy, MA | 2 |
| Spiegel, DR | 1 |
| Zaki, N | 1 |
| Goghari, VM | 1 |
| Smith, GN | 1 |
| Kopala, LC | 2 |
| Thornton, AE | 1 |
| Su, W | 1 |
| Macewan, GW | 1 |
| Lang, DJ | 1 |
| Hatta, K | 1 |
| Takebayashi, H | 1 |
| Sudo, Y | 1 |
| Katayama, S | 1 |
| Kasuya, M | 1 |
| Shirai, Y | 1 |
| Morikawa, F | 1 |
| Nakase, R | 1 |
| Ito, S | 1 |
| Kuga, H | 1 |
| Ohnuma, T | 1 |
| Usui, C | 1 |
| Nakamura, H | 1 |
| Hirata, T | 1 |
| Sawa, Y | 1 |
| Azcárraga, M | 1 |
| Stephano, S | 1 |
| Favila, R | 1 |
| Díaz-Galvis, L | 1 |
| Alvarado-Alanis, P | 1 |
| Ramírez-Bermúdez, J | 1 |
| Wu, DB | 1 |
| Lee, EH | 1 |
| Chung, WS | 1 |
| Chow, DP | 1 |
| Lee, VW | 1 |
| Wong, MC | 1 |
| Lee, KK | 1 |
| Sinkeviciute, I | 1 |
| Hugdahl, K | 1 |
| Pardo-Garcia, G | 3 |
| Amado, JA | 4 |
| Garcia-Unzueta, MT | 4 |
| Silva, PN | 3 |
| Melaragno, MI | 1 |
| Smith, Mde A | 2 |
| Ikuta, T | 3 |
| Gruner, P | 1 |
| Kane, J | 2 |
| Sevy, S | 1 |
| Kumar, A | 1 |
| Datta, SS | 1 |
| Wright, SD | 1 |
| Furtado, VA | 1 |
| Russell, PS | 1 |
| Murphy, RA | 1 |
| Hallahan, B | 1 |
| Gnanavel, S | 1 |
| Amos, AJ | 1 |
| Yung, AR | 4 |
| Amminger, GP | 2 |
| Phillips, LJ | 4 |
| Markovic, J | 1 |
| Plestic, S | 1 |
| Kostic, J | 1 |
| Walther, S | 1 |
| Moggi, F | 1 |
| Horn, H | 1 |
| Moskvitin, K | 1 |
| Abderhalden, C | 1 |
| Maier, N | 1 |
| Strik, W | 1 |
| Müller, TJ | 1 |
| Leatherman, SM | 1 |
| Liang, MH | 1 |
| Krystal, JH | 2 |
| Lew, RA | 1 |
| Valley, D | 1 |
| Thwin, SS | 1 |
| Rosenheck, RA | 6 |
| Lee, NY | 1 |
| Kim, SH | 1 |
| Cho, SJ | 1 |
| Chung, YC | 1 |
| Jung, IK | 1 |
| Kim, CY | 2 |
| Kim, DH | 1 |
| Lee, DG | 1 |
| Lee, YH | 1 |
| Lim, WJ | 1 |
| Na, YS | 1 |
| Shin, SE | 1 |
| Woo, JM | 1 |
| Yoon, JS | 2 |
| Yoon, BH | 1 |
| Ahn, YM | 1 |
| Kim, YS | 1 |
| Meltzer, HY | 4 |
| Lindenmayer, JP | 8 |
| Kwentus, J | 1 |
| Share, DB | 1 |
| Johnson, R | 1 |
| Jayathilake, K | 3 |
| Komatsu, N | 1 |
| Ishige, M | 1 |
| Muneoka, K | 1 |
| Yoshimura, M | 1 |
| Yamanaka, H | 1 |
| Suzuki, T | 6 |
| Komatsu, H | 1 |
| Hashimoto, T | 1 |
| Hasegawa, T | 1 |
| Shiina, A | 1 |
| Ishikawa, M | 1 |
| Sekine, Y | 1 |
| Shiraishi, T | 1 |
| Shimizu, E | 1 |
| Hashimoto, K | 1 |
| Di Fiorino, M | 1 |
| Montagnani, G | 1 |
| Trespi, G | 1 |
| Kasper, S | 3 |
| Hou, YC | 2 |
| Lai, CH | 2 |
| Mohammed, KA | 1 |
| Ibrahim, HK | 1 |
| Ghorab, MM | 1 |
| White, AM | 1 |
| White, AL | 1 |
| Rais, T | 1 |
| Buckley, PF | 3 |
| Schooler, NR | 10 |
| Goff, DC | 6 |
| Hsiao, J | 1 |
| Kopelowicz, A | 2 |
| Manschreck, T | 1 |
| Mendelowitz, AJ | 1 |
| Miller, del D | 3 |
| Severe, JB | 1 |
| Wilson, DR | 3 |
| Ames, D | 5 |
| Bustillo, J | 1 |
| Mintz, J | 3 |
| Kane, JM | 17 |
| Andrade, EH | 1 |
| Tasso, BC | 1 |
| Abílio, VC | 1 |
| Sato, JR | 2 |
| Brietzke, E | 4 |
| Makkos, Z | 1 |
| Furukawa, TA | 1 |
| Morrissette, DA | 1 |
| Stahl, SM | 4 |
| Ding, J | 1 |
| Gadit, AM | 1 |
| Lai, EC | 1 |
| Yang, YH | 1 |
| Gouvea, ES | 2 |
| Stilhano, RS | 1 |
| Han, SW | 1 |
| Laties, AM | 1 |
| Flach, AJ | 1 |
| Baldycheva, I | 1 |
| Rak, I | 1 |
| Earley, W | 1 |
| Lessing, C | 1 |
| Ashton, T | 1 |
| Davis, P | 1 |
| Sarpal, DK | 1 |
| Lencz, T | 5 |
| Argyelan, M | 1 |
| Karlsgodt, K | 1 |
| Hutcheson, NL | 1 |
| Sreenivasan, KR | 1 |
| Deshpande, G | 1 |
| Hadley, J | 1 |
| White, DM | 2 |
| Ver Hoef, L | 2 |
| Rizzo, LB | 1 |
| Honda, PH | 1 |
| Marston, L | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Walters, K | 1 |
| Osborn, DP | 1 |
| Parellada, E | 5 |
| Kim, SW | 1 |
| Jeong, BO | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Hwang, MY | 1 |
| Paul Amminger, G | 1 |
| Hsu, CC | 1 |
| Lin, CJ | 1 |
| Lu, T | 1 |
| Hu, LY | 1 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Shinkawa, I | 1 |
| Konishi, A | 1 |
| Abel Boenerjous, RS | 1 |
| Zirker, W | 1 |
| Masilamani, S | 1 |
| Murru, A | 1 |
| Hidalgo, D | 1 |
| Álamo, C | 2 |
| Puangthong, U | 1 |
| Pongpirul, K | 1 |
| Bonaccorso, S | 2 |
| Sodhi, M | 1 |
| Bobo, WV | 3 |
| Chen, Y | 2 |
| Tumuklu, M | 1 |
| Theleritis, C | 1 |
| Rao, SA | 1 |
| Rao, MG | 1 |
| Rao, NP | 2 |
| Varambally, S | 2 |
| Gangadhar, BN | 2 |
| Shams, ME | 1 |
| Unterecker, S | 1 |
| Falter, T | 2 |
| Hiemke, C | 2 |
| Moosavi, SM | 1 |
| Ahmadi, M | 1 |
| Mojtahedi, D | 1 |
| Yazdani, J | 1 |
| Monajemi, MB | 1 |
| Barbosa, DS | 1 |
| Bonifácio, KL | 1 |
| Nunes, SO | 1 |
| Jarius, S | 1 |
| Wildemann, B | 1 |
| Stöcker, W | 1 |
| Moser, A | 1 |
| Wandinger, KP | 1 |
| Yu, J | 1 |
| Addington, J | 4 |
| Tohen, M | 5 |
| Petrides, G | 3 |
| Hassoun, Y | 2 |
| Lopez, L | 1 |
| Braga, RJ | 1 |
| Sevy, SM | 3 |
| Kellner, CH | 3 |
| Bennett, N | 1 |
| Vasilenko, LM | 1 |
| Gorobets, LN | 2 |
| Bulanov, VS | 1 |
| Litvinov, AV | 1 |
| Ivanova, GP | 1 |
| Tsarenko, MA | 1 |
| Polyakovskaya, TP | 1 |
| Vernal, DL | 1 |
| Kapoor, S | 1 |
| Al-Jadiri, A | 1 |
| Sheridan, EM | 1 |
| Borenstein, Y | 1 |
| Mormando, C | 1 |
| David, L | 1 |
| Singh, S | 1 |
| Seidman, AJ | 1 |
| Carbon, M | 1 |
| Gerstenberg, M | 1 |
| Saito, E | 1 |
| Steinhausen, HC | 1 |
| Arango, C | 4 |
| Jullian-Desayes, I | 1 |
| Roselli, A | 1 |
| Lamy, C | 1 |
| Alberto-Gondouin, MC | 1 |
| Janvier, N | 1 |
| Venturi-Maestri, G | 1 |
| Trampush, JW | 1 |
| DeRosse, P | 1 |
| Burdick, KE | 2 |
| Goldberg, TE | 3 |
| Emsley, R | 6 |
| Asmal, L | 1 |
| du Plessis, S | 1 |
| Chiliza, B | 1 |
| Kidd, M | 1 |
| Carr, J | 1 |
| Vink, M | 1 |
| Bruns, K | 1 |
| Alblowi, MA | 1 |
| Alosaimi, FD | 1 |
| Kanaan, RA | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Lee, YM | 1 |
| Park, JM | 1 |
| Lee, BD | 1 |
| Moon, E | 1 |
| Jeong, HJ | 1 |
| Chung, YI | 1 |
| Kim, JH | 1 |
| Kim, HJ | 1 |
| Mun, CW | 1 |
| Kim, TH | 1 |
| Kim, YH | 1 |
| Hadley, N | 1 |
| Hadley, JA | 1 |
| Davis, E | 1 |
| Nikbakhat, MR | 1 |
| Arabzadeh, S | 1 |
| Zeinoddini, A | 1 |
| Khalili, Z | 1 |
| Rezaei, F | 1 |
| Mohammadinejad, P | 1 |
| Ghaleiha, A | 1 |
| Akhondzadeh, S | 1 |
| Stevenson, JM | 1 |
| Reilly, JL | 3 |
| Harris, MS | 3 |
| Patel, SR | 1 |
| Weiden, PJ | 6 |
| Prasad, KM | 1 |
| Badner, JA | 1 |
| Nimgaonkar, VL | 1 |
| Keshavan, MS | 5 |
| Sweeney, JA | 5 |
| Bishop, JR | 1 |
| Khouri, C | 1 |
| Planès, S | 1 |
| Logerot, S | 1 |
| Villier, C | 1 |
| Mallaret, M | 1 |
| Del Casale, A | 1 |
| Kotzalidis, GD | 1 |
| Sacco, M | 1 |
| Rapinesi, C | 1 |
| De Giorgi, R | 1 |
| Giardini, M | 1 |
| D'Andreagiovanni, M | 1 |
| Carlino, N | 1 |
| Brugnoli, R | 1 |
| Girardi, P | 2 |
| Marder, SR | 11 |
| Chengappa, KN | 2 |
| Wirshing, WC | 2 |
| McMeniman, M | 1 |
| Baker, RW | 2 |
| Parepally, H | 2 |
| Umbricht, D | 2 |
| Covell, NH | 1 |
| Colombel, M | 1 |
| Rebillard, C | 1 |
| Nathou, C | 1 |
| Dollfus, S | 2 |
| Harrison, RN | 1 |
| Murray, RM | 1 |
| Lee, SH | 2 |
| Paya Cano, J | 1 |
| Dempster, D | 1 |
| Curtis, CJ | 1 |
| Dima, D | 1 |
| Gaughran, F | 1 |
| Llaudó, J | 1 |
| Ayani, I | 1 |
| Martínez, J | 1 |
| Schronen, J | 1 |
| Morozova, M | 1 |
| Ivanov, M | 1 |
| Gutierro, I | 1 |
| Manschreck, TC | 1 |
| Mendelowitz, A | 2 |
| Miller, DD | 2 |
| Bustillo, JR | 1 |
| Looney, SW | 1 |
| Ustohal, L | 1 |
| Mayerova, M | 1 |
| Hublova, V | 1 |
| Prikrylova Kucerova, H | 1 |
| Ceskova, E | 2 |
| Kasparek, T | 2 |
| Dejene, SZ | 1 |
| Panchaud, A | 1 |
| Cohen, L | 1 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Morlán-Coarasa, MJ | 1 |
| Arias-Loste, MT | 1 |
| Alonso-Martín, C | 1 |
| Crespo, J | 1 |
| Romero-Gómez, M | 1 |
| Fábrega, E | 1 |
| Taylor, DM | 7 |
| Sparshatt, A | 3 |
| O'Hagan, M | 1 |
| Dzahini, O | 1 |
| Rajji, TK | 2 |
| Mulsant, BH | 7 |
| Nakajima, S | 1 |
| Caravaggio, F | 1 |
| Gerretsen, P | 1 |
| Mar, W | 1 |
| Mamo, DC | 4 |
| Sakurai, H | 1 |
| Bies, RR | 2 |
| Mimura, M | 2 |
| Kapur, S | 11 |
| Bas, A | 1 |
| Gultekin, G | 1 |
| Incir, S | 1 |
| Bas, TO | 1 |
| Emul, M | 1 |
| Duran, A | 1 |
| Hsu, CW | 1 |
| Lee, Y | 1 |
| Lee, CY | 1 |
| Lin, PY | 1 |
| Che, KI | 1 |
| Shlomi Polachek, I | 1 |
| Manor, A | 1 |
| Baumfeld, Y | 1 |
| Bagadia, A | 1 |
| Polachek, A | 1 |
| Strous, RD | 1 |
| Dolev, Z | 1 |
| Rhindress, K | 1 |
| Wellington, R | 1 |
| Carrillo de Albornoz, CM | 1 |
| Guerrero-Jimenez, M | 1 |
| Gutierrez-Rojas, L | 1 |
| Sultzer, DL | 3 |
| Davis, SM | 1 |
| Tariot, PN | 3 |
| Dagerman, KS | 2 |
| Lebowitz, BD | 1 |
| Lyketsos, CG | 2 |
| Hsiao, JK | 2 |
| Lieberman, JA | 20 |
| Schneider, LS | 4 |
| Fraguas, D | 1 |
| Merchán-Naranjo, J | 2 |
| Laita, P | 1 |
| Parellada, M | 3 |
| Moreno, D | 2 |
| Ruiz-Sancho, A | 1 |
| Cifuentes, A | 1 |
| Giráldez, M | 2 |
| Ganguli, R | 2 |
| Brar, JS | 2 |
| Mahmoud, R | 7 |
| Berry, SA | 2 |
| Pandina, GJ | 2 |
| Rotgé, JY | 1 |
| Aouizerate, B | 1 |
| Tignol, J | 1 |
| Labelle, A | 2 |
| Shammi, C | 2 |
| Mannaert, EJ | 1 |
| Mann, SW | 1 |
| Remington, G | 4 |
| Molina, JD | 1 |
| Solé, S | 1 |
| Pablo, Sd | 1 |
| López-Muñoz, F | 1 |
| Santana, G | 1 |
| Soutullo, CA | 1 |
| Graell, M | 1 |
| Paya, B | 1 |
| de la Serna, E | 2 |
| Richtand, NM | 1 |
| McNeal, KM | 1 |
| Meyer, RP | 1 |
| Lukacs, K | 1 |
| Senseney, A | 1 |
| Mintzer, J | 5 |
| Raignoux, C | 1 |
| Dusouchet, T | 1 |
| Bret, P | 3 |
| Queuille, E | 2 |
| Biscay, ML | 1 |
| Caron, J | 1 |
| Bret, MC | 3 |
| Sikich, L | 4 |
| Frazier, JA | 3 |
| McClellan, J | 3 |
| Findling, RL | 4 |
| Vitiello, B | 3 |
| Ritz, L | 2 |
| Ambler, D | 1 |
| Puglia, M | 2 |
| Maloney, AE | 2 |
| Michael, E | 1 |
| Slifka, K | 1 |
| Noyes, N | 2 |
| Hlastala, S | 2 |
| Pierson, L | 2 |
| McNamara, NK | 2 |
| Delporto-Bedoya, D | 1 |
| Anderson, R | 1 |
| Hamer, RM | 8 |
| Marshall, TS | 1 |
| McCombs, JS | 1 |
| Stafkey-Mailey, D | 1 |
| Wustmann, T | 2 |
| Preuss, UW | 2 |
| Raja, M | 2 |
| Azzoni, A | 2 |
| Lencer, R | 1 |
| Sprenger, A | 1 |
| Houthoofd, SA | 1 |
| Morrens, M | 1 |
| Sabbe, BG | 1 |
| Levine, SZ | 2 |
| Rabinowitz, J | 14 |
| Glowinski, R | 1 |
| Payman, V | 1 |
| Frencham, K | 1 |
| Fischetti, C | 2 |
| Thomas, A | 2 |
| Bishara, D | 2 |
| Cornelius, V | 3 |
| Byerly, MJ | 4 |
| Marcus, RN | 2 |
| Tran, QV | 1 |
| Eudicone, JM | 2 |
| Whitehead, R | 1 |
| Baker, RA | 1 |
| McCormack, J | 2 |
| Napolitano, B | 2 |
| Patel, RC | 2 |
| Goldman, R | 2 |
| González-Blanch, C | 2 |
| Krishnakumar, P | 1 |
| Jayakrishnan, MP | 1 |
| Beegum, MN | 1 |
| Riyaz, A | 1 |
| Oosthuizen, P | 2 |
| Koen, L | 3 |
| Niehaus, DJ | 2 |
| Medori, R | 13 |
| Janicak, PG | 2 |
| Glick, ID | 2 |
| Crandall, DT | 1 |
| McQuade, RD | 1 |
| Assunção-Talbott, S | 2 |
| Moncrieff, J | 1 |
| Cohen, D | 2 |
| Mason, JP | 1 |
| van Bruggen, M | 1 |
| Wouters, L | 1 |
| Dingemans, P | 2 |
| Linszen, D | 4 |
| Lindström, E | 3 |
| Jedenius, E | 1 |
| Levander, S | 3 |
| Takahashi, T | 1 |
| Soulsby, B | 1 |
| Suzuki, M | 2 |
| Kawasaki, Y | 2 |
| Velakoulis, D | 1 |
| Kumar, R | 1 |
| Sachdev, PS | 1 |
| Gearing, RE | 1 |
| Charach, A | 1 |
| Mata, I | 7 |
| Ayesa, R | 1 |
| Cuesta, MJ | 2 |
| Jalón, EG | 1 |
| Campos, MS | 2 |
| Peralta, V | 2 |
| Kalapatapu, RK | 1 |
| Schimming, C | 3 |
| Gallelli, L | 1 |
| Spagnuolo, V | 1 |
| Palleria, C | 1 |
| De Sarro, G | 1 |
| Ferraro, M | 1 |
| Lai, YC | 1 |
| Huang, MC | 1 |
| Chen, CH | 2 |
| Tsai, CJ | 1 |
| Pan, CH | 1 |
| Chiu, CC | 1 |
| Marston, HM | 1 |
| Young, JW | 1 |
| Martin, FD | 1 |
| Serpa, KA | 1 |
| Moore, CL | 1 |
| Wong, EH | 1 |
| Gold, L | 1 |
| Meltzer, LT | 1 |
| Azar, MR | 1 |
| Geyer, MA | 1 |
| Shahid, M | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Matsumoto, K | 1 |
| Miyakoshi, T | 1 |
| Ito, F | 1 |
| Omuro, N | 1 |
| Matsuoka, N | 1 |
| Alptekin, K | 1 |
| Hafez, J | 1 |
| Brook, S | 1 |
| Akkaya, C | 1 |
| Tzebelikos, E | 1 |
| Ucok, A | 1 |
| El Tallawy, H | 1 |
| Danaci, AE | 1 |
| Lowe, W | 1 |
| Karayal, ON | 1 |
| Khan, RA | 1 |
| Mican, LM | 1 |
| Suehs, BT | 1 |
| Dunbar, L | 2 |
| Miles, W | 2 |
| Wheeler, A | 2 |
| Sheridan, J | 2 |
| Pulford, J | 2 |
| Butler, R | 2 |
| Simmons, M | 1 |
| Stanford, C | 1 |
| Ross, M | 1 |
| Kelly, D | 2 |
| Baker, K | 1 |
| Conus, P | 1 |
| Amminger, P | 1 |
| Trumpler, F | 1 |
| Yun, Y | 1 |
| Lim, M | 1 |
| McNab, C | 1 |
| Melamed, Y | 1 |
| Daliahu, Y | 1 |
| Paleacu, D | 2 |
| Rossi, A | 1 |
| Bagalà, A | 1 |
| Del Curatolo, V | 1 |
| Scapati, F | 1 |
| Bernareggi, MM | 1 |
| Giustra, MG | 1 |
| Swadi, HS | 1 |
| Craig, BJ | 1 |
| Pirwani, NZ | 1 |
| Black, VC | 1 |
| Buchan, JC | 1 |
| Bobier, CM | 1 |
| Fuller, M | 1 |
| Shermock, K | 1 |
| Russo, P | 1 |
| Secic, M | 1 |
| Dirani, R | 1 |
| Vallow, S | 1 |
| Flanders, S | 1 |
| Magyar, GI | 1 |
| Fadgyas, I | 1 |
| Kinon, BJ | 6 |
| Chen, L | 2 |
| Ascher-Svanum, H | 5 |
| Stauffer, VL | 4 |
| Kollack-Walker, S | 3 |
| Zhou, W | 2 |
| Kirkpatrick, B | 1 |
| Vester-Blokland, E | 1 |
| Sun, W | 1 |
| Carson, WH | 2 |
| Pikalov, A | 1 |
| Lambert, M | 1 |
| De Marinis, T | 1 |
| Pfeil, J | 1 |
| Naber, D | 2 |
| Schreiner, A | 6 |
| Strack, DK | 1 |
| Leckband, SG | 1 |
| Meyer, JM | 2 |
| Dombrovski, AY | 1 |
| Ferrell, RE | 1 |
| Lotrich, FE | 1 |
| Rosen, JI | 1 |
| Wallace, M | 1 |
| Houck, PR | 3 |
| Mazumdar, S | 3 |
| Koirala, S | 1 |
| Penagaluri, P | 1 |
| Smith, C | 1 |
| Lippmann, S | 1 |
| Jummani, R | 1 |
| Hawley, C | 1 |
| Turner, M | 2 |
| Latif, MA | 2 |
| Curtis, V | 1 |
| Saleem, PT | 1 |
| Wilton, K | 1 |
| Kastelic, M | 1 |
| Koprivsek, J | 1 |
| Plesnicar, BK | 1 |
| Serretti, A | 2 |
| Mandelli, L | 1 |
| Locatelli, I | 1 |
| Grabnar, I | 1 |
| Dolzan, V | 1 |
| Mowla, A | 1 |
| Pani, A | 1 |
| Willis, M | 1 |
| Svensson, M | 1 |
| Löthgren, M | 1 |
| Eriksson, B | 1 |
| Berntsson, A | 1 |
| Persson, U | 1 |
| Serafini, G | 1 |
| Pompili, M | 1 |
| Innamorati, M | 1 |
| Tatarelli, R | 1 |
| Baldessarini, RJ | 3 |
| Macfadden, W | 1 |
| Bossie, CA | 15 |
| Turkoz, I | 6 |
| Haskins, JT | 1 |
| Khazaal, Y | 1 |
| Chatton, A | 1 |
| Claeys, F | 1 |
| Ribordy, F | 1 |
| Khan, R | 1 |
| Zullino, D | 2 |
| Maayan, LA | 1 |
| Vakhrusheva, J | 1 |
| Montejo, AL | 1 |
| Majadas, S | 1 |
| Rico-Villademoros, F | 1 |
| Llorca, G | 1 |
| De La Gándara, J | 1 |
| Franco, M | 1 |
| Martín-Carrasco, M | 1 |
| Aguera, L | 1 |
| Prieto, N | 1 |
| Strauss, M | 1 |
| Heinritz, W | 1 |
| Hegerl, U | 1 |
| Kopf, A | 1 |
| Ruzić, K | 1 |
| Rebić, J | 1 |
| Dadić-Hero, E | 1 |
| Francisković, T | 1 |
| Zivković, M | 1 |
| Mihaljević-Peles, A | 1 |
| Sagud, M | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Wentzel-Larsen, T | 1 |
| Citrome, L | 11 |
| Jaffe, A | 2 |
| Levine, J | 3 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Friedman, JH | 5 |
| Rattehalli, RD | 1 |
| Jayaram, MB | 1 |
| Smith, M | 1 |
| Wiffen, BD | 2 |
| Lex, A | 3 |
| David, AS | 3 |
| Moreno, C | 1 |
| Alvarez, M | 1 |
| Alda, JA | 1 |
| Martínez-Cantarero, C | 1 |
| Sánchez, B | 1 |
| Chan, HY | 2 |
| Chiang, SC | 2 |
| Chang, CJ | 1 |
| Gau, SS | 1 |
| Chen, JJ | 1 |
| Hwu, HG | 2 |
| Lai, MS | 1 |
| McCauley-Elsom, K | 2 |
| Gurvich, C | 1 |
| Elsom, SJ | 1 |
| Kulkarni, J | 2 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Lee, BS | 1 |
| Chiu, NY | 1 |
| Monshat, K | 1 |
| Carty, B | 1 |
| Olver, J | 1 |
| Castle, D | 2 |
| Bosanac, P | 1 |
| Johnson, JL | 2 |
| Lingler, J | 1 |
| Kaufman, EM | 1 |
| Schennach-Wolff, R | 1 |
| Seemüller, FH | 1 |
| Mayr, A | 1 |
| Maier, W | 2 |
| Klingberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 2 |
| Häfner, H | 1 |
| Sauer, H | 1 |
| Schneider, F | 1 |
| Gaebel, W | 3 |
| Jäger, M | 1 |
| Möller, HJ | 5 |
| Riedel, M | 1 |
| Lim, HK | 3 |
| Kim, JJ | 2 |
| Pae, CU | 4 |
| Lee, CU | 3 |
| Lee, C | 3 |
| Paik, IH | 2 |
| Mittal, M | 1 |
| Khan, S | 1 |
| Blum, JA | 1 |
| Pfeifer, S | 1 |
| Hatz, CF | 1 |
| Machielsen, MW | 1 |
| Di Lorenzo, R | 1 |
| Fiorini, F | 1 |
| Santachiara, S | 1 |
| Oliveira, C | 1 |
| Trias, G | 1 |
| Comeche, J | 1 |
| Bergmans, P | 1 |
| de Arce, R | 1 |
| Rouillon, F | 1 |
| Cordes, J | 1 |
| Eriksson, L | 1 |
| Smeraldi, E | 1 |
| Flynn, S | 1 |
| Schenk, C | 1 |
| Ganesan, S | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Krähenmann, R | 1 |
| Küchenhoff, B | 1 |
| Böker, H | 2 |
| Schick, M | 1 |
| van Nimwegen-Campailla, L | 1 |
| van Beveren, N | 2 |
| Laan, W | 2 |
| van den Brink, W | 2 |
| Santoro, V | 1 |
| D'Arrigo, C | 2 |
| Spina, E | 2 |
| Micò, U | 1 |
| Muscatello, MR | 1 |
| Zoccali, R | 2 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Fleischhacker, WW | 2 |
| Case, M | 1 |
| Conley, R | 1 |
| Jacob, J | 1 |
| Boaz, TL | 1 |
| Constantine, RJ | 1 |
| Robst, J | 1 |
| Becker, MA | 1 |
| Howe, AM | 1 |
| Moons, T | 1 |
| Claes, S | 1 |
| Martens, GJ | 1 |
| Peuskens, J | 1 |
| Van Loo, KM | 1 |
| Van Schijndel, JE | 1 |
| De Hert, M | 1 |
| van Winkel, R | 1 |
| Caseiro, O | 2 |
| Pardo, G | 1 |
| Takeuchi, H | 1 |
| Watanabe, K | 2 |
| Johnston, TG | 1 |
| Danivas, V | 1 |
| Behere, RV | 1 |
| Venkatasubramanian, G | 1 |
| Mandrioli, R | 1 |
| Mercolini, L | 2 |
| Lateana, D | 1 |
| Boncompagni, G | 1 |
| Raggi, MA | 2 |
| Lataster, J | 1 |
| Thewissen, V | 1 |
| Lataster, T | 1 |
| Lardinois, M | 1 |
| Delespaul, PA | 1 |
| Myin-Germeys, I | 1 |
| Olfson, M | 1 |
| Gerhard, T | 1 |
| Huang, C | 1 |
| Crystal, S | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 2 |
| Gruneir, A | 2 |
| Herrmann, N | 2 |
| Rochon, P | 1 |
| Opjordsmoen, S | 2 |
| Melle, I | 1 |
| Friis, S | 1 |
| Haahr, U | 1 |
| Johannessen, JO | 1 |
| Larsen, TK | 1 |
| Rund, BR | 1 |
| Simonsen, E | 1 |
| Vaglum, P | 1 |
| McGlashan, TH | 1 |
| Malempati, RN | 1 |
| Bond, DJ | 1 |
| Kunz, M | 2 |
| Malemati, C | 1 |
| Cheng, A | 1 |
| Yatham, LN | 1 |
| Devanand, DP | 3 |
| Schultz, S | 1 |
| Sultzer, D | 1 |
| de la Pena, D | 2 |
| Gupta, S | 5 |
| Colon, S | 2 |
| Pelton, GH | 2 |
| Andrews, H | 1 |
| Levin, B | 2 |
| Schmoll, D | 1 |
| Calarge, CA | 1 |
| Barak, Y | 3 |
| Plopski, I | 1 |
| Tadger, S | 1 |
| Heil, M | 1 |
| Ojeda, N | 1 |
| Zabala, A | 1 |
| García, J | 1 |
| Eguíluz, JI | 1 |
| Gutiérrez, M | 1 |
| Marsanić, VB | 1 |
| Aukst-Margetić, B | 1 |
| Grgić, N | 1 |
| Kusmić, E | 1 |
| Ortiz, V | 1 |
| Valdizan, E | 1 |
| McEvoy, JP | 7 |
| Ring, KD | 1 |
| Hamer, RH | 1 |
| LaVange, LM | 1 |
| Swartz, MS | 1 |
| Perkins, DO | 4 |
| Nussbaum, AM | 1 |
| de Arce Cordón, R | 1 |
| Eding, E | 1 |
| Marques-Teixeira, J | 1 |
| Milanova, V | 2 |
| Rancans, E | 1 |
| Roy-Desruisseaux, J | 1 |
| Landry, J | 1 |
| Bocti, C | 1 |
| Tessier, D | 1 |
| Hottin, P | 1 |
| Trudel, JF | 1 |
| Melkersson, K | 1 |
| Berinder, K | 1 |
| Hulting, AL | 1 |
| Kumar, D | 1 |
| Muppa, M | 1 |
| Kablinger, A | 1 |
| Kjelby, E | 1 |
| Carpiniello, B | 1 |
| Mellino, G | 1 |
| Pintore, S | 1 |
| Puddu, L | 1 |
| Pinna, F | 1 |
| Prabhakar, M | 1 |
| Haynes, WG | 1 |
| Coryell, WH | 1 |
| Chrischilles, EA | 2 |
| Arndt, S | 3 |
| Ellingrod, VL | 2 |
| Warren, L | 1 |
| Fiedorowicz, JG | 1 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Popović, V | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Stojanović, M | 1 |
| Meng, X | 1 |
| Hochfeld, M | 1 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Reist, C | 3 |
| Wu, JC | 1 |
| Lilja, Y | 1 |
| Mukherjee, J | 1 |
| Gripeos, D | 1 |
| Constantinescu, C | 1 |
| Ozdemir, V | 1 |
| Letmaier, M | 1 |
| Painold, A | 1 |
| Holl, AK | 1 |
| Grohmann, R | 1 |
| Vergin, H | 1 |
| Teng, PR | 1 |
| Lane, HY | 1 |
| Altamura, AC | 1 |
| Csernansky, JG | 1 |
| Leucht, S | 1 |
| Davis, JM | 2 |
| Ghaffari, N | 1 |
| Dossett, E | 1 |
| Lee, RH | 1 |
| Aghajanian, P | 1 |
| Marras, C | 1 |
| Fischer, H | 1 |
| Anderson, GM | 1 |
| Hyson, C | 1 |
| Rochon, PA | 1 |
| Rosa, F | 1 |
| Thomas, P | 1 |
| Sherif, T | 1 |
| Tsunoda, K | 1 |
| Lambert, T | 1 |
| Emmerson, B | 1 |
| Hustig, H | 1 |
| Resseler, S | 1 |
| Jacobs, A | 1 |
| Butcher, B | 1 |
| Bachman, P | 1 |
| Jalbrzikowski, M | 1 |
| Bearden, CE | 1 |
| Giuliano, AJ | 1 |
| Yakutis, L | 1 |
| Youngstrom, EA | 1 |
| Breiger, D | 1 |
| Hooper, SR | 1 |
| Kilian, R | 1 |
| Steinert, T | 1 |
| Schepp, W | 1 |
| Weiser, P | 1 |
| Jaeger, S | 1 |
| Pfiffner, C | 1 |
| Frasch, K | 1 |
| Eschweiler, GW | 1 |
| Messer, T | 2 |
| Croissant, D | 1 |
| Becker, T | 1 |
| Längle, G | 1 |
| Howland, RH | 2 |
| Barteček, R | 1 |
| Juřica, J | 1 |
| Zrůstová, J | 1 |
| Pindurová, E | 1 |
| Žourková, A | 1 |
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Barnett, PG | 1 |
| Scott, JY | 1 |
| Suzuki, Y | 1 |
| Fukui, N | 1 |
| Tsuneyama, N | 1 |
| Watanabe, J | 1 |
| Ono, S | 1 |
| Sugai, T | 1 |
| Saito, M | 1 |
| Inoue, Y | 1 |
| Someya, T | 1 |
| Salinas Botrán, A | 1 |
| Urgelés Puértolas, D | 1 |
| Peregrin Abad, E | 1 |
| Croarkin, PE | 1 |
| Daskalakis, ZJ | 1 |
| Zverova, M | 1 |
| Weedon, JC | 1 |
| Elmouchtari, A | 1 |
| Sunakawa-McMillan, A | 1 |
| Zaytseva, Y | 1 |
| Gurovich, IY | 1 |
| Goland, E | 1 |
| Storozhakova, YA | 1 |
| San, L | 1 |
| Arranz, B | 1 |
| Perez, V | 2 |
| Safont, G | 1 |
| Ramirez, N | 1 |
| Dueñas, R | 1 |
| Alvarez, E | 2 |
| Faries, D | 3 |
| Phillips, G | 1 |
| Nyhuis, AW | 1 |
| Sugihara, T | 1 |
| Stauffer, V | 1 |
| Bocharov, AV | 1 |
| Kondakova, VE | 1 |
| Tuleninov, ES | 1 |
| García de Jalón, E | 1 |
| Ibáñez, B | 1 |
| Sánchez-Torres, AM | 1 |
| Milovancevic, MP | 1 |
| Miletic, V | 1 |
| Deusic, SP | 1 |
| Gajic, SD | 1 |
| Tosevski, DL | 1 |
| Schultz, SK | 3 |
| Andrews, HF | 1 |
| Banga, A | 1 |
| Connor, DF | 1 |
| Valdizán, EM | 1 |
| Alphs, L | 2 |
| Olson, WH | 1 |
| Fastenau, J | 1 |
| Hulihan, J | 1 |
| Hoblyn, JC | 1 |
| Leatherman, S | 1 |
| Weil, L | 1 |
| Lew, R | 1 |
| Díaz, I | 1 |
| Pai, N | 1 |
| Deng, C | 1 |
| Vella, SL | 1 |
| Huang, XF | 1 |
| Thampi, A | 1 |
| Berger, GE | 1 |
| Simmons, MB | 1 |
| Dip, G | 1 |
| Jin, H | 1 |
| Shih, PA | 1 |
| Golshan, S | 1 |
| Mudaliar, S | 1 |
| Henry, R | 1 |
| Glorioso, DK | 1 |
| Kraemer, HC | 1 |
| Jeste, DV | 6 |
| Montalvo, I | 1 |
| Ortega, L | 1 |
| López, X | 1 |
| Solé, M | 1 |
| Monseny, R | 1 |
| Franch, J | 1 |
| Vilella, E | 1 |
| Förstl, H | 1 |
| Pandina, G | 2 |
| Bilder, R | 1 |
| Ismail, Z | 1 |
| Emeremni, CA | 1 |
| Rosen, J | 2 |
| Gnjidic, D | 1 |
| Hilmer, SN | 1 |
| Power, GA | 1 |
| Ling, SM | 1 |
| Bonner, AF | 1 |
| McMullen, TL | 1 |
| Zugman, A | 1 |
| Pan, PM | 1 |
| Mansur, RB | 1 |
| Asevedo, E | 1 |
| Cunha, GR | 1 |
| Silva, PF | 1 |
| Higuchi, Y | 1 |
| Sumiyoshi, T | 1 |
| Seo, T | 1 |
| Miyanishi, T | 1 |
| Hartshorn, JC | 1 |
| Martino Maze, CD | 1 |
| Javitt, DC | 2 |
| Cienfuegos, A | 2 |
| Miniati, M | 1 |
| Silipo, G | 1 |
| Allingham, BH | 1 |
| Robinson, J | 1 |
| Voruganti, L | 1 |
| Cortese, L | 1 |
| Owyeumi, L | 1 |
| Kotteda, V | 1 |
| Cernovsky, Z | 1 |
| Zirul, S | 1 |
| Awad, A | 1 |
| Fernandez, HH | 1 |
| Schmitt, GJ | 1 |
| Meisenzahl, EM | 1 |
| Dresel, S | 2 |
| Tatsch, K | 2 |
| Rossmüller, B | 2 |
| Frodl, T | 1 |
| Hahn, K | 2 |
| Martin, A | 1 |
| L'Ecuyer, S | 1 |
| Tsai, C | 1 |
| Puzantian, T | 1 |
| Corson, PW | 1 |
| O'Leary, DS | 1 |
| Andreasen, NC | 1 |
| Livingston, M | 1 |
| Livingston, H | 1 |
| Wirshing, DA | 1 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Merlo, MC | 1 |
| Hofer, H | 1 |
| Gekle, W | 1 |
| Berger, G | 1 |
| Ventura, J | 1 |
| Panhuber, I | 1 |
| Latour, G | 1 |
| Gianfrancesco, FD | 1 |
| Grogg, AL | 1 |
| Mahmoud, RA | 2 |
| Wang, RH | 2 |
| Nasrallah, HA | 2 |
| Munarriz, R | 1 |
| Bennett, L | 1 |
| Goldstein, I | 1 |
| Hamner, MB | 1 |
| Faldowski, RA | 1 |
| Ulmer, HG | 1 |
| Frueh, BC | 1 |
| Huber, MG | 1 |
| Arana, GW | 1 |
| Keller, R | 1 |
| Mongini, F | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Levinton, C | 1 |
| Robinson, K | 1 |
| Sajatovic, M | 2 |
| Mullen, JA | 2 |
| Sweitzer, DE | 2 |
| Danileviciūte, V | 1 |
| Morikawa, M | 1 |
| Kishimoto, T | 1 |
| Czobor, P | 6 |
| Volavka, J | 7 |
| Sheitman, B | 6 |
| Cooper, TB | 5 |
| Chakos, M | 4 |
| Meibach, RC | 1 |
| Relan, P | 1 |
| Gupta, N | 1 |
| Mattoo, SK | 1 |
| Bromet, EJ | 1 |
| Davidson, M | 6 |
| Wright, T | 1 |
| Libretto, SE | 1 |
| Forchuk, C | 1 |
| Jewell, J | 1 |
| Tweedell, D | 1 |
| Steinnagel, L | 1 |
| Jerrell, JM | 1 |
| Potkin, SG | 2 |
| Saha, AR | 1 |
| Kujawa, MJ | 1 |
| Ali, M | 1 |
| Stock, E | 1 |
| Stringfellow, J | 1 |
| Ingenito, G | 1 |
| Brunelleschi, S | 1 |
| Zeppegno, P | 1 |
| Risso, F | 1 |
| Cattaneo, CI | 1 |
| Torre, E | 1 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 2 |
| Bouras, N | 2 |
| Harvey, PD | 4 |
| Napolitano, JA | 1 |
| Mao, L | 5 |
| Gharabawi, G | 7 |
| Fric, M | 1 |
| Laux, G | 1 |
| Bashford, RA | 1 |
| Sheitman, BB | 2 |
| Apiquian, R | 2 |
| Fresán, A | 2 |
| Herrera, K | 1 |
| Ulloa, RE | 2 |
| Lóyzaga, C | 1 |
| Gutiérrez, D | 1 |
| Nicolini, H | 2 |
| Yamanouchi, Y | 1 |
| Kitajima, T | 1 |
| Ozaki, N | 1 |
| Garyfallos, G | 1 |
| Dimelis, D | 1 |
| Kouniakis, P | 1 |
| Sidiropoulos, N | 1 |
| Karastergiou, A | 1 |
| Lavrentiadis, G | 1 |
| Giouzepas, J | 1 |
| Fokas, K | 1 |
| Daniel, DG | 2 |
| Simpson, G | 2 |
| Romano, SJ | 2 |
| Odawara, T | 1 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 2 |
| Tollefson, GD | 3 |
| Zhang, F | 1 |
| Breier, A | 2 |
| Goyal, RS | 1 |
| Goyal, SB | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Holtmann, M | 1 |
| Meyer, AE | 1 |
| Pitzer, M | 1 |
| Schmidt, MH | 1 |
| Pelagotti, F | 1 |
| Santarlasci, B | 1 |
| Vacca, F | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Chong, SA | 2 |
| Verma, SK | 2 |
| Knegtering, R | 2 |
| Castelein, S | 2 |
| Bous, H | 1 |
| Van Der Linde, J | 1 |
| Kluiter, H | 1 |
| van den Bosch, RJ | 2 |
| Armstrong, L | 1 |
| Randal, P | 1 |
| De Ronchi, D | 1 |
| Lorenzi, C | 1 |
| Berardi, D | 1 |
| Saxe, T | 1 |
| Lasser, RA | 9 |
| Advokat, C | 1 |
| Dixon, D | 1 |
| Schneider, J | 1 |
| Comaty, JE | 1 |
| Mensink, GJ | 1 |
| Slooff, CJ | 1 |
| Alméras, N | 1 |
| Després, JP | 1 |
| Villeneuve, J | 1 |
| Demers, MF | 1 |
| Cadrin, C | 1 |
| Mottard, JP | 1 |
| Bouchard, RH | 1 |
| Patel, MX | 3 |
| Young, C | 2 |
| Samele, C | 1 |
| Huq, ZU | 1 |
| Nolan, K | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Migliardi, G | 1 |
| Morgante, L | 1 |
| Ancione, M | 1 |
| Madia, A | 1 |
| Baskys, A | 1 |
| Kafantaris, V | 1 |
| Coletti, DJ | 1 |
| Dicker, R | 1 |
| Padula, G | 1 |
| Pleak, RR | 1 |
| Alvir, JM | 1 |
| Berecz, R | 1 |
| Dorado, P | 1 |
| De La Rubia, A | 1 |
| Cáceres, MC | 1 |
| Degrell, I | 1 |
| Lejeune, J | 1 |
| Larmo, I | 1 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Karavatos, A | 1 |
| Gonzalez-Heydrich, J | 1 |
| Fleisher, CA | 1 |
| Hsin, O | 1 |
| Raches, D | 1 |
| Bourgeois, BF | 1 |
| Biederman, J | 1 |
| Bhatara, V | 1 |
| Alshari, MG | 1 |
| Warhol, P | 1 |
| McMillin, JM | 1 |
| Bhatara, A | 1 |
| Young, CL | 2 |
| Mace, S | 1 |
| Tauscher, J | 2 |
| Hussain, T | 1 |
| Agid, O | 2 |
| Verhoeff, NP | 2 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| Zipursky, RB | 2 |
| Zhu, Y | 9 |
| Eerdekens, M | 6 |
| Mintzer, JE | 2 |
| Tebartz van Elst, L | 1 |
| Bäumer, D | 1 |
| Ebert, D | 1 |
| Trimble, MR | 1 |
| Percudani, M | 1 |
| Fortino, I | 1 |
| Petrovich, L | 1 |
| Chau, A | 1 |
| Fortin, P | 1 |
| Jenkins, W | 1 |
| Eren, I | 1 |
| Ozcankaya, R | 1 |
| Altinyazar, V | 1 |
| Magdalan, J | 1 |
| Wasyko-Smolarek, M | 1 |
| Antończyk, A | 1 |
| Kochman, K | 1 |
| Przewłocki, M | 1 |
| Porebska, B | 1 |
| Finkel, S | 2 |
| Katz, IR | 3 |
| Rachid, F | 1 |
| Bertschy, G | 3 |
| Bondolfi, G | 2 |
| Aubry, JM | 2 |
| Lasser, R | 2 |
| Welch, R | 1 |
| Binder, C | 1 |
| Lutz, R | 1 |
| Köhnlein, O | 1 |
| Schmauss, M | 2 |
| Norman, R | 1 |
| Scholten, D | 1 |
| Townsend, L | 1 |
| Takhar, J | 1 |
| Haricharan, R | 1 |
| Addington, DE | 2 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Gharabawi, GM | 9 |
| Martinez, RA | 1 |
| Tune, LE | 2 |
| Greenspan, AJ | 1 |
| Bastean, JN | 1 |
| Gayubo Moreo, L | 1 |
| Martínez Pastor, CJ | 1 |
| García Recio, A | 1 |
| Hovens, JE | 1 |
| Dries, PJ | 1 |
| Melman, CT | 1 |
| Wapenaar, RJ | 1 |
| Loonen, AJ | 2 |
| Ahl, J | 1 |
| Liu-Seifert, H | 1 |
| Vieweg, WV | 1 |
| Sood, AB | 1 |
| Pandurangi, A | 1 |
| Silverman, JJ | 1 |
| Lacomblez, L | 1 |
| Aichhorn, W | 2 |
| Stuppaeck, C | 2 |
| Whitworth, AB | 1 |
| Oner, O | 1 |
| Unal, O | 1 |
| Deda, G | 1 |
| Yoshimura, R | 2 |
| Shinkai, K | 2 |
| Kakihara, S | 2 |
| Goto, M | 2 |
| Yamada, Y | 2 |
| Kaji, K | 2 |
| Ueda, N | 2 |
| Nakamura, J | 2 |
| Sacchetti, E | 4 |
| Martin, SD | 1 |
| Kim, TS | 1 |
| Lee, SJ | 1 |
| Kopala, L | 2 |
| Van Hove, I | 3 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Baselmans, P | 1 |
| Bosker, F | 1 |
| McGurk, SR | 2 |
| Carter, C | 2 |
| Green, MF | 3 |
| Xie, H | 1 |
| Ren, XS | 1 |
| Kazis, LE | 1 |
| Lee, AF | 1 |
| Huang, YH | 1 |
| Hamed, A | 1 |
| Cunningham, F | 1 |
| Herz, L | 1 |
| Miller, DR | 1 |
| De Deyn, PP | 3 |
| Brodaty, H | 5 |
| Lyons, B | 1 |
| Greenspan, A | 9 |
| Burns, A | 1 |
| Malviya, G | 1 |
| Sinha, MK | 1 |
| Bhattacharya, SK | 1 |
| Nolan, KA | 1 |
| Kline, L | 1 |
| McEvoy, J | 3 |
| Ciliberto, N | 1 |
| Urioste, R | 1 |
| Herrera-Estrella, M | 1 |
| Vazquez, A | 1 |
| Shin, YW | 1 |
| Joo, YH | 1 |
| Hong, JP | 1 |
| Lee, GH | 1 |
| Choi, SK | 1 |
| Kozarić-Kovacić, D | 1 |
| Pivac, N | 1 |
| Mück-Seler, D | 1 |
| Rothbaum, BO | 1 |
| Olivier, V | 1 |
| Chabot, B | 1 |
| Déal, C | 1 |
| Perrin, E | 1 |
| Andrezina, R | 1 |
| Glue, P | 2 |
| Masiak, M | 2 |
| Turner, MS | 1 |
| Mohl, A | 1 |
| Westlye, K | 1 |
| Benoit, M | 1 |
| Bräunig, P | 1 |
| Frazzingaro, S | 1 |
| Lombertie, ER | 1 |
| Lenert, LA | 1 |
| Rupnow, MF | 2 |
| Elnitsky, C | 1 |
| Susce, MT | 1 |
| Pan, RM | 1 |
| Koch, WH | 1 |
| Wedlund, PJ | 1 |
| Bennouna, M | 1 |
| Greene, VB | 1 |
| Defranoux, L | 1 |
| Taylor, M | 2 |
| Watt, L | 1 |
| Brown, D | 1 |
| Martin, M | 1 |
| Fraser, K | 1 |
| Kurz, A | 1 |
| Schwalen S, S | 1 |
| Schmitt, A | 1 |
| Henderson, DC | 3 |
| Nguyen, DD | 2 |
| Copeland, PM | 2 |
| Hayden, DL | 1 |
| Borba, CP | 3 |
| Louie, PM | 1 |
| Freudenreich, O | 2 |
| Evins, AE | 2 |
| Cather, C | 2 |
| McKee, JR | 1 |
| Bodfish, JW | 1 |
| Mahorney, SL | 1 |
| Heeth, WL | 1 |
| Ball, MP | 1 |
| Kozma, C | 1 |
| Long, S | 1 |
| Baser, O | 1 |
| Engelhart, L | 3 |
| Post, RM | 1 |
| Calabrese, JR | 1 |
| Tan, CH | 1 |
| Chan, YH | 1 |
| Nakonezny, PA | 3 |
| Fisher, R | 2 |
| Magouirk, B | 1 |
| Rush, AJ | 3 |
| Snowdon, J | 3 |
| Woodward, M | 1 |
| Kirwan, J | 1 |
| Clarnette, R | 1 |
| Lee, E | 1 |
| Eberhard, J | 2 |
| Jasović-Gasić, M | 1 |
| Marić, N | 1 |
| Damjanović, A | 1 |
| Kraus, JE | 1 |
| Cook, A | 1 |
| Reviere, R | 1 |
| Goldman, S | 1 |
| Girgis, RR | 1 |
| Diwadkar, VA | 1 |
| Nutche, JJ | 1 |
| Hardan, AY | 1 |
| Eden Evins, A | 1 |
| Baer, L | 1 |
| Carnahan, RM | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Waite, J | 1 |
| Yohanan, M | 1 |
| Aulakh, JS | 1 |
| Weith, J | 1 |
| Hawkins, JW | 1 |
| Lee, BH | 1 |
| Kim, YK | 2 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Caers, I | 1 |
| Kushner, S | 3 |
| Weiner, M | 1 |
| Kéri, S | 1 |
| Kelemen, O | 1 |
| Janka, Z | 1 |
| Mamo, D | 1 |
| Reiss, J | 1 |
| Mannaert, E | 3 |
| Mann, S | 1 |
| van Nimwegen, L | 2 |
| Kostulski, A | 1 |
| Wyszogrodzka-Kucharska, A | 1 |
| Rabe-Jabłońska, J | 1 |
| Smith, G | 1 |
| Love, L | 1 |
| Talling, D | 1 |
| Balshaw, R | 1 |
| Holzer, L | 1 |
| Eap, CB | 2 |
| Amador, X | 1 |
| Mehnert, A | 1 |
| Johnson, J | 1 |
| Bourgeois, JA | 1 |
| Quanbeck, C | 1 |
| Guaiana, G | 1 |
| Markova, I | 1 |
| Lazarou, EE | 1 |
| Catalano, G | 1 |
| Catalano, MC | 1 |
| Leon, YC | 1 |
| Gorman, JM | 1 |
| Bettcher, BM | 1 |
| Carmody, T | 1 |
| Rustembegovic, A | 1 |
| Sofic, E | 1 |
| Wichart, I | 1 |
| Savage, R | 1 |
| Borisov, A | 1 |
| Rosenberg, J | 1 |
| Woolwine, B | 1 |
| Tucker, M | 1 |
| May, R | 1 |
| Feldman, J | 1 |
| Nemeroff, CB | 3 |
| Miller, AH | 2 |
| Hendset, M | 1 |
| Refsum, H | 1 |
| Tanum, L | 1 |
| Maia, DP | 1 |
| Cardoso, F | 1 |
| Schubert, MH | 1 |
| Young, KA | 1 |
| Hicks, PB | 1 |
| Day, S | 1 |
| Desarkar, P | 1 |
| Nizamie, SH | 3 |
| Katz, I | 2 |
| van Iersel, MB | 1 |
| Koopmans, RT | 1 |
| Verhey, FR | 1 |
| Olde Rikkert, MG | 1 |
| Moise, D | 2 |
| Kontaxakis, VP | 1 |
| Ferentinos, PP | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Paplos, KG | 1 |
| Pappa, DA | 1 |
| Christodoulou, GN | 1 |
| Uko-Ekpenyong, G | 1 |
| Simpson, GM | 2 |
| Kujawa, M | 2 |
| Rodriguez, S | 1 |
| Dowling, NM | 1 |
| Megna, JL | 2 |
| Burgdorf, A | 1 |
| Yashaswi, V | 1 |
| Khan, A | 2 |
| Catafau, AM | 1 |
| Martin, JC | 1 |
| Schotte, A | 1 |
| Carrió, I | 1 |
| Melkersson, KI | 1 |
| Brandenberger, M | 1 |
| Schopper, C | 1 |
| Llorca, J | 1 |
| Luis Vázquez-Barquero, J | 1 |
| Pierson, K | 1 |
| Addington, D | 1 |
| Patten, S | 1 |
| Demling, JH | 1 |
| Huang, ML | 1 |
| Remmerie, B | 2 |
| Sperling, W | 1 |
| Woerner, MG | 1 |
| Gunduz-Bruce, H | 1 |
| Soto-Perello, JM | 1 |
| Khadivi, A | 1 |
| Miller, R | 1 |
| Lorell, BS | 1 |
| Lesser, ML | 1 |
| Docherty, JP | 1 |
| Lachaux, B | 1 |
| Bouhours, P | 1 |
| De Oliveira, IR | 1 |
| Juruena, MF | 1 |
| Bogunovic, O | 1 |
| Lin, WW | 1 |
| Lin, SK | 1 |
| Hwang, TJ | 1 |
| Su, TP | 2 |
| Weiden, P | 2 |
| Weissman, EM | 1 |
| Dellenbaugh, C | 1 |
| Archie, SM | 1 |
| Goldberg, JO | 1 |
| Akhtar-Danesh, N | 1 |
| Landeen, J | 1 |
| McColl, L | 1 |
| McNiven, J | 1 |
| Kahn, JP | 1 |
| Reeves, RR | 1 |
| Burke, RS | 1 |
| Parker, JD | 1 |
| Holstad, M | 1 |
| Risch, SC | 2 |
| Horner, MD | 1 |
| Palecko, S | 1 |
| Markowitz, JS | 1 |
| Nahas, Z | 1 |
| DeVane, CL | 3 |
| Raczek, M | 1 |
| Chou, KL | 1 |
| Borek, LL | 1 |
| Lim, L | 1 |
| Krystal, A | 1 |
| Thyssen, A | 1 |
| D'Hoore, P | 1 |
| Post, DE | 1 |
| Segal, M | 1 |
| Avital, A | 1 |
| Derevenski, A | 1 |
| Berstein, S | 1 |
| Sandbank, S | 1 |
| Weizman, A | 1 |
| Gu, H | 3 |
| Lazarus, A | 1 |
| Sweitzer, D | 2 |
| Olexy, C | 1 |
| Strakowski, SD | 1 |
| Keefe, RS | 1 |
| Arenovich, T | 1 |
| Shim, JC | 1 |
| Choe, BM | 1 |
| Kim, JG | 1 |
| Jae, YM | 1 |
| Kim, HC | 1 |
| Kim, SG | 1 |
| Oh, MK | 1 |
| Kelly, DL | 3 |
| Conley, RR | 5 |
| Pariente, A | 1 |
| Fourier-Réglat, A | 1 |
| Wynn, JK | 1 |
| Sprock, J | 1 |
| Light, GA | 1 |
| Widmark, C | 2 |
| Erhart, S | 2 |
| Braff, DL | 2 |
| Newport, DJ | 1 |
| Calamaras, MR | 1 |
| Donovan, J | 1 |
| Beach, AJ | 1 |
| Winn, S | 1 |
| Knight, BT | 1 |
| Gibson, BB | 1 |
| Viguera, AC | 1 |
| Owens, MJ | 1 |
| Stowe, ZN | 1 |
| Mathews, M | 1 |
| Muzina, DJ | 1 |
| Singh, D | 1 |
| O'Connor, DW | 1 |
| Mahgoub, NA | 1 |
| Blakesley, RE | 1 |
| Huber, KA | 1 |
| Katagai, H | 1 |
| Yasui-Furukori, N | 1 |
| Kikuchi, A | 1 |
| Kaneko, S | 1 |
| Belger, M | 1 |
| Sergi, MJ | 1 |
| Kee, KS | 1 |
| Villari, V | 1 |
| Rocca, P | 1 |
| Fonzo, V | 1 |
| Montemagni, C | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 1 |
| Kissling, W | 2 |
| Simpson, S | 1 |
| Kosik-Gonzalez, C | 1 |
| Rapp, JT | 1 |
| Swanson, G | 1 |
| Dornbusch, K | 1 |
| Marksteiner, J | 1 |
| Walch, T | 1 |
| Zernig, G | 1 |
| Hinterhuber, H | 1 |
| Kemmler, G | 1 |
| Ramirez-Bonilla, ML | 1 |
| Duval, F | 1 |
| Guillon, MS | 1 |
| Mokrani, MC | 1 |
| Crocq, MA | 1 |
| Garcia Duarte, F | 1 |
| Awouters, FH | 1 |
| Lewi, PJ | 1 |
| Heeg, BM | 1 |
| Antunes, J | 1 |
| Figueira, ML | 1 |
| Jara, JM | 1 |
| Marques Teixeira, J | 1 |
| Palha, AP | 1 |
| Vaz Serra, A | 1 |
| Buskens, E | 1 |
| Caleo, S | 1 |
| Gouveia-Pinto, C | 1 |
| Van Hout, BA | 1 |
| Bossie, C | 1 |
| Lipkovich, I | 1 |
| Adams, DH | 1 |
| Mallinckrodt, C | 1 |
| Baron, D | 1 |
| Houston, JP | 1 |
| Khine, TT | 1 |
| Lloyd, K | 2 |
| Jano, E | 1 |
| Johnson, M | 1 |
| Aparasu, RR | 1 |
| Carrasco-Marín, E | 2 |
| Fernandez-Prieto, L | 1 |
| Leyva-Cobián, F | 1 |
| Erdogan, A | 1 |
| Atasoy, N | 1 |
| Akkurt, H | 1 |
| Ozturk, D | 1 |
| Karaahmet, E | 1 |
| Yalug, I | 1 |
| Yalug, K | 1 |
| Ankarali, H | 1 |
| Balcioglu, I | 1 |
| Loebl, T | 1 |
| Angarita, GA | 1 |
| Pachas, GN | 1 |
| Huang, KL | 1 |
| Nino, J | 1 |
| Logvinenko, T | 1 |
| Culhane, MA | 1 |
| Ader, M | 1 |
| Garvey, WT | 1 |
| Phillips, LS | 1 |
| Musselman, DL | 1 |
| Morein, J | 1 |
| Bergman, RN | 1 |
| Curtis, VA | 1 |
| Katsafouros, K | 1 |
| Hussain, A | 1 |
| Belderbos, S | 1 |
| Currie, A | 1 |
| Price, M | 1 |
| Peperell, K | 1 |
| Oosthuizen, PP | 1 |
| Canuso, CM | 1 |
| Youssef, E | 1 |
| Dunner, DL | 1 |
| Sutton, BJ | 1 |
| Martello, D | 1 |
| Allingham, B | 1 |
| Berja, A | 1 |
| Fiedler, T | 1 |
| Gutmann, P | 1 |
| Ford, B | 1 |
| Lynch, T | 1 |
| Greene, P | 1 |
| Cozza, SJ | 1 |
| Edison, DL | 1 |
| Busatto, GF | 1 |
| Pilowsky, LS | 1 |
| Costa, DC | 1 |
| Ell, PJ | 1 |
| Kerwin, RW | 1 |
| Tekell, JL | 1 |
| Smith, EA | 1 |
| Silva, JA | 1 |
| McCarthy, RH | 1 |
| Terkelsen, KG | 1 |
| Dave, M | 1 |
| Tyson, SC | 1 |
| Keck, PE | 3 |
| Strakowski, SM | 3 |
| McElroy, SL | 2 |
| Kizer, DL | 1 |
| Balistreri, TM | 1 |
| Holtman, HM | 1 |
| DePriest, M | 1 |
| Toews, JA | 1 |
| Addington, JM | 1 |
| Murray, S | 1 |
| Haller, E | 1 |
| Araujo, L | 1 |
| Abaza, A | 1 |
| Najara, JE | 1 |
| Enikeev, ID | 1 |
| Remr, J | 1 |
| Svestka, J | 1 |
| Tourjman, V | 1 |
| Lew, V | 1 |
| Fabian, J | 1 |
| Cormier, H | 1 |
| Landry, P | 1 |
| Lalonde, P | 1 |
| Cournoyer, J | 1 |
| Doraiswamy, M | 1 |
| Martin, W | 1 |
| Metz, A | 1 |
| Deveaugh-Geiss, J | 1 |
| Edleman, RJ | 1 |
| Weinberger, DR | 1 |
| Kleinman, JE | 1 |
| Pickar, D | 2 |
| Lubick, LJ | 1 |
| Williams, TS | 1 |
| Godleski, LS | 1 |
| Sernyak, MJ | 3 |
| Eastham, JH | 1 |
| Lacro, JP | 1 |
| Gierz, M | 1 |
| Field, MG | 1 |
| Harris, MJ | 2 |
| Levin, GM | 1 |
| Lazowick, AL | 1 |
| Powell, HS | 1 |
| Gilroy, WR | 1 |
| Benazzi, F | 2 |
| Schnierow, BJ | 1 |
| Graeber, DA | 1 |
| Hargreaves, WA | 1 |
| Shumway, M | 1 |
| Carter, CS | 2 |
| Sweet, RA | 1 |
| Maxwell, RA | 1 |
| Coley, K | 1 |
| Branch, R | 1 |
| Negrón, AE | 2 |
| Leiderman, EA | 1 |
| Parkadavil, M | 1 |
| Smith, RC | 1 |
| Chua, JW | 1 |
| Lipetsker, B | 1 |
| Bhattacharyya, A | 1 |
| Meterissian, GB | 1 |
| Farah, A | 1 |
| Beale, MD | 1 |
| Casey, DE | 1 |
| Lehman, AF | 1 |
| Ramirez, LF | 1 |
| Vernon, L | 1 |
| Brescan, D | 1 |
| Simon, M | 1 |
| Jurjus, G | 1 |
| Droney, T | 1 |
| Barkin, JS | 1 |
| Pais, VM | 1 |
| Gaffney, MF | 1 |
| Küfferle, B | 2 |
| Brücke, T | 1 |
| Topitz-Schratzberger, A | 1 |
| Gössler, R | 1 |
| Vesely, C | 1 |
| Asenbaum, S | 1 |
| Podreka, I | 1 |
| Rosebush, PI | 1 |
| Kennedy, K | 1 |
| Dalton, B | 1 |
| Mazurek, MF | 1 |
| Brown, ES | 1 |
| Schreiber, S | 2 |
| Segman, RH | 2 |
| Koponen, HJ | 1 |
| Gardner, DM | 1 |
| Benzo, J | 1 |
| Zarate, CA | 2 |
| Konrad, C | 1 |
| Schormair, C | 1 |
| Eikelmann, B | 1 |
| Telger, K | 1 |
| Singh, AN | 1 |
| Golledge, H | 1 |
| Catalan, J | 1 |
| Zimnitzky, BM | 1 |
| DeMaso, DR | 1 |
| Steingard, RJ | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| Grcevich, SJ | 1 |
| Rowane, WA | 1 |
| Friedman, L | 1 |
| Schulz, SC | 1 |
| Khan, BU | 1 |
| Viale, G | 1 |
| Mechling, L | 1 |
| Maislin, G | 1 |
| Durkin, M | 1 |
| Lawrence, BJ | 1 |
| Hamilton, SH | 1 |
| Kuntz, AJ | 2 |
| Potvin, JH | 1 |
| Andersen, SW | 1 |
| Beasley, C | 1 |
| Weizer, M | 1 |
| Levy, A | 1 |
| Fogelson, DL | 1 |
| Sternbach, H | 1 |
| Payne, D | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Hillard, JR | 1 |
| Luchins, DJ | 1 |
| Klass, D | 1 |
| Hanrahan, P | 1 |
| Malan, R | 1 |
| Harris, J | 1 |
| Miller, CH | 1 |
| Mohr, F | 1 |
| Woerner, M | 1 |
| Terao, T | 2 |
| Kojima, H | 2 |
| Eto, A | 1 |
| Binder, RL | 1 |
| McNiel, DE | 1 |
| Sandberg, DA | 1 |
| Müller-Siecheneder, F | 1 |
| Müller, MJ | 1 |
| Hillert, A | 2 |
| Szegedi, A | 1 |
| Wetzel, H | 2 |
| Benkert, O | 2 |
| Gheuens, J | 1 |
| Grebb, JA | 1 |
| Hoes, MJ | 1 |
| Popli, A | 1 |
| Rangwani, SR | 1 |
| Dursun, SM | 1 |
| Oluboka, OJ | 1 |
| Devarajan, S | 1 |
| Kutcher, SP | 1 |
| Hasan, S | 1 |
| Kiraly, SJ | 1 |
| Gibson, RE | 1 |
| Ancill, RJ | 1 |
| Holliday, SG | 1 |
| Phan, TG | 1 |
| Yu, RY | 1 |
| Hersch, MI | 1 |
| Lauterbach, EC | 1 |
| Sherr, JD | 1 |
| Thaker, G | 1 |
| Sindagi, J | 1 |
| Brafman, I | 1 |
| Rudnick, A | 1 |
| Rosen, EH | 1 |
| Zilikis, N | 1 |
| Nimatoudis, I | 1 |
| Kiosses, V | 1 |
| Ierodiakonou, C | 1 |
| Klag, E | 1 |
| Gross, Y | 1 |
| Pick, CG | 1 |
| Gazzola, LR | 1 |
| Opler, LA | 1 |
| Rockwell, E | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Ollendorf, D | 1 |
| Oster, G | 1 |
| Elman, I | 1 |
| Adler, CM | 1 |
| Weisenfeld, NI | 1 |
| Waring, EW | 1 |
| Dewan, VK | 1 |
| Grewal, R | 1 |
| Brecher, M | 1 |
| Kasckow, J | 1 |
| Kunik, M | 1 |
| Pomara, N | 1 |
| Tandon, R | 1 |
| Milner, K | 1 |
| Jibson, MD | 2 |
| Love, RC | 3 |
| Bartko, JJ | 2 |
| Haas, G | 1 |
| Kim, L | 1 |
| Lee, MS | 1 |
| Sheth, S | 1 |
| Marcus, S | 1 |
| Gopalani, A | 1 |
| Palmer, A | 1 |
| Mager, T | 1 |
| Meisenzahl, E | 1 |
| Wetterling, T | 1 |
| Müssigbrodt, HE | 1 |
| Dewan, M | 1 |
| Vercueil, L | 1 |
| Foucher, J | 1 |
| Suresh, P | 1 |
| Pillai, R | 1 |
| Cetin, M | 1 |
| Ebrinç, S | 1 |
| Ağargün, MY | 1 |
| Yiğit, S | 1 |
| Healy, E | 1 |
| Subotsky, F | 1 |
| Pipe, R | 1 |
| Lehtinen, V | 1 |
| Räkkölãinen, V | 1 |
| Tacke, U | 1 |
| Olie, JP | 1 |
| Ghaoui, S | 1 |
| Bayle, FJ | 2 |
| Ghaeli, P | 1 |
| Dufresne, RL | 1 |
| Keks, NA | 1 |
| Altson, K | 1 |
| Hope, J | 1 |
| Krapivensky, N | 1 |
| Culhane, C | 1 |
| Tanaghow, A | 1 |
| Doherty, P | 1 |
| Bootle, A | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Silver, H | 1 |
| Aharon, N | 1 |
| Schwartz, M | 1 |
| Coley, KC | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Emsley, RA | 1 |
| Salbenblatt, MJ | 1 |
| Buzan, RD | 1 |
| Dubovsky, SL | 1 |
| Blumer, D | 1 |
| Wakhlu, S | 1 |
| Montouris, G | 1 |
| Wyler, AR | 1 |
| Mikhail, SW | 2 |
| Kennedy, HG | 2 |
| Masand, PS | 1 |
| Sinha, BN | 1 |
| Duggal, HS | 1 |
| Kornreich, C | 1 |
| Dan, B | 1 |
| Verbanck, P | 1 |
| Pelc, I | 1 |
| Vervarcke, J | 1 |
| Gagiano, CA | 1 |
| De Hooge, JD | 1 |
| Bray, G | 1 |
| Dose, M | 1 |
| Haushofer, M | 1 |
| Katz, G | 1 |
| Durst, R | 1 |
| Zislin, J | 1 |
| Knobler, H | 1 |
| Knobler, HY | 1 |
| Tavcar, R | 1 |
| Dernovsek, MZ | 1 |
| Green, B | 1 |
| Williams, H | 1 |
| Clarke, R | 1 |
| Martin, J | 1 |
| Sharif, ZA | 1 |
| Raza, A | 1 |
| Ratakonda, SS | 1 |
| Bhana, N | 1 |
| Spencer, CM | 1 |
| Popli, AP | 1 |
| Nicolson, R | 1 |
| McCurley, R | 1 |
| Ellis, T | 1 |
| Cudkowicz, ME | 1 |
| Sexton, PM | 1 |
| Growdon, JH | 1 |
| Elmer, KB | 1 |
| George, RM | 1 |
| Peterson, K | 1 |
| Simon, AE | 1 |
| Liddle, PF | 1 |
| Lane, CJ | 1 |
| Ngan, ET | 1 |
| Lange, CL | 1 |
| Basson, BR | 1 |
| Gilmore, JA | 1 |
| Malcolm, S | 1 |
| Lichtenberg, P | 1 |
| Kaplan, Z | 1 |
| Heck, AH | 1 |
| Haffmans, PM | 1 |
| de Groot, IW | 1 |
| Hoencamp, E | 1 |
| Currier, GW | 2 |
| Feifel, D | 2 |
| Ghaemi, SN | 1 |
| Woods, SW | 2 |
| Stolar, M | 1 |
| Charney, DS | 1 |
| Tollin, SR | 1 |
| Moutier, CY | 1 |
| Perry, W | 1 |
| Seeman, P | 1 |
| Nelson, MW | 1 |
| Kaneda, Y | 1 |
| Compton, MT | 1 |
| Scharfstein, D | 1 |
| Robins, JM | 1 |
| Eddings, W | 1 |
| Rotnitzky, A | 1 |
| Albanese, MJ | 1 |
| Yap, HL | 1 |
| Mahendran, R | 1 |
| Lim, D | 1 |
| Liow, PH | 1 |
| Lee, A | 1 |
| Phang, S | 1 |
| Tiong, A | 1 |
| Kasckow, JW | 1 |
| Tugrul, K | 1 |
| Dowd, SM | 1 |
| Strong, J | 1 |
| Khan, SR | 1 |
| Leventhal, RM | 1 |
| Brown, WA | 1 |
| Connolly, CE | 1 |
| Hayden, D | 1 |
| Herraiz, M | 1 |
| Fernández, A | 2 |
| Gastó, C | 1 |
| Benabarre, A | 2 |
| Colom, F | 2 |
| Martínez-Arán, A | 2 |
| Reinares, M | 2 |
| Diaz, E | 1 |
| Levine, HB | 1 |
| Sullivan, MC | 1 |
| Hawkins, KA | 1 |
| Cramer, JA | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Friedlander, R | 1 |
| Lazar, S | 1 |
| Klancnik, J | 1 |
| Ganesan, V | 1 |
| Kumar, TC | 1 |
| Khanna, S | 1 |
| Waldeck, T | 1 |
| Wyszynski, B | 1 |
| Medalia, A | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Olin, JT | 1 |
| Rabins, PV | 1 |
| Small, GW | 1 |
| Lebowitz, B | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
| Hwang, JP | 1 |
| Yang, CH | 1 |
| Yu, HC | 1 |
| Chang, JW | 1 |
| Cheng, CY | 1 |
| Tsai, SJ | 1 |
| Mullen, J | 1 |
| Ekstam-Smith, K | 1 |
| Kutscher, E | 1 |
| Turvey, C | 1 |
| Normann, C | 1 |
| Lieb, K | 1 |
| Walden, J | 1 |
| Parker, G | 1 |
| Malhi, G | 1 |
| Goikolea, JM | 1 |
| Corbella, B | 1 |
| Martínez, G | 1 |
| Torrent, C | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Erdemoglu, AK | 1 |
| Boratav, C | 1 |
| Shamir, E | 1 |
| Weizman, R | 1 |
| Thyrum, PT | 1 |
| Alva, G | 1 |
| Bera, R | 1 |
| Yeh, C | 1 |
| Arvanitis, LA | 1 |
| Jagadheesan, K | 1 |
| Bahk, WM | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, KS | 1 |
| Bullock, R | 1 |
| Libretto, S | 1 |
| Vermeulen, A | 1 |
| Baumann, P | 1 |
| Bilder, RM | 1 |
| Goldman, RS | 1 |
| Hoptman, M | 1 |
| Horowitz, TL | 1 |
| Bertoldo, M | 1 |
| Gianfrancesco, F | 1 |
| Durkin, MB | 1 |
| Chereau, I | 1 |
| Lancon, C | 1 |
| Patel, NC | 1 |
| Dorson, PG | 1 |
| Edwards, N | 1 |
| Mendelson, S | 1 |
| Crismon, ML | 1 |
| Chari, S | 1 |
| Gelders, YG | 1 |
| Heylen, SL | 1 |
| Vanden Bussche, G | 1 |
| Reyntjens, AJ | 1 |
| Janssen, PA | 1 |
| Mesotten, F | 1 |
| Suy, E | 1 |
| Pietquin, M | 1 |
| Burton, P | 1 |
| Heylen, S | 1 |
| Gelders, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00036114] | Phase 3 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease[NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Real-world Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-risk for Psychosis: Study Protocol for a Prospective Observational Study (SHARP-2)[NCT04010864] | 600 participants (Anticipated) | Observational [Patient Registry] | 2019-03-29 | Recruiting | |||
| Glutamate, Brain Connectivity and Duration of Untreated Psychosis[NCT02034253] | 134 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients[NCT03442101] | 156 participants (Anticipated) | Observational | 2018-04-01 | Recruiting | |||
| Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up[NCT02526030] | Phase 4 | 203 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up[NCT02532491] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-05-31 | Enrolling by invitation | ||
| Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use[NCT04105231] | Phase 2 | 130 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Neuroimaging Biomarker-Guided Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Episode in Adolescents and Young Adults With Mood Disorders: A Randomized, Double-Blind, Controlled Study[NCT05465928] | 120 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment[NCT01786239] | 50 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychos[NCT03568500] | Phase 4 | 44 participants (Actual) | Interventional | 2018-05-21 | Completed | ||
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.[NCT00932529] | Phase 4 | 226 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)[NCT00216528] | Phase 4 | 527 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study[NCT00640562] | Phase 3 | 216 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)[NCT00330863] | Phase 4 | 357 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Lorazepam Effects on Neuroimaging Measures: A Pilot Study[NCT04671836] | Early Phase 1 | 0 participants (Actual) | Interventional | 2022-01-31 | Withdrawn (stopped due to No longer interested in conducing study) | ||
| Preventing Morbidity in First Episode Schizophrenia, Part II[NCT00320671] | Phase 4 | 198 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Clinical Research Center for Dementia of South Korea (CREDOS)[NCT01198093] | 800 participants (Anticipated) | Observational | 2005-11-30 | Recruiting | |||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine[NCT00378183] | Phase 4 | 120 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder[NCT00236353] | Phase 3 | 86 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder[NCT01198353] | Phase 4 | 67 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.[NCT00337662] | Phase 4 | 628 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o[NCT00325689] | Phase 4 | 323 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia[NCT00621998] | Phase 4 | 60 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study[NCT00272597] | Phase 4 | 30 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Clinical Management of Metabolic Problems in Patients With Schizophrenia[NCT00423878] | Phase 4 | 215 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062] | 300 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)[NCT00216632] | Phase 4 | 99 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Electronic Schizophrenia Treatment Adherence Registry, eSTAR[NCT00283517] | 2,046 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia[NCT00132314] | Phase 3 | 382 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia[NCT00220714] | Phase 4 | 80 participants | Interventional | 2004-11-30 | Active, not recruiting | ||
| Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective[NCT03501160] | 8 participants (Actual) | Observational | 2018-06-12 | Completed | |||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Antipsychotic Discontinuation in Alzheimer's Disease[NCT00417482] | Phase 4 | 180 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Metabolic Effects of Newer Antipsychotics in Older Patients[NCT00245206] | Phase 4 | 406 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years[NCT00230893] | 99 participants | Observational | 2005-07-31 | Completed | |||
| Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade[NCT00233467] | 0 participants (Actual) | Observational | 2005-09-01 | Withdrawn (stopped due to Funding expired; no subjects enrolled as this was a retrospective chart review) | |||
| Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.[NCT00034762] | Phase 3 | 473 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With [NCT00297388] | Phase 3 | 40 participants (Actual) | Interventional | Completed | |||
| Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control[NCT00283179] | Phase 3 | 83 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison[NCT00034892] | Phase 3 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients[NCT01119638] | Phase 4 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence[NCT00385801] | Phase 2 | 31 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from Baseline to Day 43 in the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) psychosis score (Delusions [Domain A]+Hallucinations [Domain B]) in the Full Analysis Set (FAS). The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains. For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), The NPI-NH Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual domain scores, to yield a possible total score of 0 to 24. Lower scores correspond to less severity. A negative change score from baseline indicates improvement. (NCT02035553)
Timeframe: Day 43
| Intervention | Score on the NPI-NH scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Pimavanserin 40 mg | -3.76 |
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms. (NCT01786239)
Timeframe: 16 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline BPRS Score | Week 16 BPRS Score | |
| Omega-3 Capsules & Risperidone | 41.64 | 22.5868 |
| Placebo & Risperidone | 42.38 | 27.2235 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure. (NCT03568500)
Timeframe: Up to 8 weeks
| Intervention | percentage of MITs (Mean) |
|---|---|
| Schizophrenia | 88.94 |
| Schizoaffective Disorder | 72.29 |
| First Episode Psychosis | 91.04 |
| Total | 86.57 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet [MIT]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure. (NCT03568500)
Timeframe: Up to 8 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Schizophrenia | 64.34 |
| Schizoaffective Disorder | 62.99 |
| First Episode Psychosis | 62.51 |
| Total | 63.37 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | -1.50 |
| Risperidone | -1.04 |
Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment. (NCT00640562)
Timeframe: 12 week
| Intervention | Kg/m^2 (Mean) |
|---|---|
| Seroquel XR | 29.07 |
| Risperidone | 28.80 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12week: descriptive statistic of CGI by visit and treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Seroquel XR | 91 |
| Risperidone | 88 |
"Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.~The SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40~Change from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments." (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 2.74 |
| Risperidone | 3.88 |
"The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.~CDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.~The sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression." (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 7.31 |
| Risperidone | 5.53 |
These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 86.38 |
| Risperidone | 76.64 |
21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Mean) |
|---|---|
| Seroquel XR | -29.83 |
| Risperidone | -23.02 |
30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 102.26 |
| Risperidone | 100.51 |
Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit (NCT00640562)
Timeframe: 12 week from screening visit to last visit
| Intervention | KG (Least Squares Mean) |
|---|---|
| Seroquel XR | 61.20 |
| Risperidone | 90.80 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: Change of drug use from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 14 |
| Risperidone | 17 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: 12 week from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 12 |
| Risperidone | 11 |
(NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | participants (Number) |
|---|---|
| Injectable | 81 |
| Oral | 80 |
Brief Psychiatric Rating Scale (BPRS) psychosis cluster. Score range is based on the score range for individual items rather than the factor total because is factors have different numbers of items. Score range is 1 -7 where 1 + no symptomatology and 7 = very severe symptoms. (NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Injectable | 1.8 |
| Oral | 2.0 |
The highest severity of each of 24 adverse event (AE) that was assessed.over the 30 month study period. The mean severity on a scale of 1 (none) to 4 very severe symptom was recorded at each biweekly visit. Results for each variable are summarized over time so that each subject has a single mean severity rating for each AE. There is no named scale. Each of the side effects measured is named in ways that are clear to medical readers e.g anorexia. The range is 1 none to 4 very severe. Therefore, a higher scale score is worse. (NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruising easily | Rash | Urticaria (hives, itching) | Blurred vision | sedation/drowsiness | Restlessness | Insomnia | Malaise (weakness, fatigue) | Stiffness | Tremor | Dizziness | Headache | Fever | Sore Throat | Dry Mouth | Hypersalivation | Enuresis | Constipation | Diarrhea | Anorexia (loss of appetite) | Nausea | Vomiting | Menstrual Irregularity | Breast tenderness/galactorrhea | |
| Injectable | 1.43 | 1.53 | 1.60 | 1.76 | 2.34 | 2.48 | 2.38 | 2.22 | 2.01 | 1.77 | 1.82 | 1.99 | 1.27 | 1.64 | 2.36 | 1.76 | 1.63 | 1.75 | 1.65 | 1.89 | 1.78 | 1.48 | 1.62 | 1.39 |
| Oral | 1.48 | 1.44 | 1.71 | 1.91 | 2.53 | 2.43 | 2.36 | 2.14 | 1.97 | 1.75 | 1.78 | 1.89 | 1.24 | 1.57 | 2.25 | 1.84 | 1.56 | 1.64 | 1.68 | 1.69 | 1.72 | 1.51 | 1.55 | 1.32 |
Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content. Scores range from-7 (not assessed) to 7 (very severe) Subjects with scores of 3 or less on all 4 items for 2 consecutive visits are deemed responders, subjects with 4 or greater and any of the aforementioned items for 2 consecutive study visits are non responders. Additionally, the subjects response on the Clinical Global Impressions Scale. A Clinical Global Improvement CGI) rating of much or very much improved on 2 consecutive ratings were deemed a responder. Percentages and confidence intervals were used to report response outcome. Response status was assessed throughout the duration of the study; a participant can be deemed a responder any time between weeks 1-week 12. The possible range for this outcome is a score of 4 to 28 (NCT00320671)
Timeframe: this outcome was assessed throughout the study.
| Intervention | percentage of response (Number) |
|---|---|
| Percentage of Participants That Reposonded to Aripiprazole | 62.8 |
| Percentage of Participants That Reposonded to Risperidone | 56.8 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.38 |
| NEO-RIS | 0.11 |
| EO-RIS | -0.16 |
Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia). (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.31 |
| NEO-RIS | -0.13 |
| EO-RIS | -0.24 |
Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.06 |
| NEO-RIS | -0.03 |
| EO-RIS | -0.02 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0). (NCT00337662)
Timeframe: Weeks 0, 3, 4, 6, 8, 12
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change from Week 0 to Week 3 | Change from Week 0 to Week 4 | Change from Week 0 to Week 6 | Change from Week 0 to Week 8 | Change from Week 0 to Week 12 | |
| EO-RIS | -30.80 | -32.53 | -32.90 | -34.10 | -35.09 |
| NEO-RIS | -11.90 | -14.81 | -16.23 | -18.10 | -18.62 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2). (NCT00337662)
Timeframe: Weeks 2, 3, 4, 6, 8, 12
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change from Week 2 to Week 3 | Change from Week 2 to Week 4 | Change from Week 2 to Week 6 | Change from Week 2 to Week 8 | Change from Week 2 to Week 12 | |
| NEO-OLZ | -5.85 | -9.67 | -13.06 | -14.73 | -17.02 |
| NEO-RIS | -6.94 | -9.82 | -11.25 | -13.13 | -13.53 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=50% Reduction - Yes | >=50% Reduction - No | |
| EO-RIS | 87 | 51 |
| NEO-RIS | 67 | 122 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=50% Reduction - Yes | >=50% Reduction - No | |
| NEO-OLZ | 67 | 112 |
| NEO-RIS | 67 | 122 |
Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| Required overnight stay in hospital: Yes | Required overnight stay in hospital: No | |
| EO-RIS | 10 | 127 |
| NEO-RIS | 9 | 175 |
Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Low total bilirubin | High creatine phosphokinase | High creatinine | High hemoglobin A1c | Low sodium | High prolactin | |
| EO-RIS | 2 | 5 | 3 | 2 | 4 | 7 |
| NEO-OLZ | 5 | 6 | 2 | 6 | 4 | 7 |
| NEO-RIS | 3 | 1 | 4 | 7 | 4 | 8 |
The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=20% Reduction - Yes | >=20% Reduction - No | |
| EO-RIS | 119 | 19 |
| NEO-RIS | 94 | 95 |
The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=20% Reduction - Yes | >=20% Reduction - No | |
| NEO-OLZ | 94 | 85 |
| NEO-RIS | 94 | 95 |
Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 80.29 | -1.73 |
| NEO-OLZ | 78.69 | 1.01 |
| NEO-RIS | 78.57 | -0.20 |
Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 94.60 | -1.94 |
| NEO-OLZ | 93.53 | 0.68 |
| NEO-RIS | 93.81 | -0.58 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | kilogram per square meter (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 31.13 | 0.10 |
| NEO-OLZ | 29.97 | 0.63 |
| NEO-RIS | 31.05 | 0.43 |
Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | kilograms (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 90.67 | 0.30 |
| NEO-OLZ | 88.28 | 1.85 |
| NEO-RIS | 90.25 | 1.29 |
Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 77.90 | -0.94 |
| NEO-OLZ | 80.49 | -0.98 |
| NEO-RIS | 80.84 | -2.52 |
Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 82.39 | -0.56 |
| NEO-OLZ | 85.57 | -1.13 |
| NEO-RIS | 85.32 | -2.05 |
Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 123.20 | -2.36 |
| NEO-OLZ | 123.20 | 0.01 |
| NEO-RIS | 124.30 | -1.35 |
Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis. (NCT00423878)
Timeframe: 24 weeks
| Intervention | mg/dL non-HDL cholesterol (Least Squares Mean) |
|---|---|
| Switch Group | -20.2 |
| Stay Group | -10.8 |
(NCT00423878)
Timeframe: Measured at Month 6
| Intervention | participants (Number) |
|---|---|
| Switch Group | 22 |
| Stay Group | 18 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. Patients without an event were censored at 24 months after the date of randomization. (NCT00132314)
Timeframe: From randomization until date of first re-hospitalization, assessed up to 24 months
| Intervention | years (Median) |
|---|---|
| Injectable Risperidone | NA |
| Oral Antipsychotic | 1.97 |
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model. (NCT00132314)
Timeframe: 24 months
| Intervention | participants (Number) | |
|---|---|---|
| Patients with psychiatric hospitalization | Patients without psychiatric hospitalization | |
| Injectable Risperidone | 72 | 115 |
| Oral Antipsychotic | 81 | 101 |
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Abnormal Involuntary Movement Scale (AIMS) assesses signs of tardive dyskinesia, a movement disorder that can occur with prolonged use of antipsychotic medication. The AIMS score ranges from 0 to 35, with higher scores indicating more severe symptoms. For each subject, the change in AIMS score between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in AIMS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Risperidone | 0.24 |
Extrapyramidal signs, also known as Parkinsonian signs, refer to signs of tremor, rigidity, and bradykinesia (slowed movement) that are seen in Parkinson's disease. Assessment of extrapyramidal signs (EPS) were made with the use of the Simpson-Angus scale (which ranges from 1-40) with higher scores indicating more extrapyramidal signs. For each subject, the change in EPS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in EPS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.20 |
| Risperidone | 0.34 |
The MMSE assesses cognition. Scores range from 0-30, with higher scores indicating better cognition. For each subject, the change in MMSE between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in MMSE over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.13 |
| Risperidone | -0.77 |
Physical Self-Maintenance Scale, which ranges from 1 to 30, with higher scores indicating WORSE functioning. For each subject, the change in PSMS between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in PSMS (worse functioning) over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.80 |
"A relapse occurred in Phase B (post-randomization) if both of the following criteria were met:~Increase in the Neuropsychiatric Inventory (NPI) core score of 30% or more OR a 5-point increase from the baseline NPI score at the end of Phase A~A score of 6 (much worse) or 7 (very much worse) on the Clinical Global Impression-Change (CGI-C) at any visit." (NCT00417482)
Timeframe: 0-16 weeks in Phase B (16-32 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Phase B Arm 1: Risperidone-Risperidone | 15 |
| Phase B Arm 2: Risperidone -Placebo | 8 |
| Phase B Arm 3: Placebo-Placebo | 24 |
Same definition and criteria as the primary outcome (NCT00417482)
Timeframe: 16-32 weeks in Phase B (32-48 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Arm 1: Risperidone - Risperidone | 2 |
| Arm 2: Risperidone - Placebo | 13 |
The Treatment Emergent Symptom Scale (TESS) assesses 26 somatic symptoms. Total scores range from 0-26, with a score of 0 or 1 for each item. Higher scores indicate more somatic symptoms. For each subject, the change in TESS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in TESS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.21 |
For each subject, the change in weight in pounds between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in weight over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.32 |
| Risperidone | 0.73 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week) (NCT00385801)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | NA |
| Risperidone | NA |
After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below (NCT00385801)
Timeframe: 12 weeks
| Intervention | visit with negative UBE (Mean) |
|---|---|
| Placebo | 1.81 |
| Risperidone Consta | 0.87 |
114 reviews available for risperidone and Psychoses
| Article | Year |
|---|---|
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
Topics: Antipsychotic Agents; Aripiprazole; Dementia; Humans; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
New Antipsychotic Medications in the Last Decade.
Topics: Adult; Antipsychotic Agents; Humans; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Humans; Network Meta-Analysis; Off-La | 2022 |
Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Male; Psychotic Disorders; Risperidone; Sex | 2022 |
Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
Topics: Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Humans; Paliperidone Palmitate; P | 2022 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Psychotic Disorders; Risperidone; Secondary | 2020 |
Antipsychotics in Postpartum Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Postpartum Period; Psychotic Diso | 2020 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network M | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen | 2021 |
Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients.
Topics: Aged; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone; Schizop | 2021 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parki | 2017 |
Psychiatric symptoms associated with porphyria: A case report and brief review.
Topics: Adult; Antipsychotic Agents; Hispanic or Latino; Humans; Male; Paliperidone Palmitate; Porphyrias; P | 2017 |
Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Antipsychotic Agents; Child; Humans; Olanzapine; Psychiatric Status Rating Scales; Psych | 2018 |
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Drug-Related Side Effects and Adverse Reactions; | 2018 |
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature.
Topics: Adult; Female; Humans; Menstruation Disturbances; Psychotic Disorders; Risperidone; Tranquilizing Ag | 2018 |
Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Controlled Clinical Trials as Topic; Delayed-Acti | 2019 |
Men and women respond differently to antipsychotic drugs.
Topics: Antipsychotic Agents; Clozapine; Female; Humans; Male; Olanzapine; Psychoses, Substance-Induced; Psy | 2020 |
Risperidone for Psychosis-Induced Aggression or Agitation.
Topics: Aggression; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone | 2019 |
A Case of New Onset Psychosis in a Young Woman with Minimal Response to Risperidone, Ultimately Diagnosed with N-Methyl-D-Aspartate Receptor Encephalitis: A Review of this Under-Recognized Condition.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antipsychotic Agents; Female; Humans; Psycho | 2015 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Pipe | 2013 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Th | 2014 |
Antipsychotic switching in schizoaffective disorder: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Drug Substitution; Humans; Piperazines; Psychotic Disorders; Ran | 2016 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
Neurotoxicity and nephrotoxicity caused by combined use of lithium and risperidone: a case report and literature review.
Topics: Acute Kidney Injury; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Humans; Lithium; Mal | 2016 |
[Atypical antipsychotics in first-episode psychosis: a review].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Psychotic | 2008 |
Serotonin and dopamine interactions in psychosis prevention.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Antagoni | 2008 |
[Turner-syndrome and psychosis: a case report and brief review of the literature].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Chromosome Aberrati | 2009 |
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Attention; Cognition; Cognition Disorders; Double-Blind Method; Humans; Psycho | 2008 |
Confabulation: a spontaneous and fantastic review.
Topics: Antipsychotic Agents; Behavior Therapy; Brain; Brain Damage, Chronic; Brain Mapping; Deception; Delu | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2009 |
Risperidone versus placebo for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Brief Psychiatric Rating Scale; Humans; Mental Status Sc | 2010 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabete | 2010 |
Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission.
Topics: Antipsychotic Agents; Clozapine; Humans; Psychotic Disorders; Receptors, Dopamine D1; Receptors, Dop | 2009 |
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy; Humans; Olanzapine; Pat | 2011 |
[Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition; Dementia; Female; Humans; Male; Mental Dis | 2012 |
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Nervous System Physiological Phenomena; Ol | 2012 |
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Using antipsychotics in elderly patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delusions; Hallucinations; Humans; Olanzapine; Pirenzep | 2002 |
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
Topics: Adolescent; Amisulpride; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic | 2002 |
[Organic catatonic disorder].
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Bromocriptine; Catatonia; Dopamine Agonists; Dopamine A | 2003 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
New antipsychotics and schizophrenia: a review on efficacy and side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cognition; Dibenzothiazepines; Drug | 2004 |
Novel antipsychotics in bipolar and schizoaffective mania.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Psychotic Disorders; Ri | 2004 |
Tardive dyskinesia rates with atypical antipsychotics in older adults.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dose | 2004 |
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical | 2004 |
The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P- | 2004 |
Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.
Topics: Benzodiazepines; Clinical Trials as Topic; Clozapine; Drug Industry; Humans; Olanzapine; Outcome Ass | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothia | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled | 2004 |
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2004 |
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascular; Double-Bl | 2005 |
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cluster Analysis; Drug Administration S | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepin | 2006 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; P | 2005 |
The psychological effects of leech therapy after penile auto-amputation.
Topics: Adult; Amputation, Surgical; Antipsychotic Agents; Humans; Leeching; Male; Penis; Psychotic Disorder | 2006 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psycho | 2006 |
Risperidone augmentation of clozapine: a critical review.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Dysk | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapi | 2006 |
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Double-Blind Method; Fem | 2007 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkins | 2007 |
Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Clinical Trials, Phase | 2007 |
Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Black People; Delayed-Action Preparations; Humans; I | 2007 |
Atypical antipsychotics: new drugs, new challenges.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Humans; Olanzapine; Psychotic D | 2007 |
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
Topics: Antipsychotic Agents; Haloperidol; History, 20th Century; History, 21st Century; Humans; Isoxazoles; | 2007 |
Psychosis in Parkinson's disease: diagnosis and treatment.
Topics: Clozapine; Diagnosis, Differential; Humans; Parkinson Disease; Psychotic Disorders; Risperidone | 1995 |
Management of late-life psychosis.
Topics: Adult; Age Factors; Age of Onset; Aged; Clozapine; Drug Administration Schedule; Humans; Middle Aged | 1996 |
New developments in the pharmacologic treatment of schizoaffective disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Clinical Trials as Topic; Clozapine; Dru | 1996 |
Clinical experience with risperidone.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Psychotic Disorders; Risperidone; Sc | 1996 |
Pharmacoeconomics of antipsychotic drug therapy.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cost-Benefit Analysis; Drug Costs; Econom | 1996 |
Risperidone-induced neuroleptic malignant syndrome: a case report and review.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examin | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Evaluating outcomes of treatments for persons with psychotic disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Costs; Health Care Reform; Humans; Olanzapine; Pirenzepi | 1996 |
Treatment strategies for agitation and psychosis in dementia.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Clozapine; | 1996 |
New antipsychotic medications: what advantages do they offer?
Topics: Antipsychotic Agents; Clozapine; Drug Costs; Humans; Psychotic Disorders; Risperidone; Schizophrenia | 1997 |
[New antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines; | 1997 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
The treatment of psychosis in late life.
Topics: Age Factors; Aged; Antipsychotic Agents; Clozapine; Decision Trees; Delirium; Diagnosis, Differentia | 1998 |
Antipsychotic agents and bipolar disorder.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl | 1998 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Recent developments in the management of psychosis.
Topics: Antipsychotic Agents; Clozapine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Respon | 1998 |
Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Confidence Intervals; Female; | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
Pharmacologic management of psychosis in dementia.
Topics: Aged; Antipsychotic Agents; Clozapine; Comorbidity; Delusions; Dementia; Hallucinations; Humans; Psy | 1999 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
[New antipsychotic agents].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazole | 1999 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone | 2000 |
Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.
Topics: Age Factors; Aggression; Animals; Antipsychotic Agents; Clinical Trials as Topic; Dementia; Dopamine | 2000 |
Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis.
Topics: Antipsychotic Agents; Humans; Hypochondriasis; Psychotic Disorders; Risperidone | 2000 |
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe | 2000 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Pharmacology and clinical experience with risperidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Psychotic Disorders; Risperidone | 2000 |
Optimal dosing with risperidone: updated recommendations.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Top | 2001 |
Priapism associated with conventional and atypical antipsychotic medications: a review.
Topics: Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Clozapine; Erectile Dysfunction; Female; Fo | 2001 |
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Multicent | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
Risperidone in the treatment of psychoses in the elderly: a case report series.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Mal | 2002 |
Tardive dyskinesias and antipsychotics: a review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Humans; Ola | 2002 |
258 trials available for risperidone and Psychoses
| Article | Year |
|---|---|
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Lipids; Metabolome; Psychoses, Substance-Induced; Psycho | 2022 |
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; T | 2022 |
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial.
Topics: Antipsychotic Agents; Australia; Cognition; Female; Humans; Paliperidone Palmitate; Psychotic Disord | 2023 |
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospe | 2019 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Human | 2020 |
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzap | 2020 |
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Child; Female; Humans; Male; Molindone; Olanzapine; | 2021 |
A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.
Topics: Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Psychotic Disorders; Risperidone; White Matt | 2021 |
Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.
Topics: Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids | 2021 |
Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study.
Topics: Antipsychotic Agents; Basal Ganglia; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Risper | 2021 |
Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; T | 2021 |
Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cognition Disorders; Cohort Studie | 2021 |
Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cannabidiol; Cannabis; Humans; Middle Aged; Psychotic Disor | 2021 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Early Diagnosis; Fema | 2017 |
Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combination; | 2017 |
Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals: A 3 months randomized study.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Cytokines; Female; | 2018 |
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Bipolar Disorder; Brief Psychiatric Rating Scale; | 2019 |
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical I | 2019 |
Examination of heterogeneity in treatment response to antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Deprescriptions; Female; Humans; Kaplan-Meier Estimate; Male; Medicatio | 2019 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up St | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans | 2014 |
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2016 |
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Me | 2013 |
Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Antipsychotic Agents; Cerebellar Cortex; Corpus Striatum; Female; Functional Neur | 2013 |
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hallucinations; Hospitaliz | 2013 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Attention; Basal Ganglia; Brain; Double-Blind Method; Female; Glo | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Administration Schedu | 2014 |
White matter changes associated with antipsychotic treatment in first-episode psychosis.
Topics: Anisotropy; Antipsychotic Agents; Aripiprazole; Brain; Diffusion Tensor Imaging; Double-Blind Method | 2014 |
A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders | 2014 |
A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 2014 |
Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depression; Dibenzothiazepines; Dose-Respo | 2014 |
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2015 |
Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cataract; Dibenzothiazepines; Female; Humans; Male; M | 2015 |
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connecto | 2015 |
Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication.
Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Causality; Female; Humans; Magnetic Resonance Ima | 2015 |
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In | 2015 |
Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Humans; | 2015 |
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Ou | 2015 |
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Prospective Stu | 2015 |
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Ou | 2015 |
Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Double-Blind Method; Female; Flupenthixol; Humans; Ima | 2015 |
Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Amygdala; Antipsychotic Agents; Female; Gray Matter; Humans; Magnetic Reson | 2016 |
Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
Topics: Adolescent; Adult; Analgesics; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; | 2016 |
Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison.
Topics: Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Dose-Response Relationship, Drug; Double-Bli | 2016 |
Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1).
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Dis | 2016 |
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2016 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Midd | 2016 |
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
Topics: Adult; Aged; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance | 2016 |
Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dentate Gyrus; Dose-Response Relationship, Drug; Double-B | 2017 |
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Topics: Activities of Daily Living; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepin | 2008 |
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Topics: Adolescent; Benzodiazepines; Blood Glucose; Body Mass Index; Child; Diagnostic and Statistical Manua | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Delayed-Action Preparations; Diagnostic and Statisti | 2008 |
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Female; Follow-Up Stud | 2008 |
[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Topics: Antipsychotic Agents; Catchment Area, Health; Delayed-Action Preparations; France; Hospitalization; | 2007 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manu | 2008 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-R | 2009 |
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Early D | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Educational Status; Female; Hum | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperido | 2009 |
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Counseling; Double-Blind Method; Female; Humans; Ma | 2009 |
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow- | 2009 |
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hyperprol | 2010 |
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Female; Fo | 2010 |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Men | 2009 |
Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Estonia; Europe; Female; Follow-Up S | 2010 |
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
Topics: Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; F | 2010 |
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Behavioral Symptoms; Caregivers; Dou | 2010 |
Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Human | 2010 |
Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Carbohydrates; Chronic Disease; Delayed-Act | 2010 |
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.
Topics: Adult; Antipsychotic Agents; Aspartame; Benzodiazepines; Carbonated Beverages; Clozapine; Dibenzothi | 2009 |
Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.
Topics: Adolescent; Anthropometry; Antidepressive Agents, Second-Generation; Body Mass Index; Body Size; Bod | 2010 |
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Dysk | 2010 |
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relation | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Ha | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis.
Topics: Affective Symptoms; Antipsychotic Agents; Benzodiazepines; Humans; Marijuana Smoking; Medication Adh | 2010 |
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Ag | 2010 |
The heterogeneity of antipsychotic response in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B | 2011 |
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2011 |
Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Administration Schedule; Female; Humans; Injecti | 2011 |
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Topics: Alzheimer Disease; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Humans; Psychomoto | 2012 |
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Citalopram; Double-Blind Method; Female; Humans; Male | 2011 |
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Topics: Adult; Benzodiazepines; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2012 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans | 2012 |
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum | 2011 |
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzodiazepines; Depression; Dibenzothiazepines; Fem | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition; Dibenzothiazepines; Femal | 2013 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2012 |
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fem | 2012 |
Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Huma | 2012 |
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Chronic Disease; Delayed-Action Preparations; Fe | 2012 |
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Cognition Disorders; Double-Blind Method; | 2012 |
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Topics: Antipsychotic Agents; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Prep | 2012 |
Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Delayed-Action Preparations; Female; Humans; Kaplan | 2012 |
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; | 2012 |
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Interview, Ps | 2012 |
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Female; Follow-Up Studies; Haloperidol; Hu | 2012 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logis | 2013 |
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Do | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bi | 2013 |
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2013 |
A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Topics: Aged, 80 and over; Citalopram; Dementia; Double-Blind Method; Female; Humans; Male; Psychiatric Stat | 2013 |
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2002 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dop | 2002 |
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebrovascular Circulation; Female; Follow-Up Studies; | 2002 |
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.
Topics: Acute Disease; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms.
Topics: Adult; Antipsychotic Agents; Comorbidity; Double-Blind Method; Humans; Male; Middle Aged; Military P | 2003 |
Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.
Topics: Ambulatory Care; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Drug Therap | 2002 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperi | 2003 |
Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Diagnostic and Stat | 2002 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hosp | 2003 |
Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients.
Topics: Adult; Amenorrhea; Drug Administration Schedule; Female; Hospitals, Psychiatric; Humans; Hyperprolac | 2003 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
Comparison of three antipsychotics in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Emergency Services, | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-B | 2004 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Femal | 2003 |
A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.
Topics: Adolescent; Adult; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Prolactin | 2004 |
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged | 2004 |
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Acti | 2004 |
A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Psychiatric Status Ratin | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Plasma risperidone concentrations during combined treatment with sertraline.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; | 2004 |
Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study.
Topics: Acute Disease; Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bri | 2004 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Drug Administration | 2004 |
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2004 |
A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepin | 2004 |
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Delayed-Act | 2004 |
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
Topics: Adolescent; Adult; Aged; Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Clopenthixol; Drug T | 2005 |
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 2005 |
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Female | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
The effects of clozapine and risperidone on spatial working memory in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Diagnosis, Computer-Assisted | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; | 2005 |
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Delayed-Action Preparati | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing | 2005 |
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; | 2005 |
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
Topics: Adolescent; Adult; Amoxapine; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind M | 2005 |
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cluster Analysis; Drug Administration S | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depression; Double-Blind Method; Fem | 2005 |
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Hu | 2005 |
Long-acting risperidone in stable patients with schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Delayed-Action Preparations; Female; Humans; Injecti | 2005 |
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Delayed-Action Preparati | 2005 |
Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; Dementia; Female; Humans; | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Double-Blind M | 2005 |
Risperidone liquid in psychotic disorders--efficacy and attitudes.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Dyskinesia, Drug-Induced; Female; H | 2005 |
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; | 2005 |
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dose-Response Relationship, Drug; | 2006 |
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Blood Pressure; Body Mass Index; Bod | 2005 |
[Therapy of mental states at high risk for psychosis: preliminary results from Hungary].
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Hungary; Male; Psychoth | 2006 |
Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Male; | 2006 |
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Canada; Clozapine; Cohort Studie | 2006 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Res | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2006 |
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Double-Blind Method; Fem | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Gala | 2006 |
Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Age | 2007 |
Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Cholinergic Antagonists; Data I | 2006 |
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 2006 |
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Dose-Response Relationship | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder, Ma | 2006 |
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass Index; Female; Follo | 2006 |
Patient-based and clinician-based support for the remission criteria in schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Logistic Models; Male; Patients; Physicians; Psychiatri | 2007 |
Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Middle | 2007 |
Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Topics: Administration, Oral; Adult; Body Weight; Cardiovascular System; Female; Hospitalization; Humans; In | 2007 |
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Chlorpromazine; Female; Follow-Up Studies; Human | 2007 |
Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; | 2006 |
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Clozapine; Cross-Over Studi | 2007 |
Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Humans; Hyperprolactinemia; Mal | 2007 |
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; D | 2007 |
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Dibenzothiaze | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; | 2007 |
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Topics: Aged, 80 and over; Antipsychotic Agents; Citalopram; Dementia; Double-Blind Method; Female; Hospital | 2007 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparatio | 2007 |
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Humans; Placebos; Polypharmacy; Psych | 2007 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Awareness; Health Status; Humans; Psych | 2008 |
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Awareness; Cognition Disorders; Delayed-Act | 2007 |
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Demography; Diagnostic and Statistical Manual of Menta | 2008 |
Risperidone and liver function tests in children and adolescents: a short-term prospective study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Antipsychotic Agents; Aspartate Aminotransfe | 2008 |
A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men.
Topics: Adult; Antipsychotic Agents; Cocaine-Related Disorders; Delayed-Action Preparations; Depressive Diso | 2008 |
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Human | 2008 |
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Gl | 2008 |
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Culture; Dibe | 2008 |
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Blood Glucose; Body Mass Index; Cholesterol; Delayed-Actio | 2008 |
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Capsules; Dose-Response Relationship, Drug | 2008 |
Psychotic symptoms in patients with bipolar mania.
Topics: Adolescent; Adult; Age of Onset; Bipolar Disorder; Comorbidity; Diagnostic and Statistical Manual of | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Cerebral Cortex; Dopamine D2 Receptor Antago | 1995 |
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.
Topics: Aged; Bipolar Disorder; Chronic Disease; Comorbidity; Dementia; Female; Hospitalization; Humans; Hyp | 1995 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.
Topics: Akathisia, Drug-Induced; Ambulatory Care; Clozapine; Cognition Disorders; Cross-Over Studies; Humans | 1996 |
Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Approval; Drug Utilization; Fe | 1995 |
Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Female; Hospitalization; Humans; Male; Prospective Stu | 1996 |
Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antipsychotic Agents; Female; Humans; Longitudinal Studie | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Ba | 1998 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depr | 1998 |
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Pirenzepine; Psychot | 1998 |
Risperidone: treatment response in adult and geriatric patients.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Drug Administration Schedule; Female; Geriatric Psyc | 1998 |
The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
Topics: Antipsychotic Agents; Attitude to Health; Cost-Benefit Analysis; Health Care Costs; Health Status; H | 1999 |
Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
Topics: Adult; Amphetamine; Antipsychotic Agents; Clozapine; Dopamine Antagonists; Dopamine Uptake Inhibitor | 1999 |
Risperidone in the treatment of elderly patients with psychotic disorders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, D | 1999 |
A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Drug Administration | 1999 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1999 |
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Delusions; Dyskinesia, Drug-I | 2000 |
Clozapine and risperidone treatment of psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Blind Method; Humans; | 2000 |
Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Brain; Female; Frontal Lobe; Hippocampus; Humans; Male; | 2000 |
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administrat | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Hospitaliza | 2000 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Safety and efficacy of risperidone in substance abusers with psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2001 |
Risperidone in the treatment of first episode psychosis.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase IV as Topic; Female; Humans; Male; Middle Aged; | 2001 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal | 2001 |
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar | 2001 |
Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Drug Packaging; Female; Humans; Male; Middle Aged; Pat | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dibenzothiazepines; Female; Humans | 2001 |
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Female; Humans; | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio | 2002 |
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Area Under | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
Pilot clinical investigation of risperidone in the treatment of psychotic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Evaluation; Fema | 1990 |
494 other studies available for risperidone and Psychoses
| Article | Year |
|---|---|
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
Topics: Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Locom | 2012 |
Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Drug Evaluation, Preclin | 2013 |
Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.
Topics: Adult; Brain; Corpus Striatum; Female; Glutamic Acid; Humans; Image Processing, Computer-Assisted; M | 2022 |
Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Male; Paliperidone Palmitate; Prodrugs; P | 2023 |
Atypical, but Not Typical, Antipsychotic Drugs Reduce Hypersynchronized Prefrontal-Hippocampal Circuits during Psychosis-Like States in Mice: Contribution of 5-HT2A and 5-HT1A Receptors.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Hippocampus; Mice; Phencyclidine; Prefrontal | 2022 |
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Child; Drug Monitoring; Humans; Pal | 2022 |
Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
Topics: Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Humans; Male; Psychotic Disorders; Risk | 2022 |
Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Longitudinal Studies; Olanzapine; Psychoti | 2022 |
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Mania; Olanzapine; Psychotic Disorders; Risperidone | 2022 |
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders | 2022 |
Epigenetic clock analysis of blood samples in drug-naive first-episode schizophrenia patients.
Topics: Aging; DNA Methylation; Epigenesis, Genetic; Humans; Infant; Infant, Newborn; Psychotic Disorders; R | 2023 |
Hippocampal Hyperconnectivity to the Visual Cortex Predicts Treatment Response.
Topics: Antipsychotic Agents; Hippocampus; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Risperid | 2023 |
Cardiometabolic Monitoring and Sociodemographic and Clinical Characteristics of Youths Prescribed Antipsychotic Medications.
Topics: Adolescent; Adult; Antipsychotic Agents; Cardiovascular Diseases; Female; Humans; Lipids; Male; Psyc | 2023 |
Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals.
Topics: Antipsychotic Agents; Glutamic Acid; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; N | 2023 |
Converting From Intramuscular to Oral Risperidone in a Nursing Home Resident.
Topics: Antipsychotic Agents; Humans; Nursing Homes; Psychotic Disorders; Risperidone | 2023 |
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; P | 2023 |
SOMATIC SYMPTOM DISORDER RESPONDING TO RISPERIDONE TREATMENT.
Topics: Antipsychotic Agents; Humans; Medically Unexplained Symptoms; Psychotic Disorders; Risperidone; Trea | 2023 |
[Oculogyric crisis as an isolated extrapyramidal symptom of auto-intoxication with risperidone].
Topics: Antipsychotic Agents; Diagnosis, Differential; Dystonia; Female; Humans; Ocular Motility Disorders; | 2019 |
Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Prognosis; Psychotic Disorders; Rispe | 2020 |
Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Germany; Humans; Kidney Function Tests; Male; | 2019 |
Risperidone-induced cataract in a young female.
Topics: Antipsychotic Agents; Cataract; Female; Humans; Lens, Crystalline; Psychotic Disorders; Risperidone; | 2020 |
Treatment with the antipsychotic risperidone is associated with increased M1-like JAK-STAT1 signature gene expression in PBMCs from participants with psychosis and THP-1 monocytes and macrophages.
Topics: Adult; Antipsychotic Agents; Cytokines; Female; Humans; Janus Kinases; Leukocytes, Mononuclear; Macr | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Prolactin response to antipsychotics: An inpatient study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Hyperprolactinemia; | 2020 |
Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients.
Topics: Antipsychotic Agents; Glutamic Acid; Humans; Psychotic Disorders; Risperidone; Schizophrenia | 2020 |
Blood gene expression changes after Risperidone treatment in an antipsychotic-naïve cohort of first episode of psychosis patients.
Topics: Antipsychotic Agents; Gene Expression; Humans; Psychiatric Status Rating Scales; Psychotic Disorders | 2020 |
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naïve first-episode psychosis patients.
Topics: Antipsychotic Agents; Brain; Humans; Psychotic Disorders; Risperidone; White Matter | 2021 |
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.
Topics: Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antipsychotic | 2020 |
Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia.
Topics: Adult; Amygdala; Animals; Antipsychotic Agents; Bipolar Disorder; Callithrix; Case-Control Studies; | 2020 |
LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort.
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; DNA Methylation; Female; Humans; Long | 2020 |
Newer Formulations of Risperidone: Remarks About Risperidone ISM
Topics: Antipsychotic Agents; Humans; Psychotic Disorders; Risperidone | 2020 |
Overcoming Complications in Management of a Difficult-to-Treat Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Adolescent Psychiatry; Antidepressive Agents; Antipsychotic Agents; Diphenhydramine; Fem | 2020 |
Towards safer risperidone prescribing in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Humans; Psychotic Disorders; Risperidone | 2021 |
Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Outpatients; Psychotic Disorders; Quetiapine Fumarate | 2021 |
Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Olanzapine; Prescriptions; Psychot | 2021 |
Brief psychotic disorder associated with quarantine and mild COVID-19.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; COVID-19; Humans; Lorazepam; Ma | 2020 |
Abrupt Late-onset Psychosis as a Presentation of Coronavirus 2019 Disease (COVID-19): A Longitudinal Case Report.
Topics: Acute Disease; Antipsychotic Agents; COVID-19; COVID-19 Nucleic Acid Testing; Humans; Longitudinal S | 2021 |
Psychosis in a primary hyperparathyroidism patient with mild hypercalcemia: A case report.
Topics: Aged; Antipsychotic Agents; Female; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Parathyroid | 2021 |
The Antipsychotic Risperidone Alters Dihydroceramide and Ceramide Composition and Plasma Membrane Function in Leukocytes In Vitro and In Vivo.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cell Membrane; Ceramides; Female; Humans; Leukocytes, | 2021 |
Cotard Syndrome in an Adolescent With a First Episode of Psychosis.
Topics: Adolescent; Antipsychotic Agents; Delusions; Electroconvulsive Therapy; Female; Humans; Psychotic Di | 2021 |
A Prepubertal Girl with Delusions of Pregnancy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delusions; Female; Humans; Hyperprolactinemia; | 2021 |
Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional Connectivity.
Topics: Brain; Brain Mapping; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Risperidone; Schizoph | 2022 |
Risperidone-Induced Acute Urinary Retention in a Patient With Major Depressive Disorder With Psychotic Features: a Case Report.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Psychotic Disorders; Risperidone; Urinary | 2021 |
BDNF in antipsychotic naive first episode psychosis: Effects of risperidone and the immune-inflammatory response system.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Humans; Psychotic Disorders; Risperidone; S | 2021 |
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.
Topics: Adult; Benzodiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapi | 2021 |
Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
Topics: Alzheimer Disease; Antipsychotic Agents; Hallucinations; Humans; Psychomotor Agitation; Psychotic Di | 2017 |
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cytochrome P-450 CYP2D6; Dose-Response Rela | 2017 |
Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antigens, CD; Antigens, Differentiation, Myelomonocytic; | 2017 |
Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances.
Topics: Animals; Antipsychotic Agents; Biological Availability; Blood Proteins; Brain; Drug Delivery Systems | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
The forgotten entity of cycloid psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Female; Humans; Psychotic Dis | 2017 |
An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning.
Topics: Adult; Antipsychotic Agents; Arsenic Poisoning; Citalopram; Humans; Male; Obsessive-Compulsive Disor | 2017 |
An Unexpected Circumstance: Acute Dystonic Reaction in the Setting of Clozapine Administration.
Topics: Acute Disease; Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Dystonia; Humans; Male; Ps | 2019 |
Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Corpus Striatum; Female; gamma-Aminobutyric | 2018 |
T
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Biomarkers, Pharmacological; Body Mass I | 2018 |
Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance.
Topics: Antipsychotic Agents; Benzodiazepines; Guidelines as Topic; Humans; Olanzapine; Psychotic Disorders; | 2017 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Dis | 2018 |
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2018 |
Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Hospitals, Psychiatric; Humans; Middle | 2018 |
Meditation induced psychosis: Case report.
Topics: Adult; Antipsychotic Agents; GABA Modulators; Haloperidol; Humans; Lorazepam; Male; Meditation; Prom | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill | 2019 |
A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Catatonia; Ceremonial Behavior; Electroconvulsive Therapy; Humans; Male | 2018 |
[Asperger Syndrome and/or Clinical High Risk of Psychosis? A Differential Diagnostic Challenge].
Topics: Adolescent; Asperger Syndrome; Child; Child, Preschool; Cognitive Behavioral Therapy; Combined Modal | 2018 |
Injectable Risperidone During Hemodialysis.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections; Male; Psychotic Disord | 2018 |
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes, Gestational; Female; Humans; Olanzapine; Pipera | 2018 |
Prolonged Psychosis Associated with Left Insular Stroke: Talking to God in the Walls.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Cerebral Cortex; Electroencephalography; Hallucination | 2018 |
The Use of Carbamazepine to Expedite Metabolism of Risperidone Long-Acting Injection Through Induction of CYP3A4 in a Patient With Extrapyramidal Symptoms.
Topics: Adult; Basal Ganglia Diseases; Carbamazepine; Cytochrome P-450 CYP3A; Delayed-Action Preparations; E | 2018 |
[Evaluation of verbal inhibitory control with the Stroop Test in early episodes of psychosis with the experience of traumatic events in infancy].
Topics: Adolescent; Age Factors; Aripiprazole; Child; Child, Preschool; Executive Function; Female; Humans; | 2018 |
Mitochondrial DNA copy number is associated with psychosis severity and anti-psychotic treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; DNA Copy Number Variations; DNA, Mitochondrial; Female; Huma | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Cloz | 2018 |
Symptomatic Extreme Elevation of Prolactin Related to Risperidone Use.
Topics: Adult; Antipsychotic Agents; Female; Humans; Prolactin; Psychotic Disorders; Risperidone; Young Adul | 2018 |
Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytokines; Female; Gene Expression; Gene Expression Regulat | 2019 |
l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients.
Topics: Agmatine; Antipsychotic Agents; Arginine; Case-Control Studies; Citrulline; Female; Humans; Male; Ol | 2019 |
Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis.
Topics: Adult; Antipsychotic Agents; Cytokines; Female; Humans; Male; Psychotic Disorders; Receptors, Cytoki | 2019 |
Acute agranulocytosis when switching from risperidone to paliperidone.
Topics: Adolescent; Agranulocytosis; Antipsychotic Agents; Comorbidity; Drug Substitution; Humans; Male; Neu | 2019 |
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Fe | 2019 |
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 C | 2019 |
Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Dopamine; Genotype; Humans; Paliperidone Pal | 2019 |
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 | 2019 |
Antipsychotics Do Not Influence Neurological Soft Signs in Children and Adolescents at Ultra-High Risk for Psychosis: A Pilot Study.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Male; Neuropsychological Tests; Pilot Projects; Ps | 2019 |
Prescribing patterns in adolescent psychiatric practice: an important role of antipsychotics.
Topics: Adolescent; Adolescent Psychiatry; Antidepressive Agents; Antipsychotic Agents; Child; Drug Prescrip | 2019 |
[Risperidone and carbamazepine-induced syndrome of inappropriate antidiuretic hormone secretion: case study].
Topics: Antimanic Agents; Antipsychotic Agents; Carbamazepine; Female; Humans; Inappropriate ADH Syndrome; M | 2019 |
The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.
Topics: Animals; Antipsychotic Agents; Humans; Immunosuppressive Agents; Inflammation; Male; Mice; Mice, Inb | 2019 |
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
Topics: Animals; Antipsychotic Agents; Body Weight; Female; Ghrelin; Hyperglycemia; Leptin; Mice; Mice, Inbr | 2019 |
Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis.
Topics: Adult; Dopamine Agents; Humans; Longitudinal Studies; Male; Psychotic Disorders; Risperidone; Schizo | 2013 |
Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up.
Topics: Antipsychotic Agents; Child; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Follow-Up Stu | 2013 |
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Substitution; Female; France; Humans; | 2013 |
Comparative safety of antipsychotics: another look at the risk of diabetes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapine; Cohort Studies; Diabe | 2013 |
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Canada; Dementia; Dibenzothiazepines | 2013 |
Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Frontal Lobe; Humans; Image Proc | 2013 |
Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Topics: Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administ | 2013 |
Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Brazil; Down-Regulation; Female; Gene Expression; Humans; Male; Psychia | 2013 |
Psychosis improved dysphonia.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clonazepam; Diagnosis, Differential | 2013 |
Poststroke psychosis in an 8-year-old child with moyamoya disease.
Topics: Antipsychotic Agents; Child; Humans; Male; Moyamoya Disease; Psychotic Disorders; Risperidone; Strok | 2013 |
Biased reporting of results in patients at ultra-high risk of psychosis.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Female; Humans; Male; Psychotherapy; Psychotic D | 2013 |
Dr McGorry and colleagues reply.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Female; Humans; Male; Psychotherapy; Psychotic D | 2013 |
Concordant response to pharmacotherapy in monozygotic twins with schizoaffective disorder.
Topics: Affect; Alopecia; Antipsychotic Agents; Diseases in Twins; Drug Therapy, Combination; Emotions; Huma | 2013 |
A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine; Drug Administration R | 2014 |
Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
Topics: Adult; Antipsychotic Agents; Appetite; Body Weight; Female; Humans; Isoxazoles; Paliperidone Palmita | 2014 |
Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone.
Topics: Animals; Antipsychotic Agents; Chemistry, Pharmaceutical; Drug Compounding; Excipients; Half-Life; H | 2016 |
Premature thelarche in an 8-year-old girl following prolonged use of risperidone.
Topics: Antipsychotic Agents; Breast; Child; Female; Humans; Psychotic Disorders; Puberty, Precocious; Rispe | 2014 |
Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis.
Topics: Antipsychotic Agents; Down-Regulation; Female; Follow-Up Studies; Gene Expression; Humans; Male; Psy | 2014 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cor | 2014 |
Prognosis of a brief psychotic episode.
Topics: Adult; Antipsychotic Agents; Evidence-Based Medicine; Female; Humans; Prognosis; Psychotic Disorders | 2014 |
The response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Psychotic Disorders; Risperidone; Schizophrenia | 2014 |
Psychosis with Huntington's disease: role of antipsychotic medications.
Topics: Aggression; Antipsychotic Agents; Humans; Huntington Disease; Male; Middle Aged; Psychotic Disorders | 2014 |
No better solution for antipsychotic treatment with regard to long-term safety and effectiveness.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Piperazines; Psycho | 2015 |
Changes in gene expression and methylation in the blood of patients with first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; DNA Methylation; Female; Gene Express | 2014 |
Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Drug Costs; Drug Substitution; Drugs, Generic; Female; H | 2015 |
Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytokines; Depression; Female; Flow Cytometry; Humans; Male | 2014 |
Prescribing of antipsychotics in UK primary care: a cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Child; Cohort St | 2014 |
Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
Topics: Adult; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Fema | 2015 |
Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depression; Female; Humans; Male; Middle Aged; Obsessive-C | 2015 |
Risperidone exacerbates Psychosis: A paradoxical phenomenon?
Topics: Antipsychotic Agents; Humans; Hydrocephalus; Male; Psychoses, Substance-Induced; Psychotic Disorders | 2015 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Female | 2015 |
Elderly nursing home resident with head drop.
Topics: Aged; Antipsychotic Agents; Dopamine Antagonists; Dystonia; Dystonic Disorders; Female; Humans; Psyc | 2015 |
Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Benzodiazepines; Chemot | 2015 |
Successful treatment of tuberous sclerosis with psychosis and obsessive-compulsive disorder: A case report.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Diso | 2015 |
Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Biomarkers; C-Reactive Protein; Clozapine; Female; Hu | 2016 |
Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone.
Topics: Antioxidants; Antipsychotic Agents; Biomarkers; Humans; Lipid Peroxidation; Oxidative Stress; Psycho | 2015 |
Psychotic syndrome associated with anti-Ca/ARHGAP26 and voltage-gated potassium channel antibodies.
Topics: Adult; Antibodies; Antipsychotic Agents; Calcium; Cerebellum; Diazepam; Female; GTPase-Activating Pr | 2015 |
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Genetic Loci; Humans; Male; Outcome A | 2015 |
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Feeding and Eating Disorders; Fema | 2015 |
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic | 2015 |
Rhabdomyolysis with Acute Renal Failure and Deep Vein Thrombosis Induced by Antipsychotic Drugs: A Case Report.
Topics: Acute Kidney Injury; Antipsychotic Agents; Humans; Loxapine; Male; Psychotic Disorders; Rhabdomyolys | 2015 |
Elevated risperidone serum concentrations during acute inflammation, two cases.
Topics: Acute Disease; Adult; Antipsychotic Agents; C-Reactive Protein; Female; Humans; Inflammation; Middle | 2015 |
Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.
Topics: Adult; Antipsychotic Agents; Female; Humans; Movement Disorders; Psychotic Disorders; Risperidone; S | 2015 |
Concerns over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Cerebral Cortex; Connectome; Female; Hippocampus; Huma | 2016 |
Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Genome-Wide Assoc | 2016 |
[Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
Topics: Antipsychotic Agents; Dantrolene; Female; Humans; Intellectual Disability; Middle Aged; Muscle Relax | 2016 |
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis.
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Comorbidity; Gilbert Disease; Humans; Intellectual D | 2016 |
Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia".
Topics: Antipsychotic Agents; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia | 2016 |
Long-acting injectable risperidone as an option in first-episode psychosis.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Psychotic Disorders; Risperidone; Schizop | 2016 |
[Can men be included in the population subjected to puerperal psychosis? A case report].
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Delusions; Denial, Psychological; | 2016 |
Gene-expression analysis of clozapine treatment in whole blood of patients with psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Gene Expression; Gene Expression Profiling; Humans; | 2016 |
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Ps | 2017 |
Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Adult; Antipsychotic Agents; Cohort Studies; Female; Heart Defects, Con | 2016 |
Paliperidone palmitate: factors predicting continuation with treatment at 2 years.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; | 2016 |
Cognition and Dopamine D
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognitive Dysfunction; Corpus Striatum; Female; Humans; | 2017 |
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Female; Humans; Mal | 2017 |
Recurrent Psychotic Episodes with a Near-monthly Cycle.
Topics: Antipsychotic Agents; Child; Diagnosis, Differential; Female; Humans; Menstruation; Periodicity; Psy | 2016 |
Sex Differences in Psychiatric Hospitalizations of Individuals With Psychotic Disorders.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill; Female; Hospitalization; H | 2017 |
[Antypsychotic-induced central pontine myelinolysis in a congenital adrenal hyperplasia subject].
Topics: Adrenal Hyperplasia, Congenital; Adult; Antipsychotic Agents; Humans; Male; Myelinolysis, Central Po | 2017 |
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzap | 2017 |
Rapid onset psychosis after reduction of the risperidone dose.
Topics: Adult; Antipsychotic Agents; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia, Paranoid | 2008 |
Using risperidone for Alzheimer's dementia-associated psychosis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Humans; Psychotic Disorders; Rispe | 2008 |
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; California; Databases, Factual; Deci | 2009 |
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Humans; Male; O | 2008 |
Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cohort Studies; De | 2009 |
Acute disseminated encephalomyelitis presenting as acute psychotic disorder.
Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, D | 2008 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Injections, Intramuscular; Length of S | 2009 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cross-S | 2009 |
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cross-Sectional Studies; Estradiol; Fem | 2009 |
Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Female; | 2010 |
A symptom self-rating scale for schizophrenia (4S): psychometric properties, reliability and validity.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Communication; Female; Humans; Longitudinal Studies; | 2009 |
Medication adherence for children and adolescents with first-episode psychosis following hospitalization.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Cohort Studies; Dibenzothiazepines; Epidem | 2009 |
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Pipera | 2009 |
A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman.
Topics: Antipsychotic Agents; Female; Fever; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Psychotic | 2009 |
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Delayed-Action Pr | 2009 |
Asenapine effects in animal models of psychosis and cognitive function.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Attention; Benzodiazepines; Cognition; Dibe | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
[Therapeutic intervention for group with risk of psychosis--Sendai At-risk Mental State And First Episode].
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognitive Behavioral Therapy; Combined Mod | 2009 |
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Diabetes Mellitus, Type 2 | 2009 |
The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Cytochrome P-450 CYP2D6; Female; Humans; Male; Middle A | 2009 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidit | 2009 |
Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Female; Hospitali | 2009 |
[Use of Hunperdal Richter in psychiatry].
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Drugs, Generic; Female; Humans; Hungary; | 2009 |
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Cytochrome P-450 Enzyme | 2009 |
Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Biotransformation; Community Mental Health Cente | 2012 |
Priapism and risperidone.
Topics: Adolescent; Alcoholism; Anemia, Sickle Cell; Antipsychotic Agents; Cocaine-Related Disorders; Humans | 2009 |
Hyperprolactinemia in an adolescent with psychotic disorder on risperidone.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Psychotic Disorders; Risperido | 2009 |
MDR1 gene polymorphisms and response to acute risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Me | 2010 |
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Topics: Adult; Antipsychotic Agents; Confidence Intervals; Female; Health Care Costs; Health Resources; Hosp | 2010 |
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Endpoint Determination; F | 2010 |
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Confidence Intervals; Cross-Sectional Studies; Delayed | 2010 |
[Risperidone intoxication in a patient with a genetic predisposition as "poor [non]metabolizer"].
Topics: Adult; Antipsychotic Agents; Chromosomes, Human, Pair 22; Cyclohexanols; Cytochrome P-450 CYP2D6; De | 2010 |
The influence of side effect of antipsychotic on the course of treatment in adolescent.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Drugs, Generic; Female; Hospitalization; H | 2010 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Recommendations on the drug treatment of psychosis in Parkinson's disease.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Parkinson Disease; Psychotic Disorders; Quetiapine | 2010 |
Correlates, change and 'state or trait' properties of insight in schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Clinical Trials as Topic; Cohort Stud | 2010 |
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Biomarkers; Bipolar Disorder; Body Mass Index; Ch | 2010 |
Trends in antipsychotic prescribing practices in an urban community mental health clinic.
Topics: Administration, Oral; Anticonvulsants; Antipsychotic Agents; Case Management; Community Mental Healt | 2010 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Ha | 2010 |
Starvation causes acute psychosis due to anterior thalamic infarction.
Topics: Acute Disease; Adult; Antipsychotic Agents; Factor V; Female; Humans; Infarction; Ketosis; Positron- | 2010 |
Psychiatric manifestations as the leading symptom in an expatriate with dengue fever.
Topics: Antipsychotic Agents; Dengue; Female; Haiti; Humans; Psychotic Disorders; Risperidone | 2010 |
The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections; Italy; Length of Stay | 2010 |
Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cohort Studies; Diagnosti | 2011 |
Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical Manual of Menta | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
[Catatonic dilemma in a schizoaffective patient with combined lithium-risperidone administration].
Topics: Antimanic Agents; Antipsychotic Agents; Brain; Catatonia; Clozapine; Diagnosis, Differential; Dopami | 2010 |
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders.
Topics: Adult; Benzodiazepines; Clozapine; Drug Interactions; Drug Therapy, Combination; Duloxetine Hydrochl | 2010 |
Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Comorbidity; Delayed-Action Pre | 2011 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodi | 2011 |
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Movement Disorders; Olanzapine; Psychotic Disorders; | 2010 |
Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Behavioral Symptoms; Cognition; Delayed-Action Preparations | 2011 |
Electroconvulsive therapy in the treatment of delirious mania: a report of 2 patients.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Catatonia; Delirium; Electroconvulsive Therapy; Fema | 2010 |
Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.
Topics: Chromatography, Liquid; Humans; Isoxazoles; Linear Models; Paliperidone Palmitate; Psychotic Disorde | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Fe | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; | 2012 |
Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Clopenthixo | 2009 |
[Delusion of parasitosis due to Wegener's granulomatosis].
Topics: Antipsychotic Agents; Delusions; Dibenzothiazepines; Granulomatosis with Polyangiitis; Humans; Immun | 2011 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervas | 2011 |
[Evaluation of prescription practices of long acting injectable risperidone in French hospitals].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar | 2011 |
Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Female; Humans; Longitudinal St | 2012 |
Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with risperidone and clozapine in an adolescent girl - A case report.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Diagnostic Errors; Female; Fluvoxamine; Humans; Obsessi | 2011 |
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia.
Topics: Aged; Blood-Brain Barrier; Dementia; Domperidone; Dopamine Antagonists; Dopamine D2 Receptor Antagon | 2011 |
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Female; Gluco | 2011 |
A cytochrome P450 inhibitor in a stable schizophrenic patient: a drug interaction.
Topics: Adult; Antifungal Agents; Antipsychotic Agents; Bipolar Disorder; Cytochrome P-450 CYP2D6 Inhibitors | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; | 2011 |
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Butyrophenones; Clozapine; Delayed-Action Preparations | 2011 |
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
Topics: Academic Medical Centers; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?
Topics: Administration, Oral; Adult; Anti-Allergic Agents; Antipsychotic Agents; ATP Binding Cassette Transp | 2012 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol | 2012 |
Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Paliperidone | 2011 |
Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pregnancy; | 2012 |
Antipsychotics and mortality in Parkinsonism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies | 2012 |
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hospital Administration; H | 2012 |
The challenges of clinical psychopharmacological management.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Community Mental Health Services; Comorbidity; Coopera | 2012 |
Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; H | 2012 |
Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Dopamine Antagonists; Drug | 2012 |
Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Isoxazoles; Japan; Ma | 2012 |
[Postpartum psychosis associated with cabergoline].
Topics: Adult; Antipsychotic Agents; Cabergoline; Cesarean Section; Dopamine Agonists; Ergolines; Female; Ha | 2013 |
Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Transient psychosis due to caregiver burden in a patient caring for severely demented spouses.
Topics: Alzheimer Disease; Antipsychotic Agents; Caregivers; Female; Humans; Middle Aged; Psychotic Disorder | 2012 |
Recovery in schizophrenia: focus on neurocognitive functioning.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Cognition Disorders; Executive Function; Female; Hu | 2012 |
Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Child; Depression; Diazepam; Female; Humans; Lupus Erythe | 2013 |
Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Compulsive Behavior; Humans; Intellectual Disabi | 2012 |
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Topics: Antipsychotic Agents; Drug Costs; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophre | 2012 |
Veteran subjects willingness to participate in schizophrenia clinical trials.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Female; Humans; Logistic Models; Male; Middle | 2013 |
Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Topics: Adult; Age Factors; Antipsychotic Agents; Biomarkers; Drug Substitution; Female; Humans; Hyperprolac | 2013 |
[Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Brain tumor in a patient with attenuated psychosis syndrome.
Topics: Adolescent; Antipsychotic Agents; Brain Neoplasms; Cognitive Behavioral Therapy; Combined Modality T | 2013 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; | 2013 |
Postictal psychosis: implications for nursing.
Topics: Aged; Aggression; Anticonvulsants; Antipsychotic Agents; Epilepsy, Complex Partial; Female; Humans; | 2013 |
A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Databases as Topic; Female; Hospitalization; Hospitals, | 2002 |
Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Attention Deficit and Disruptive B | 2002 |
Liquid risperidone in the treatment of psychotic agitation.
Topics: Administration, Oral; Antipsychotic Agents; Biological Availability; Clinical Trials as Topic; Human | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Antipsychotic Agents; Autistic Disorder; Bipolar Disorder; Child; Humans; Male; Priapism; Psychotic | 2002 |
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Topics: Adolescent; Adult; Antipsychotic Agents; Citalopram; Dibenzothiazepines; Drug Therapy, Combination; | 2002 |
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Follow-Up St | 2002 |
Probable dementia with Lewy bodies and risperidone-induced delirium.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Humans; Lewy Body Disease; Male; Psychotic | 2002 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
A case of risperidone-induced priapism.
Topics: Adult; Antipsychotic Agents; Humans; Male; Priapism; Psychotic Disorders; Risperidone | 2003 |
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost-Benefit Analysis; Costs and Cost | 2003 |
Role changes experienced by clinical staff in relation to clients' recovery from psychosis.
Topics: Adult; Anecdotes as Topic; Antipsychotic Agents; Attitude of Health Personnel; Clozapine; Female; Hu | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Topics: Adult; Antipsychotic Agents; Catechol O-Methyltransferase; Chi-Square Distribution; Dopamine D2 Rece | 2003 |
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Cohort Studies; Female; | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Symptomatic bradyarrhythmia secondary to risperidone.
Topics: Antipsychotic Agents; Bradycardia; Dose-Response Relationship, Drug; Electrocardiography, Ambulatory | 2003 |
Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report.
Topics: Adolescent; Antipsychotic Agents; Catatonia; Creatine Kinase; Humans; Male; Psychotic Disorders; Ris | 2003 |
Dropout rates with olanzapine or risperidone: a multi-centre observational study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Meta-Analysis as Topic; Multicen | 2004 |
Psychosis--a need for preemptive intervention?
Topics: Adult; Antipsychotic Agents; Humans; Male; Military Personnel; Psychotic Disorders; Risperidone; Sin | 2003 |
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?
Topics: Diagnosis, Differential; Female; Humans; Middle Aged; Psychotic Disorders; Risperidone; Selective Se | 2004 |
Risperidone questioned as dementia first-line treatment.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Psychotic Disorders; Risperidone | 2004 |
Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combinati | 2004 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary | 2004 |
Prognostic indicators for early discontinuation of risperidone long-acting injection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Databases, Factual; Delayed-Act | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; | 2004 |
Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up.
Topics: Adolescent; Aggression; Antipsychotic Agents; Fluvoxamine; Hospitalization; Humans; Hypothyroidism; | 2004 |
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzazepines; Benzodiazepines; Carbon Radioisotopes; Clozap | 2004 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Tem | 2004 |
Antipsychotic drug prescribing in the elderly is cause for concern.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Data Collection; Drug Prescriptions; Drug Utilization; | 2004 |
Risperidone-induced rabbit syndrome in mood disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Hallucinations; Humans; M | 2004 |
[Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław].
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Ag | 2004 |
Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Biological Availability; Diagnostic and Statistic | 2004 |
[Management of the atypical antipsychotic olanzapine in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State hospital].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dibenzothiazepines; Do | 2004 |
Mesial temporal sclerosis and psychiatric symptoms: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Brain; Depression; Diagnosis, Differential; Electroence | 2004 |
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Ejaculation; Female; Humans; Hyperprolactinemia; Male; | 2004 |
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Child, Presc | 2005 |
[Cerebral infarct and atypical antipsychotic agents].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cerebral Infarction; Dementia, Vascu | 2004 |
Risperidone and breast-feeding.
Topics: Adult; Antipsychotic Agents; Breast Feeding; Dose-Response Relationship, Drug; Female; Humans; Infan | 2005 |
A case of psychosis with temporal lobe epilepsy: SPECT changes with treatment.
Topics: Antipsychotic Agents; Brain; Cerebrovascular Circulation; Child; Epilepsy, Temporal Lobe; Humans; Ma | 2005 |
Little effects of low dosage of levomepromazine on plasma risperidone levels.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dose-Response Relationship, | 2005 |
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antipsychotic Agents; Aspartate Aminotransferases | 2005 |
Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2005 |
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Comorbidity; Fema | 2005 |
Post-malarial neuropsychiatric syndrome.
Topics: Antipsychotic Agents; Humans; Malaria, Falciparum; Male; Middle Aged; Psychotic Disorders; Risperido | 2005 |
Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male | 2005 |
Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
Topics: Adult; Aged; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochro | 2005 |
Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.
Topics: Adult; Antipsychotic Agents; Brain Hemorrhage, Traumatic; Cholinesterase Inhibitors; Cognition Disor | 2005 |
Atypical anti-psychotics in the real world--a naturalistic comparative outcome study.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiaz | 2005 |
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo | 2005 |
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Comorbidi | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort St | 2005 |
Bipolar depression: the role of atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Tolerance; Follow-Up Studies; Humans; | 2004 |
Plasma risperidone levels and clinical response in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Asian People; Drug Monitoring; Female; Humans; Isoxazoles; Male; Palipe | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Ag | 2005 |
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; H | 2006 |
Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Longitudina | 2006 |
Possible antipsychotic effect of fluvoxamine.
Topics: Antipsychotic Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Drug Admi | 2005 |
Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study.
Topics: Adolescent; Adult; Antipsychotic Agents; Demography; Female; Follow-Up Studies; Functional Lateralit | 2006 |
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Chronic Disease; Clozap | 2006 |
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cross-S | 2006 |
Pisa syndrome in a patient in a wheelchair taking valproic acid.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dystonia; Humans; Male; Psyc | 2006 |
The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Drug Administration Schedule; Female; | 2006 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
Psychosis of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cause of Death; Controlled Clinical | 2006 |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Corpus Striatum; D | 2006 |
Anticholinergics in dementia and other confounding problems.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Benztropine; Dementia; Drug Resistance; Humans; Muscari | 2006 |
Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Topics: Adolescent; Antipsychotic Agents; Drug Monitoring; Female; Galactorrhea; Gynecomastia; Humans; Hyper | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Clinical Trials as Topic; Delayed- | 2006 |
To what extent do the PANSS and CGI-S overlap?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Female; Humans; Male; Psychiatric Status Rati | 2006 |
Treatment of olfactory hallucinations with topiramate.
Topics: Adult; Antipsychotic Agents; Fructose; Hallucinations; Humans; Male; Neuroprotective Agents; Prisons | 2006 |
Antipsychotic treatment improves outcome in herpes simplex encephalitis: a case report.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Comorbidity; Delusions; Encephalitis, Herpes Simpl | 2006 |
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dose-Response Re | 2006 |
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Hu | 2006 |
Risperidone long-acting injection in practice - more questions than answers?
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, | 2006 |
Health resource utilization associated with switching to risperidone long-acting injection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Fe | 2006 |
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Delayed-Actio | 2006 |
Psychosis following acute Sydenham's chorea.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Chorea; Fear; Hallucinations; Humans; Male; Mitral | 2007 |
Duration of risperidone treatment for BPSD.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Drug Administration Schedule; Female; Humans; Male | 2006 |
Risperidone-induced erythema multiforme minor.
Topics: Adult; Antipsychotic Agents; Erythema Multiforme; Female; Humans; Male; Middle Aged; Psychotic Disor | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; H | 2005 |
Risperidone-induced hyperprolactinemia in adolescents: A case series.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Depressive Disorder, Major; Diagnostic and Statistica | 2006 |
Improving medication adherence with orally disintegrating tablets.
Topics: Administration, Oral; Antipsychotic Agents; Chemistry, Pharmaceutical; Humans; Male; Patient Complia | 2006 |
Lingual lesions with orally disintegrating risperidone.
Topics: Absorption; Administration, Oral; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Female; Hu | 2006 |
Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Corpus Striatum | 2006 |
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Topics: Adult; Antipsychotic Agents; Biotransformation; Female; Humans; Isoxazoles; Male; Middle Aged; Palip | 2006 |
[Neurotoxicity related to lithium-risperidon combination treatment in a patient with schizoaffective disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Cognition Disorders; Drug Interactions; Drug Therapy, Combin | 2007 |
Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder; Child; Drug | 2006 |
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Comorbidity; Dementia, Vascular; Dose-R | 2007 |
Splitting and pill splitting.
Topics: Adult; Aged; Borderline Personality Disorder; Cost Savings; Defense Mechanisms; Drug Costs; Female; | 2007 |
Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Cost Savings; Drug Costs; Hospitals, Veterans; Humans; New Je | 2007 |
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dose-Response | 2007 |
Characteristics of psychotic patients with foreign accent syndrome.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 2007 |
Managing psychosis in pregnancy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Child Custody; Cooperative Behavior; | 2007 |
Delusional experience of self as receiver of email in schizoaffective disorder.
Topics: Aged, 80 and over; Antipsychotic Agents; Awareness; Computer Literacy; Culture; Delusions; Electroni | 2007 |
Psychotic disorder in a patient with central and extrapontine myelinolysis.
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Antipsychotic Agents; Baclofen; Fema | 2007 |
Quetiapine in the successful combination treatment of an assaultive patient with treatment-resistant schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Resistance; Drug Therapy, Com | 2007 |
Early use of clozapine for poorly responding first-episode psychosis.
Topics: Adolescent; Adult; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2007 |
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Psychia | 2007 |
The use of atypical antipsychotics in French psychiatric hospitals.
Topics: Adult; Age Factors; Amisulpride; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; Benzo | 2007 |
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Fetal Blood; Haloperidol; | 2007 |
Depot risperidone in elderly patients: the experience of an Australian aged psychiatry service.
Topics: Aged; Australia; Delayed-Action Preparations; Female; Geriatric Psychiatry; Humans; Male; Mental Hea | 2007 |
A report of successful treatment of psychosis in epilepsy with risperidone.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Epilepsy; Humans; Male; Psychotic Disorde | 2007 |
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Topics: Aged, 80 and over; Antipsychotic Agents; Combined Modality Therapy; Dementia, Multi-Infarct; Electro | 2007 |
Analysis of treatment effectiveness in longitudinal observational data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Interpretation, Statistical; Female; Humans; Long | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Human | 2007 |
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.
Topics: Adolescent; Adult; Aging; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Body Weight; Chil | 2007 |
Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Topics: Adolescent; Adolescent Medicine; Age Factors; Antipsychotic Agents; Dose-Response Relationship, Drug | 2008 |
Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.
Topics: Antipsychotic Agents; Budgets; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Hospi | 2008 |
Evaluating dose response from flexible dose clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relatio | 2008 |
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Electrooculography; Female; Fix | 2008 |
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; | 2008 |
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Benzodiazepines; Cross-Sectiona | 2008 |
Long-acting risperidone improves negative symptoms in stable psychotic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chemistry, Pharmaceutical; Data In | 2008 |
Risperidone depot in the treatment of psychosis associated with multiple sclerosis -- a case report.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Middle Aged; Multiple Sclerosis; | 2008 |
Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Health Resources; Humans; In | 2008 |
Lessons to be learned from CATIE and CUtLASS.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Health Care Cos | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
[Edema related to treatment with olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Therapy, Combination; Edema; | 2009 |
New antipsychotic agent, risperidone, introduced.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychotic Disorders; Risperidone | 1994 |
Risperidone in Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Parkinson Disease; Piperidines; Psychotic Disorders; Rispe | 1994 |
Risperidone in adolescents.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 1994 |
Prolonged erection associated with risperidone treatment.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Piperidines; Priapism; Psychotic Disorders; R | 1995 |
Risperidone augmentation of clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Isoxazoles; Male; Piperid | 1995 |
Two cases of risperidone-induced neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Piperidines | 1995 |
Pharmacokinetic interaction between risperidone and clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combination; Humans; Isoxaz | 1995 |
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Topics: Adult; Age Factors; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Dr | 1995 |
Risperidone and tardive dyskinesia: a case report.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; | 1995 |
Risperidone and NMS?
Topics: Adult; Antipsychotic Agents; Female; Humans; Neuroleptic Malignant Syndrome; Psychotic Disorders; Ri | 1995 |
Risperidone and neuroleptic malignant syndrome: a case report.
Topics: Adult; Female; Humans; Neuroleptic Malignant Syndrome; Psychotic Disorders; Risperidone | 1995 |
[Clinical evaluation of risperidone].
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychotic Disorders; Risperidone | 1993 |
"Awakenings" effect with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Humans; Parkinson Disease; Psychotic Disorders; | 1995 |
Risperidone side effects.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Leukocyte Count; Leukope | 1996 |
Agranulocytosis after addition of risperidone to clozapine treatment.
Topics: Adult; Agranulocytosis; Clozapine; Drug Therapy, Combination; Female; Humans; Psychotic Disorders; R | 1996 |
Neuroleptic malignant syndrome with risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Intellectual Disability; Male | 1996 |
Risperidone: a once-daily dosage schedule.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Psychotic Disorders; Risperidone | 1995 |
Severe depression with risperidone-induced EPS in an elderly schizoaffective patient.
Topics: Aged; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug- | 1996 |
Manic symptoms associated with initiation of risperidone.
Topics: Adult; Bipolar Disorder; Humans; Male; Middle Aged; Psychotic Disorders; Risperidone; Schizophrenia | 1996 |
A naturalistic outcome study of risperidone treatment among hospital patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Hospita | 1996 |
Risperidone and ECT combination therapy: a case series.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder; Elect | 1995 |
Risperidone-induced ejaculatory and urinary dysfunction.
Topics: Adult; Ejaculation; Humans; Male; Psychotic Disorders; Risperidone; Urination Disorders | 1996 |
Outcome of risperidone therapy in elderly patients with chronic psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Humans; Inpatients; Male; Psychotic | 1996 |
Risperidone: once-daily dosage.
Topics: Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1996 |
Induction of mania by risperidone resistant to mood stabilizers.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Protracted akathisia after risperidone withdrawal.
Topics: Aged; Akathisia, Drug-Induced; Drug Administration Schedule; Female; Humans; Psychotic Disorders; Ri | 1997 |
Extrapyramidal side effects with low-dose risperidone.
Topics: Adult; Antipsychotic Agents; Delusions; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; | 1997 |
Risperidone-induced galactorrhea.
Topics: Adult; Antipsychotic Agents; Female; Galactorrhea; Humans; Psychotic Disorders; Risperidone | 1997 |
Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Depressive Disorder; Dyskinesia, Drug-Induced; Female | 1997 |
Switching between clozapine and risperidone treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedu | 1997 |
[Risperidone after clozapine in therapy refractory schizoaffective psychosis--a case report].
Topics: Adult; Amitriptyline; Antipsychotic Agents; Clozapine; Depressive Disorder; Dose-Response Relationsh | 1997 |
Use of risperidone in psychotic disorder following ischemic brain damage.
Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Humans; Psychotic Disorders; Retrospective Studies; | 1996 |
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
Topics: Adult; Aggression; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
Impact of risperidone on the use of mental health care resources.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; California; Chronic Disease; Cost-Be | 1997 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psyc | 1997 |
Alteration in the recommended dosing schedule for risperidone.
Topics: Adult; Databases as Topic; Drug Administration Schedule; Drug Prescriptions; Female; Hospitalization | 1998 |
Risperidone and allergic reactions.
Topics: Aged; Drug Eruptions; Drug Hypersensitivity; Edema; Epilepsy; Humans; Male; Psychotic Disorders; Res | 1998 |
A naturalistic study of clinical use of risperidone.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Drug Utilization; Female; Follow-Up Studies; H | 1998 |
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Risperidone-induced galactorrhea associated with a prolactin elevation.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Galactorrhea; Humans; Prolact | 1998 |
High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome.
Topics: Aged; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Neuroleptic Malignant Syndrom | 1998 |
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Hypothermia | 1998 |
Catatonia-like events after valproic acid with risperidone and sertraline.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Catatonia; Drug Interactions; D | 1998 |
Choosing among old and new antipsychotics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Psychotic Disorders; Receptors, Dop | 1996 |
Progression of abnormal involuntary movements during risperidone treatment.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Psychotic Disorders; Risperidone | 1998 |
Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study.
Topics: Antipsychotic Agents; Cognition Disorders; Female; Humans; Huntington Disease; Middle Aged; Psychoti | 1998 |
Quality of life and atypical antipsychotics.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psych | 1998 |
Use of risperidone in psychosis associated with Huntington's disease.
Topics: Antipsychotic Agents; Female; Humans; Huntington Disease; Middle Aged; Psychotic Disorders; Risperid | 1998 |
Olanzapine and negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Middle Aged; Olanzapine; Pire | 1998 |
Treatment with risperidone of an acute psychotic episode in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antipsychotic Agents; CD4 Lymphocyte Count; Humans; Male; | 1998 |
Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Circadian Rhythm; Humans; Male; Middle Aged; Psychotic Disorde | 1998 |
Return of menstruation after switching from risperidone to olanzapine.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Humans; Menstruation; Olanzapine; | 1998 |
Gynecomastia with risperidone-fluoxetine combination.
Topics: Adult; Antipsychotic Agents; Drug Combinations; Fluoxetine; Gynecomastia; Humans; Male; Psychiatric | 1999 |
Risperidone as an adjunct to valproic acid.
Topics: Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Male; Middle Aged; Psycho | 1999 |
New antipsychotic drugs produce better outcomes.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Management; Drug Costs; Humans; Mental Hea | 1997 |
Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Hospitals, Psychiatric; Hospitals, State; Humans; Ma | 1999 |
Schizophreniform disorder: exception proves the rule.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Prospective | 1999 |
Risperidone and associated amenorrhea: a report of 5 cases.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Mental | 1999 |
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dementia; Drug Admin | 1999 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Weight gain: side effect of atypical neuroleptics?
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Body Mass Index; C | 1999 |
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Hum | 1999 |
Risperidone-induced tardive dystonia and psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Dystonia; Facial Muscles; Humans; Male; Middle Aged; Neck Mus | 1999 |
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Geriatri | 1999 |
Risperidone for the treatment of monosymptomatic hypochondriacal psychosis.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Humans; Hypochondriasis; Male; Paranoid D | 1999 |
Quetiapine in adolescent psychosis.
Topics: Adolescent; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Huma | 1999 |
A dose-outcome analysis of risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Dose-Response Rel | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1999 |
The publication policy in Duodecim.
Topics: Antipsychotic Agents; Finland; Humans; Periodicals as Topic; Policy Making; Psychotic Disorders; Ris | 1996 |
[Risperidone and the "salami science"].
Topics: Antipsychotic Agents; Authorship; Finland; Humans; Journalism; Psychotic Disorders; Risperidone | 1996 |
Elevated serum triglycerides with clozapine resolved with risperidone in four patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Male; Psychotic Disorders; Risk Factors; Risperidone | 1999 |
Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Community Mental Health Services; Dose-Resp | 1999 |
Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dyskinesia, Drug-Induced | 2000 |
Risperidone treatment for psychosis in end-stage Friedreich's ataxia.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Friedreich Ataxia; Humans; Male; Psychoti | 2000 |
Treatment of the interictal psychoses.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Therapy, Combin | 2000 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Homicide, novel antipsychotics, and non-compliance.
Topics: Adult; Antipsychotic Agents; Homicide; Humans; Male; Psychotic Disorders; Risperidone; Treatment Ref | 2000 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Risperidone-induced obsessive-compulsive symptoms: a reappraisal.
Topics: Adult; Antipsychotic Agents; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Disorders; Rispe | 2000 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic | 2000 |
[Jet lag causing or exacerbating psychiatric disorders].
Topics: Antipsychotic Agents; Disease Susceptibility; Humans; Jet Lag Syndrome; Male; Middle Aged; Psychotic | 2000 |
Antipsychotic drugs and risk of homicide.
Topics: Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Homicide; Humans; Patient Compliance; | 2000 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis.
Topics: Adult; Aggression; Clozapine; Drug Administration Schedule; Humans; Male; Middle Aged; Psychiatric S | 2000 |
Advantages of depot antipsychotics.
Topics: Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Homicide; Humans; Patient Compliance; | 2000 |
Risperidone for the treatment of psychosis associated with neurosarcoidosis.
Topics: Adult; Antipsychotic Agents; Humans; Male; Psychotic Disorders; Risperidone; Sarcoidosis | 1997 |
Risperidone-associated priapism.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Priapism; Psychotic Disorders; Risperidone | 1997 |
Psychosis only skin deep.
Topics: Adult; Darier Disease; Humans; Isotretinoin; Male; Military Personnel; Military Psychiatry; Psychoti | 2000 |
Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Humans; Israel; Olanzapine; Pirenzepine; Pr | 2000 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human | 2000 |
Risperidone addition and psychotic exacerbation.
Topics: Delusions; Drug Therapy, Combination; Humans; Male; Middle Aged; Psychoses, Substance-Induced; Psych | 2001 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen | 2001 |
Risperidone-induced ejaculatory dysfunction: a case report.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Male; Psychotic Disorders; Risperidone; Sexual Dys | 2001 |
Hypothesis and hypothesis testing in the clinical trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Inference in randomized studies with informative censoring and discrete time-to-event endpoints.
Topics: Antipsychotic Agents; Biometry; Computer Simulation; Humans; Models, Statistical; Placebos; Psychoti | 2001 |
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Dat | 2001 |
Risperidone added to clozapine: impact on serum prolactin levels.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Cross-Sectio | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M | 2001 |
Obsessive--compulsive disorder and psychosis.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Obse | 2001 |
The relationship between Usher's syndrome and psychosis with Capgras syndrome.
Topics: Aged; Antipsychotic Agents; Capgras Syndrome; Diagnosis, Differential; Female; Hearing Loss, Sensori | 2001 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |
The efficacy and safety of risperidone for the treatment of geriatric psychosis.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chi-Square Dis | 2001 |
Increased plasma concentration of maprotiline by coadministration of risperidone.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fema | 2002 |
Are the atypical antipsychotic drugs antidepressants?
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depr | 2002 |
Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2001 |
Risperidone and Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; Risperidone | 2002 |
Risperidone in chorea and psychosis of Huntington's disease.
Topics: Adult; Antipsychotic Agents; Female; Humans; Huntington Disease; Psychotic Disorders; Risperidone | 2002 |
Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Female; Humans; Long-Term Care; Male | 2002 |
Risperidone-induced Pisa syndrome.
Topics: Adult; Antipsychotic Agents; Dystonic Disorders; Female; Humans; Intellectual Disability; Posture; P | 2002 |
A case of brief psychosis associated with an arachnoid cyst.
Topics: Antipsychotic Agents; Arachnoid Cysts; Hallucinations; Headache; Humans; Magnetic Resonance Imaging; | 2002 |
Valproic acid and risperidone.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Interactions; Epilepsy; Female; Humans; Psyc | 2002 |
Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Child; Female; Health Care Costs; Humans; Male; Manag | 2002 |
[General practice study with atypical neuroleptics. Differences in tolerance].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzothiazepines; Family P | 2002 |
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Pat | 2002 |
The lesson from a yellow psychotic patient.
Topics: Adult; Antipsychotic Agents; Delusions; Humans; Hypothyroidism; Male; Myxedema; Psychotic Disorders; | 2002 |
Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder; Female; Humans; Isoxazoles; Male; Middle Age | 1992 |
Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Electrocardiography; Female; Hormones; Humans; Is | 1989 |